




AIRWAY EPITHELIAL CELLS AS TARGETS OF GLUCOCORTICOID 






in partial fulfillment of the requirements for the degree 
“Doctor rerum naturalium (Dr. rer. nat.)” 
of the Georg-August University Göttingen 
 
within the “Molecular Medicine” Study Program 











Göttingen, December 2016 
 




Prof. Dr. Holger M. Reichardt  
Institute for Cellular and Molecular Immunology 
University Medical Center Göttingen 
 
Prof. Dr. Frauke Alves 
Department of Hematology and Oncology 
University Medical Center Göttingen 
 
Prof. Dr. Uwe Groß  
Institute for Medical Microbiology 
University Medical Center Göttingen 
 
Additional Members of the Examination Board 
 
Prof. Dr. Lutz Walter 
Department of Primate Genetics 
German Primate Center, Göttingen 
 
Prof. Dr. mult. Thomas Meyer 
Department of Psychosomatic Medicine and Psychotherapy 
University Medical Center Göttingen 
 
Prof. Dr. Hubertus Jarry 
Department of Clinical and Experimental Endocrinology 
University Medical Center Göttingen 
 
 
Date of the oral examination: 10th February, 2017 
 




I hereby declare that I have written this Ph.D. thesis entitled “Airway Epithelial Cells as 
Targets of Glucocorticoid Therapy in Inflammatory Lung Diseases” independently and 
with no other sources and aids than quoted. This thesis has not been submitted in any 






        
Carina Klaßen 
 
Göttingen, December 2016 
 




Glucocorticoids (GCs) have been a mainstay in the treatment of various autoimmune and 
allergic diseases for many decades due to their potent anti-inflammatory activities. The 
beneficial effects of GCs are mediated by the glucocorticoid receptor (GR) mainly through 
modulation of target gene expression via transactivation or transrepression. Despite their 
therapeutic potency, the use of GCs is limited as their broad activity profile may lead to 
the development of severe side effects. Therefore, a better understanding of the precise 
mode and site of GC-action could help to improve this therapeutic regimen. 
Allergic airway inflammation (AAI) as a model of asthma was induced in GRdim mice to 
dissect the molecular mechanisms of GCs. These mice carry a point mutation that impairs 
GR-dimerization and thus interferes with gene transactivation. Treatment of AAI with 
dexamethasone (Dex) failed to diminish clinical symptoms in the airways of GRdim mice, 
indicating that an intact GR-dimerization interface was essential for therapeutic efficacy 
in this disease model. As previous data had revealed that GCs presumably target 
structural cells of the lung in the treatment of AAI rather than immune cells, it was tested 
whether airway epithelial cells (AECs) were essential targets. Hence, AAI was induced in 
GRspc mice that specifically lack the GR in alveolar type II epithelial (AT-II) cells. Dex 
repressed AAI in GRspc mice only partially, highlighting that AT-II cells play a crucial role for 
the efficacy of GC-therapy. Notably, GC-treatment of acute lung injury (ALI), another 
pulmonary disease, was not impaired in GRspc mice. 
A potential link between GC-target site and mode of action was confirmed by expression 
analysis of various inflammatory genes in the lung, which revealed that GRdim and GRspc 
mice behaved similarly with regard to transcriptional control. Furthermore, antibody-
conjugated betamethasone nanoparticles were investigated as a novel vehicle for AT-II 
cell-directed delivery of GCs in AAI but did not show any efficacy in improving disease 
symptoms. 
Taken together, the findings reported in this thesis bring about a novel concept of GC-
therapy of allergic asthma, indicating that its efficacy depends on GR-dependent gene 
regulation in AECs. This notion paves the way for a future cell-directed delivery of GCs as 
an interesting approach for the improvement of GC-therapy in allergic asthma with fewer 
side effects. 
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The lung is one of the largest organs of the human body. The blood-air barrier in the 
alveoli of the lung allows direct contact of the blood circulation with oxygen from the 
environmental air. Therefore, the lung is highly susceptible to both exogenous and 
endogenous insults such as infectious bacteria and viruses, allergens or air pollutants. As 
consequence, the development of various lung diseases like asthma or acute lung injury 
(ALI) is very common. Many of these diseases are not curable and treatment is still very 
challenging. Despite their many side effects, glucocorticoids (GCs) are often the first- or 
last-line treatment. 
 
1.1 The Airway Epithelium as Frontline Defense Against Inflammatory Lung 
Diseases 
 
Most lung diseases are characterized by airway dysfunction and an extensive distortion of 
the lung architecture, frequently involving the epithelial lining of the lung. Over the past 
few decades, airway epithelial cells (AECs) were shown to be key mediators in the 
development of inflammatory lung diseases and important targets for novel therapeutic 
approaches. 
 
1.1.1 Composition of the Airway Epithelium 
 
The respiratory tract represents one of the largest surfaces of the human body covering 
an area that exceeds 120 m² (Hasenberg et al., 2013). It can be divided in two 
compartments according to their distinct functions. The conducting airways consist of the 
nose, the trachea and bronchi. Inhaled air is warmed, moistened and filtered from foreign 
particles and pathogens. The main function of the conducting airways is to transport air 
to the lung parenchyma where the gas exchange occurs. The lung parenchyma or the 
respiratory surface is comprised of the respiratory bronchi and alveoli (Hollenhorst et al., 
2011; Holt et al., 2008).  
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Several secretory and ciliated epithelial cells with different morphologies and functions 
are forming the characteristic pseudostratified epithelium of the conducting airways 
(Camelo et al., 2014; Hollenhorst et al., 2011; Whitsett and Alenghat, 2014) (fig. 1). 
 
Figure 1: Cell types of the airway epithelium. The conducting airways are lined by a pseudostratified 
epithelium with various ciliated and secretory epithelial cells like goblet cells, clara cells, basal cells and 
neuroendocrine cells. In contrast, the alveoli in the lung parenchyma are formed only by AT-I and AT-II cells. 
 
Mucous cells or goblet cells contain membrane-bound mucin granules. They produce and 
release mucus into the airway lumen to trap foreign particles (Camelo et al., 2014; Knight 
and Holgate, 2003). Ciliated epithelial cells are the most common cell type within the 
airways and account for 50% of all epithelial cells (Knight and Holgate, 2003). Foreign 
particles that are trapped in mucus are cleared from the airways by beating their motile 
cilia in the ascending direction (Camelo et al., 2014; Hollenhorst et al., 2011). The amount 
of mucus and the efficacy of the mucociliary clearance are influenced by injury or 
infection (Whitsett and Alenghat, 2014). Basal cells are widely distributed throughout the 
airways. They are located beneath the surface epithelium and directly attached to the 
epithelial basement membrane which forms a barrier to the underlying mesenchymal 
compartment. Serving as stem cells for ciliated and secretory cells, basal cells play a 
crucial role in the regeneration of the airway epithelium following inflammatory insults 





















Primary Bronchiole Bronchi Branch
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cells are found as single cells or in clusters as neuroepithelial bodies (NEBs). They are 
thought to sense stimuli such as hypoxia and to contribute to the regulation of growth 
and regeneration of other AECs (Knight and Holgate, 2003; Rock et al., 2011). Clara cells, 
also known as club cells, are additional secretory cells of the conducting airways and 
often reside close to NEBs. They contribute to the maintenance and repair of bronchioles 
i.e. clara cells metabolize xenobiotics, produce bronchial surfactants and specific anti-
proteases (Knight and Holgate, 2003; Zheng et al., 2013).  
Progressive branching of bronchioles eventually gives rise to alveolar ducts and alveoli 
that are part of the lung parenchyma. The distinct arrangement of the alveolar 
compartment directly reflects its main function as respiratory surface (Hasenberg et al., 
2013). A large contact area is maintained at the blood-air barrier thereby requiring 
minimal place (Hollenhorst et al., 2011). The alveolar compartment comprises two types 
of alveolar epithelial cells: alveolar type I (AT-I) cells and type II (AT-II) cells. Squamous AT-
I cells cover approximately 90% of the alveolar surface, which is due to their flattened 
phenotype (Camelo et al., 2014). Together with microvascular endothelial cells they form 
the blood-air barrier, which is also known as alveolar-capillary barrier, and facilitate 
efficient gas exchange. Moreover, AT-I cells have an important role in the fluid 
homeostasis of the lung as they are involved in ion and water transport (Hollenhorst et 
al., 2011). In contrast to AT-I cells, AT-II cells are smaller in size but higher in number in 
the alveoli (Hollenhorst et al., 2011). Their main function is the production and recycling 
of surfactant proteins which are stored in lamellar bodies. Surfactant reduces the surface 
tension of the alveoli thereby preventing it from collapsing, thus allowing efficient gas 
exchange (Hasenberg et al., 2013; Hollenhorst et al., 2011; Rock et al., 2011). AT-II cells 
are believed to serve as progenitor of AT-I cells and allow the repair of alveolar damage 
(Hasenberg et al., 2013; Hollenhorst et al., 2011). 
The integrity and permeability of the airway epithelium are sustained by tight junctions, 
which  are composed of various transmembrane proteins like occludin, claudin, junctional 
adhesion molecules (JAMs), and E-cadherin, as well as adaptor proteins such as β-catenin 
and zonula occludens (ZO) (Arora and Kale, 2013; Holgate, 2007). The different proteins 
interact to form a tight connection between neighboring AECs enabling adhesion and 
intercellular communication. In addition, tight junctions also prevent the entry of foreign 
material and bacteria (Camelo et al., 2014). Furthermore, epithelial integrity involving 
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cell-cell and cell-extracellular matrix (ECM) interactions is supported by desmososomes, 
hemidesmosomes and adherens junctions (Arora and Kale, 2013; Camelo et al., 2014). 
Notably, damage of tight junctions is a major hallmark of many lung diseases like asthma 
or ALI, and may cause increased epithelial permeability and inflammatory responses in 
the airways (Whitsett and Alenghat, 2014). 
Importantly, many cell types of the innate and adaptive immune system reside within the 
airway epithelium. The conducting airways contain dense networks of antigen-presenting 
cells (APCs) such as macrophages and dendritic cells (DCs). Intraepithelial T cells, mast 
cells, plasma cells and to some extent naïve B cells reside in the lamina propria 
underneath the epithelial basement membrane. In the lung parenchyma, it is mainly 
alveolar macrophages which are present, as well as minor DC and T cell populations (Holt 
et al., 2008). 
 
1.1.2 AECs in Innate and Adaptive Immune Responses 
 
For many years, AECs were believed to exclusively function as a physical barrier against 
potential pathogens which are subsequently removed from the airways by mucociliary 
clearance. In recent years, it has become evident that AECs secrete a plethora of different 
regulatory and effector molecules that are involved in the frontline defense against these 
pathogens. Protease inhibitors, enzymes like lysozyme, defensins, mucins, lactoferrin, 
pentraxins, small molecules such as reactive oxygen species (ROS) and nitric oxide (NO), 
and many more are known to play a crucial role in neutralizing pathogens (Holt et al., 
2008; Kato and Schleimer, 2007; Schleimer et al., 2007). Secretion of these anti-microbial 
mediators is thought to be regulated by pattern recognition receptors (PRRs) including 
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) (fig. 2). AECs are able to sense 
pathogen-associated molecular patterns (PAMPs) or danger-associated molecular 
patterns (DAMPs) via expression of PRRs (Whitsett and Alenghat, 2014). TLR4 is involved 
in sensing inhaled allergens and thus contributes to the development of a T helper type 2 
(TH2) cell-driven immune response. Other TLRs like TLR3, TLR7, TLR8 and TLR9 are 
involved in the recognition of viral antigens, e.g. from respiratory syncytial virus (RSV) or 
influenza A virus (IAV) (Holtzman et al., 2014). NLRs including NOD1 and NOD2, as well as 
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the NLPR3 inflammasome complex sense viral and fungal antigens (Holtzman et al., 2014; 
Kato and Schleimer, 2007). 
Activation of PRRs leads to the production and secretion of AEC-derived cytokines and 
chemokines, which serves to regulate the immune responses in the airways. Most 
importantly, secretion of type I and III interferons (IFNs) including IFN-β and IFN-λ 
improves antiviral defense mechanisms and prevents the development of respiratory 
diseases. Moreover, secretion of interleukin (IL)-10 and transforming growth factor-β 
(TGF-β) acts as a negative feedback mechanism in response to pro-inflammatory 
cytokines and suppresses inflammatory responses in the airways (Holtzman et al., 2014; 
Kato and Schleimer, 2007; Weitnauer et al., 2016).  
AEC-derived cytokines and chemokines mediate the recruitment and activation of both 
innate and adaptive immune cells to further modulate immune responses in the lung. 
 
Figure 2: AECs as modulators of innate and adaptive immune responses in the lung. AECs express a wide 
array of PRRs including TLRs and NLRs. In response to PRR activation, they secrete a plethora of anti- and 
pro-inflammatory cytokines and chemokines that drive the recruitment of various immune cells like DCs, T 
cells and B cells in the airways. Figure taken from Kato and Schleimer, 2007. 
 
The recruitment and local survival of DCs is mainly mediated by the secretion of CCL20 
and GM-CSF. The latter also drives monocyte differentiation into the myeloid and 
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plasmacytoid DC subsets. Moreover, secretion of thymic stromal lymphopoietin (TSLP) by 
AECs drives DCs to initiate a TH2 immune response (Kato and Schleimer, 2007; Schleimer 
et al., 2007). 
In response to different inflammatory stimuli, AECs mediate the recruitment of distinct T 
cell subsets into the airways. TH1 cells migrate into the airways in response to CXCL9, 
CXCL10 and CXCL11 whereas recruitment of TH2 cells is mediated by CCL17 and CCL22. 
Furthermore, AECs are able to interact with T cells via the secretion of cytokines and 
expression of various surface molecules like CD40, Fas and Fas-ligand (FasL). AECs express 
B7 homologs that act as co-stimulatory molecules and are important regulators for the 
activation of T cells. Secretion of IL-33 by AECs enhances the TH2 immune response by 
initiating the production of TH2-specific cytokines (Kato and Schleimer, 2007; Schleimer et 
al., 2007). 
B cells can be activated following secretion of IL-6 and TGF-β by AECs. Moreover, AECs 
express B cell activating factor of the tumor necrosis factor (TNF) family (BAFF) as well as 
a proliferation inducing ligand (APRIL) that both play crucial roles in the activation, 
differentiation and survival of B cells. BAFF and APRIL induce class-switch recombination 
(CSR) and mediate production of immunoglobulin (Ig) A and IgM in the airways. Polymeric 
forms of these Igs bind to the polymeric Ig receptor (pIgR), which mediates the transport 
across the airway epithelium into the airway lumen. This forms a crucial mechanism for 
the neutralization of potential antigens in the airways (Kato and Schleimer, 2007; 
Schleimer et al., 2007). 
 
1.1.3 AT-II Cells as Defender of the Alveolar Compartment 
 
In recent years, a lot of research particularly focused on the role of AT-II cells in regulating 
immune responses in the airways. AT-II cells are primarily known for their production of 
the four surfactant proteins SP-A, SP-B, SP-C and SP-D that regulate the surface tension of 
the alveoli. Noteworthy, SP-A and SP-D play crucial roles in innate immune responses in 
the airways. Both surfactant proteins are collectins that either directly bind bacterial 
lipopolysaccharides (LPS) or bind to the surface of pathogens which causes pathogen 
aggregation and subsequently removal by secretion of further antimicrobial substances 
like lysozyme (Fehrenbach, 2001; Hasenberg et al., 2013; Mason, 2006). In addition, 
surfactant proteins can act as opsonins and thereby enhance phagocytosis by local 
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immune cells such as alveolar macrophages (Fehrenbach, 2001; Hasenberg et al., 2013; 
Mason, 2006). Innate immune responses are supported by AT-II cells through the 
expression of TLRs, especially TLR2 and TLR4, as well as expression of complement factor 
C3 (Mason, 2006; Weitnauer et al., 2016). 
Like other AECs, AT-II cells secrete a variety of cytokines and chemokines including IL-1β, 
TNF-α, IL-6 and IL-8 that can modulate the differentiation and recruitment of various 
immune cells (Mason, 2006). AT-II cells have been shown to secrete monocyte 
chemotactic protein 1 (MCP-1) and RANTES (regulated on activation, normal T cell 
expressed and secreted) that both attract macrophages. SP-A is also able to regulate 
macrophage functions including the secretion of ROS or NO (Fehrenbach, 2001). 
Interestingly, AT-II cells express both major histocompatibility complex (MHC)-I and MHC-
II. In the context of autoimmunity, AT-II cells were found to be able to present antigens to 
CD4+ T cells via MHC-II molecules (Gereke et al., 2009). Nevertheless, the antigen-
presenting function of AT-II cells remains controversial and needs to be further evaluated. 
Moreover, activation and proliferation of T cells were shown to be decreased by SP-A and 
SP-D, as well as by the secretion of TGF-β (Fehrenbach, 2001). In addition, T cell tolerance 
towards non-pathogenic antigens in the alveoli was found to be induced by AT-II cells (Lo 
et al., 2008).  
 
1.2 Asthma - A Heterogeneous Disease 
 
Asthma is a highly prevalent disease of the airways leading to bronchoconstriction and 
chronic inflammation, and is associated with mucus hypersecretion and most importantly 
airway hyperresponsiveness (AHR) (Ishmael, 2011; Shifren et al., 2012). AHR refers to a 
condition in which the airways contract too easily, either spontaneously or in response to 
stimulation. Typical triggers are cold air, physical exercise, emotional stress, inhaled 
allergens and respiratory infections (Drazen et al., 2015; Ishmael, 2011). Asthma patients 
suffer from recurrent episodes of clinical symptoms comprising wheeze, cough, chest 
tightness and breathlessness (Drazen et al., 2015; Holgate, 2011a). Asthma symptoms are 
mostly intermittent and reversible, but in some patients they may persist with irreversible 
airway damage (Holgate, 2011a; Nakawah et al., 2013).  
Asthma can develop at any age, but first symptoms most often appear already during 
childhood. Most likely due to endocrine factors, women are more often affected than 
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men (Drazen et al., 2015; Langen et al., 2013; Martinez and Vercelli, 2013). During the last 
decades, asthma has become a major health problem in many countries worldwide with 
high socioeconomic importance due to the high increases in global prevalence and 
morbidity (Langen et al., 2013; Martinez and Vercelli, 2013). The World Health 
Organization (WHO) estimates that approximately 235 million people (status: 2013) 
worldwide suffer from asthma. In addition, it is the most common chronic disease in 
children. Due to the fact that asthma is often undiagnosed or undertreated especially in 
developing countries, the true number of asthma patients could be significantly higher 
(Martinez and Vercelli, 2013, WHO Asthma Fact Sheet No. 307, 2013).  
In the past, asthma was often believed to be a single disease entity. In recent years, 
however, it has become clear that asthma is a heterogeneous disease which involves a 
complex interplay of genetic and environmental factors (Campo et al., 2013; Ishmael, 
2011; Martinez and Vercelli, 2013). On the one hand, genome-wide association studies 
(GWAS) identified variations in a number of different genes related to a higher risk for the 
development of asthma (Martinez and Vercelli, 2013). On the other hand, the increased 
environmental exposure to certain allergens (house dust mite, pollen, animal dander, 
mould), tobacco smoke, chemicals and air pollution, is also a critical risk factor (Galli et al., 
2008; Holgate, 2011a; Martinez and Vercelli, 2013). Moreover, urbanization and Western-
lifestyle with excessive hygiene behavior ("hygiene-hypothesis") have been proposed to 
be disadvantageous (Liu, 2015; Ponte et al., 2016). 
Because of the heterogenic origin of asthma, several disease variants with different 
etiologic and pathophysiological outcomes exist (Campo et al., 2013; Ishmael, 2011; 
Rothe, 2013; Shifren et al., 2012; Wenzel, 2012). Occupational asthma, obesity-induced 
asthma, as well as intrinsic and non-atopic asthma are the best known examples (Campo 
et al., 2013; Rothe, 2013; Wenzel, 2012). Allergic or atopic asthma, however, is the most 
common variant accounting for about 60% of all cases. Furthermore, asthma phenotypes 
can be further subdivided into so-called endotypes based on distinct pathophysiological 
mechanisms including distinct biomarkers (Campo et al., 2013; Rothe, 2013).  
Noteworthy, asthma is often mistaken for chronic obstructive pulmonary disease (COPD). 
In contrast to asthma, COPD is characterized by permanent obstruction of the airways 
predominantly occurring in elderly people. In rare cases, asthma patients develop COPD 
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which is also known as asthma-COPD overlap syndrome (ACOS) (Drazen et al., 2015; 
Nakawah et al., 2013). 
 
1.2.1 Allergic Pathophysiology of Asthma 
 
Up to now, the exact mechanism underlying the development of the allergic inflammation 
in asthma is not fully understood. A complex interplay of cells of the innate and adaptive 
immune system together with structural cells of the lung and a plethora of inflammatory 
mediators initiates and drives the allergic cascade (fig. 3). 
Various birth cohort studies revealed that rhinovirus infections in infants are a major 
cause for the development of the allergic airway inflammation. Early viral infections lead 
to a substantial damage of the airway epithelium which makes it more susceptible to 
certain triggers (Guilbert and Denlinger, 2010; Martinez and Vercelli, 2013). Inhaled 
allergens are able to escape from mucociliary clearance and penetrate the disrupted 
airway epithelium. Professional APCs such as DCs recognize these allergens and 
subsequently phagocytose them. DCs migrate to local lymph nodes where they process 
them into small allergenic peptides which are presented to naïve T cells (Bloemen et al., 
2007; Galli et al., 2008; Verstraelen et al., 2008). Interaction of DCs with T cells is 
mediated via MHC-II molecules together with co-stimulatory molecules including B7-1 
and B7-2 (CD80 and CD86) (Holgate, 2012a). Naïve T cells undergo clonal expansion and 
differentiate into TH2 cells under the influence of polarizing cytokines, in this case mainly 
IL-4. This in turn leads to the production and secretion of TH2 cell-specific cytokines, most 
importantly IL-3, IL-4, IL-5, IL-9, IL-13 and GM-CSF that drive the following steps of the 
allergic cascade (Holgate, 2011a; Verstraelen et al., 2008). In addition, allergen-triggered 
AECs can also activate T cells and DCs by the secretion of IL-25, IL-33 and TSLP, which 
cause their migration into the airways. At the same time, these cytokines can also activate 
type 2 innate lymphoid cells (ILC2) that are another important source of TH2-specific 
cytokines and amplify the TH2 cell-specific responses in asthma (Holgate, 2012a; van Rijt 
et al., 2016; Scanlon and McKenzie, 2012). In comparison to TH2 cells, the exact role of 
ILC2 cells as source of TH2-specific cytokines is unknown (Fahy, 2015). ILC2 cells have been 
hypothesized to orchestrate the immune responses between AECs and cells of innate and 
adaptive immunity (van Rijt et al., 2016). 
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TH2 cells induce CSR in B cells mainly through secretion of IL-4 and IL-13, but also via the 
co-stimulatory molecule CD40L (Holgate, 2012a). During the allergic cascade, plasma cells 
mainly secrete IgE antibodies. IgE enters the systemic circulation and binds to its high-
affinity receptor FcεRI on mast cells and basophils (Bloemen et al., 2007; Galli et al., 
2008). Binding of IgE to mast cells, sensitizes them for future allergen re-exposure. Each 
IgE antibody, which is bound to a single mast cell, is specific for a distinct allergen (Galli et 
al., 2008). Thus, mast cells are the major effector cells during allergen sensitization and 
also in the early-asthmatic responses. These early-phase reactions usually occur within 
minutes after allergen re-exposure.  
 
Figure 3: Immunological pathways involved in the pathogenesis of allergic asthma. Following allergen 
sensitization, the early-phase response is mainly characterized by mast cell degranulation. This initiates the 
recruitment of additional inflammatory cells that secrete further pro-inflammatory mediators. During the 
late-phase response, eosinophils become the major effector cells of airway damage and dysfunction in 
allergic asthma. Eosinophil-dominated inflammation is induced and maintained by TH2 cells. Continuing 
allergen exposure leads to the development of chronic inflammation which is characterized by substantial 
damage of structural cells of the lung. Taken from Galli et al., 2008. 
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Allergens cross-link mast cell-bound IgE antibodies which leads to FcεRI aggregation and 
causes mast cell degranulation (Galli et al., 2008; Verstraelen et al., 2008). Subsequently, 
preformed inflammatory mediators such as histamine, serine proteases, TNF-α, 
prostaglandins and leukotrienes, as well as chemokines like IL-8 are released. The rapidly 
secreted mediators cause immediate symptoms like cough, bronchoconstriction and 
increased mucus secretion (Bloemen et al., 2007; Galli et al., 2008; Verstraelen et al., 
2008). Furthermore, mast cell degranulation also contributes to the initiation of the late-
phase asthmatic response, which occurs several hours after allergen re-exposure. Mast 
cell-derived inflammatory mediators promote the activation and recruitment of further 
inflammatory cells to the site of action (Galli et al., 2008).  
Allergen-stimulated TH2 cells are not only important in the induction of the allergic 
cascade, but also play a substantial role in the ongoing inflammation by excessive 
secretion of cytokines. Together with IL-4 and IL-13, IL-9 is known to mediate the 
generation of more mast cells and directly contributes to AHR and mucus hypersecretion 
(Bloemen et al., 2007). IL-5 and GM-CSF mediate eosinophil maturation and migration to 
inflamed sites (Bloemen et al., 2007; Holgate, 2012a; Verstraelen et al., 2008). As 
mentioned earlier, eosinophils are the major effector cells in this late-phase response. 
Secretion of eosinophil granule proteins such as major basic protein (MBP), eosinophil 
cationic protein (ECP), eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase 
(EP) cause major tissue damage especially to endothelial cells and the ECM (Bloemen et 
al., 2007). Together with TH2 cytokines, these eosinophil-derived mediators promote the 
recruitment of more eosinophils and TH2 cells to the inflammatory site, which fosters an 
ongoing eosinophil-driven inflammation in the allergic airways (Bloemen et al., 2007; 
Verstraelen et al., 2008). 
A chronic airway inflammation develops when allergen exposure is either repetitive or 
continuous. Then, airway remodeling occurs due to the persistent interaction between 
inflammatory cells and structural cells of the lung (Bloemen et al., 2007; Galli et al., 2008; 
Verstraelen et al., 2008). The formation of the so-called epithelial-mesenchymal trophic 
unit (EMTU) is the consequence of continuous damage to AECs and the underlying 
mesenchymal cells. This unit is thought to regulate airway remodeling by sustaining the 
TH2-specific response, e.g. through secretion of TSLP (Galli et al., 2008). Structural 
changes in the allergic airways include hyperplasia of goblet cells along with increased 
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mucus hypersecretion, deposition of ECM proteins such as fibronectin and collagen, as 
well as airway wall thickening which includes the airway epithelium, airway smooth 
muscle cells and the lamina reticularis. Moreover, subepithelial fibrosis and vascular 
permeability are induced (Bloemen et al., 2007; Galli et al., 2008; Verstraelen et al., 
2008). Eventually, airway remodeling substantially affects lung function and can lead to 
irreversible damage (Galli et al., 2008). 
 
1.2.2 Traditional and Novel Concepts for the Treatment of Asthma 
 
Current therapeutic approaches have little or no effect on the natural history of asthma, 
meaning they cannot prevent the development of the disease. Furthermore, these 
approaches are not able to cure asthma (Holgate, 2012b).  
As allergen sensitization is the crucial step in the development of asthma, allergen 
avoidance should be a good prophylactic strategy. However, this strategy is 
controversially discussed and had only limited success in the past (Holgate, 2013). 
Avoidance of common allergens such as house dust mite did not reduce asthma 
symptoms in adults whereas it seemed to be effective in children (Martinez and Vercelli, 
2013).  
In line with this notion, there has been only limited success with allergen-specific 
immunotherapy. Here, patients receive multiple injections of a distinct allergen to induce 
immunological tolerance towards that allergen. Once tolerance has been established, it 
can last for several years thereby preventing the development of asthma symptoms. 
Nevertheless, this method is only effective in patients that are sensitized to a single 
allergen (e.g. animal dander or pollen). Most asthma patients, however, are sensitized to 
multiple allergens (Holgate, 2013; Holgate and Polosa, 2008). Thus, environmental control 
and immunotherapy are less suitable approaches for asthma management, and 
symptom-relieving and controller therapies are still required to interfere with the 
inflammatory responses and airway remodeling processes (Holgate and Polosa, 2008). 
Pharmacological strategies include the use of anti-inflammatory agents and 
bronchodilators. 
For decades, inhaled GCs (ICs) have been a mainstay in the treatment of asthma. Despite 
the complexity of the disease, ICs effectively control asthma symptoms by suppressing 
the inflammatory responses in the allergic airways (Barnes, 2011a; Martinez and Vercelli, 
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2013). They are often used in combination with long-acting β2-agonists (LABAs) that are 
the most effective bronchodilators. LABAs like salmeterol and formoterol directly induce 
airway smooth muscle relaxation irrespective of the inciting bronchoconstricting stimulus 
(Barnes, 2011a, 2012). LABAs can potentiate GC-actions and vice versa. Both are very 
effective in improving lung function and in reducing asthma exacerbations (Barnes, 2012; 
Holgate and Polosa, 2008). Nevertheless, LABAs should never be used without GCs as this 
can worsen the inflammatory responses and lead to severe asthma exacerbations 
(Barnes, 2011a, 2012). In contrast to LABAs, short-acting β2-agonists (SABAs) like 
salbutamol and terbutaline are used alone (without GCs) and provide quick relieve of 
sudden asthma exacerbations (Holgate and Polosa, 2008). 
Other anti-inflammatory approaches include the use of leukotriene receptor antagonists. 
Leukotrienes are pro-inflammatory mediators that are mainly secreted by mast cells to 
promote tissue damage. Antagonists like montelukast have been shown to improve 
asthma symptoms by mediating airway smooth muscle relaxation and diminishing mucus 
secretion. Unfortunately, these beneficial effects are not as effective as those mediated 
by ICs (Barnes, 2011a; Holgate, 2012b; Martinez and Vercelli, 2013). 
An advanced understanding of the pathophysiological mechanisms of asthma has led to 
the development of biologic agents targeting distinct aspects of the allergic cascade. 
Omalizumab is currently the only monoclonal antibody for the treatment of asthma that 
has been approved by the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) (Barnes, 2012; Campo et al., 2013). It targets the Fcε3 region of IgE 
antibodies that is required for binding to the high-affinity receptor FcεRI. Hence, mast 
cell-mediated effects in the early-phase and late-phase of the allergic cascade can be 
blocked (Holgate, 2012b, 2013). Treatment with omalizumab has been shown to be very 
effective in reducing asthma symptoms, although part of the patients responded only 
moderately or were even completely refractory (Holgate, 2012b, 2013). So far, no 
biomarkers have been identified to distinguish between responders and non-responders 
of omalizumab (Barnes, 2012). Additional limiting factors are the large doses that are 
required to treat patients, as well as the resulting high costs of asthma treatment 
(Martinez and Vercelli, 2013). 
TH2 cytokines have been of major interest for the development of monoclonal antibodies 
in the treatment of asthma (Holgate, 2012a). They play crucial roles in different steps of 
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the allergic cascade and contribute to inflammation by interaction with other immune 
cells, as well as structural cells of the lung. 
Mepolizumab targets IL-5 which is an essential cytokine for eosinophil maturation and 
recruitment. Use of this antibody was found to reduce sputum and circulating eosinophils 
whereas airway-resident and bone marrow eosinophils were only reduced to half. 
Importantly, only selected patients showed improved symptoms (Holgate, 2012a, 2012b; 
Martinez and Vercelli, 2013). 
Pitrakinra is a mutated form of IL-4 that blocks binding of both IL-4 and IL-13 to the IL-4Rα 
receptor subunit. Treatment showed minor effects in the late-phase responses in selected 
patients. Thus, clinical studies with pitrakinra have been largely disappointing (Barnes, 
2012; Holgate, 2013; Martinez and Vercelli, 2013).  
IL-13 can be blocked by lebrikizumab, but again, symptoms were only improved in 
selected patients (Barnes, 2012; Holgate, 2012a; Martinez and Vercelli, 2013). In this case, 
however, the identification of periostin as a biomarker has been of major interest as it 
allows to distinguish between responders and non-responders to lebrikizumab treatment. 
High levels of periostin, an AEC-derived ECM protein, were found in those patients who 
responded well to the treatment (Holgate, 2012a; Martinez and Vercelli, 2013). 
Currently, many other monoclonal antibodies e.g. specific for IL-25, IL-33 and GM-CSF, are 
being tested in clinical trials for their use in asthma (Barnes, 2012). Nevertheless, these 
monoclonal antibodies mostly work in distinct endotypes of asthma with the expression 
of distinct biomarkers. Moreover, it is unlikely that interference with one single cytokine 
is sufficient for effective treatment as a plethora of inflammatory mediators is involved in 
the allergic responses of asthma (Barnes, 2012). 
 
1.2.3 Murine Models of Allergic Airway Inflammation 
 
The knowledge of the exact pathophysiology and immunomechanisms involved in the 
development of asthma is still incomplete. For obvious ethical reasons, comprehensive 
studies in asthma patients are restricted to morphological and in vitro analyses (Kips et 
al., 2003). In vitro models with specific cell lines seem to be informative for studying the 
asthma pathogenesis. However, their use is limited because they often do not reflect the 
in vivo situation sufficiently enough. In asthma, complex interactions between immune 
cells and structural cells of the lung, as well as other biological and chemical processes 
I n t r o d u c t i o n  | 15 
 
throughout the whole human body, mediate the outcome of the disease (Zosky and Sly, 
2007). 
For more than 100 years, animal models have been extensively used to investigate the 
different pathophysiological mechanisms in asthma. So far, most knowledge has been 
derived from numerous studies with animals although different aspects of the human 
situation are missing. Moreover, animal models are the best tool for developing and 
testing potential therapeutic approaches for asthma (Bates et al., 2009; Shin et al., 2009; 
Zosky and Sly, 2007). 
Mice are the most popular species for mimicking allergic responses in the airways. 
Amongst others, this is due to various practical advantages like low costs and a short 
gestation period (Bates et al., 2009; Shin et al., 2009). Furthermore, the availability of 
genetically characterized inbred strains allows good reproducibility (Kips et al., 2003). 
Different processes or molecules can easily be manipulated in mice by a wide range of 
immunological and molecular biological tools, allowing to gain a better understanding of 
their importance in asthma. This can be done by using transgenic technologies or by using 
distinct antagonists or agonists to interfere with that distinct molecule or process (Bates 
et al., 2009; Kips et al., 2003; Zosky and Sly, 2007).  
Under normal circumstances, mice do not develop asthma naturally. An allergic airway 
inflammation (AAI) needs to be induced which mimics the main features of the human 
disease (Kips et al., 2003; Nials and Uddin, 2008). Mice can be sensitized with different 
compounds to which they are normally not exposed. Model allergens include house dust 
mite, cockroach antigens, and aspergillus fumigatus, although ovalbumine (OVA) is most 
commonly used (Zosky and Sly, 2007). Mice are usually sensitized several times by 
intraperitoneal (i.p.) injections of the respective model allergen together with an 
adjuvant. In case of the AAI model, aluminium hydroxide (alum) is used to boost a TH2-
response. Following sensitization, allergen exposure is performed either by using aerosols 
or by nasal instillation of the respective allergen (Bates et al., 2009; Kips et al., 2003; Nials 
and Uddin, 2008). This strategy leads to a strong TH2-cell mediated inflammation in the 
airways characterized by elevated IgE levels, eosinophilia and structural changes like 
goblet cell hyperplasia and epithelial hypertrophy (Nials and Uddin, 2008; Zosky and Sly, 
2007). Of note, mice develop AHR only in response to bronchoconstricting stimuli like 
metacholine (Shin et al., 2009; Zosky and Sly, 2007). Another limiting factor is the lack of 
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chronicity in this acute model. Human asthma is characterized by chronic lung 
inflammation. In mice, however, approaches with long-term exposure to allergens failed 
to induce any chronic inflammation. Extended exposure rather led to decreased 
inflammatory responses in the airways with the development of immune tolerance 
towards the model allergen (Bates et al., 2009; Nials and Uddin, 2008; Zosky and Sly, 
2007). Unfortunately, there is no uniform model for allergen sensitization and exposure 
as different time points and durations of treatment can significantly influence the severity 
and outcome of inflammation (Bates et al., 2009). Additional limiting factors are obvious 
differences in human and murine lung physiology, as well as immunological differences 
(Zosky and Sly, 2007). 
Although murine models of AAI can provide promising results for future therapeutic 
approaches, interpretation and extrapolation to human asthma remain very challenging. 
 
1.3 ALI and Acute Respiratory Distress Syndrome - A Paradigm Shift 
 
In 1967, Ashbaugh and colleagues were the first to use the term "acute respiratory 
distress syndrome" (ARDS) to describe a group of critically ill patients with acute onset of 
respiratory failure (Ashbaugh et al., 1967). ARDS is not a distinct pulmonary disease but 
rather the most severe manifestation of a continuous inflammatory process that is known 
as acute lung injury (ALI) (Butt et al., 2016; Mackay and Al-Haddad, 2009). ALI can be the 
consequence to a plethora of inflammatory insults to the lung that can be either direct or 
indirect. Typical direct causes are pneumonia, gastric aspiration, contusion or pulmonary 
embolism. Indirect insults include sepsis, trauma, pancreatitis, blood transfusions and 
drug abuse (Howell and Bellingan, 2009). Most cases of ALI are associated with sepsis 
(Mackay and Al-Haddad, 2009). Of note, patients with similar insults would never show 
the same course of the disease since environmental factors such as age, sex, predisposing 
pulmonary diseases and smoking history substantially affect the pathogenesis (Howell 
and Bellingan, 2009). Currently, a lot of research is dealing with the role of genetic factors 
regarding the susceptibility and disease course of ALI. Certain polymorphisms in genes 
encoding for angiotensin converting enzyme (ACE), IL-10 or vascular endothelial growth 
factor (VEGF) were shown to be protective concerning mortality (Reddy and Kleeberger, 
2009; Sharp et al., 2015). 
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The multi-factorial origin of ALI extensively hinders its diagnosis. In general, ALI is 
characterized by its acute onset with bilateral pulmonary infiltrates of leukocytes, edema 
formation and hypoxia. Differential diagnosis is indispensable because of the non-specific 
symptoms. Other pulmonary diseases, as well as many cardiac diseases present with 
similar symptoms and need to be considered to allow correct diagnosis of ALI (Saguil and 
Fargo, 2012). Due to these diagnostic difficulties, ALI and ARDS remain underdiagnosed. 
Thus, ALI has a remarkable impact on public health care as there is a higher incidence 
than reported (Rubenfeld et al., 2005). It is estimated that approximately 17-34 persons 
per 100.000 develop ALI every year in the USA. Around 70% of all ALI patients suffer from 
ARDS and the mortality rate in ALI patients is between 35-40% (Laycock and Rajah, 2010; 
(Mackay and Al-Haddad, 2009). Importantly, patients mostly die due to complications of 
the underlying insult or multi-organ failure (Laycock and Rajah, 2010). 
 
1.3.1 Pathophysiology of ALI 
 
Regardless of the exact inflammatory insult, ALI patients show a similar pathophysiology 
which is incompletely understood (Mackay and Al-Haddad, 2009). The immune responses 
taking place in ALI are not locally restricted to the lung. Namely, the innate immune 
system plays a crucial role in regulating communication systemically between the lung 
and other organs that are directly involved in the progression of the disease (Han and 
Mallampalli, 2015).  
The acute or exudative phase of ALI starts a few hours after the initial direct or indirect 
inflammatory insult to the lung (fig. 4). Alveolar macrophages sense PAMPs and DAMPs 
via TLR-signaling. In response, they secrete a broad range of cytokines, most importantly 
IL-1β, IL-6, IL-8, IL-10 and TNF-α, which leads to the recruitment and activation of 
circulating monocytes and neutrophils, as well as other leukocytes (Butt et al., 2016; Han 
and Mallampalli, 2015; Johnson and Matthay, 2010).  
The excessive recruitment and activation of neutrophils is mediated by IL-8 and 
represents a major hallmark of the pathogenesis of ALI. Degranulation of neutrophils 
leads to the secretion of various pro-inflammatory mediators like leukotrienes, proteases, 
platelet-activating factors (PAFs), elastase and ROS. This results in hypoxemia and 
provokes massive epithelial and endothelial injury thus reducing the lung compliance. In 
I n t r o d u c t i o n  | 18 
 
addition, accumulation of neutrophils at inflamed tissue sites leads to the formation of 
so-called neutrophil-extracellular traps (NETs). On the one hand, NETs can build a barrier 
to inhibit further spread of pathogens. On the other hand, increased NETosis initiates cell 
death mechanisms and may cause additional tissue damage (Butt et al., 2016; Han and 
Mallampalli, 2015; Narasaraju et al., 2011; Sharp et al., 2015). Epithelial and endothelial 
cell injury and death provokes the disruption of the alveolar-capillary barrier integrity.  
 
Figure 4: An alveolus in a healthy and injured state during ALI. An insult to the lung leads to massive 
infiltration of leukocytes into the airways which is dominated by neutrophils. Alveolar macrophages secrete 
a plethora of inflammatory cytokines promoting tissue damage and airway dysfunction. Damage to the 
epithelial and endothelial barrier causes vascular leakage and the development of pulmonary edema. In 
addition, coagulation is initiated whereas fibrinolysis is impaired. Fibroblasts further promote alveolar 
damage by inducing fibrosis in the alveolar epithelium and endothelium. Figure taken from Johnson and 
Matthay, 2010. 
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Downregulation of sodium channels and sodium-potassium pumps impairs fluid transport 
in the alveoli (Johnson and Matthay, 2010; Sharp et al., 2015). Vascular leakage occurs 
and protein-rich edema fluid enters the alveoli and interstitium leading to the formation 
of hyaline membranes. Consequently, there is a loss in surfactant production by alveolar 
epithelial cells (Johnson and Matthay, 2010). 
In addition to the formation of pulmonary edema, platelet- and fibrin-rich thrombi are 
formed by impaired fibrinolysis and increased coagulation (Laycock and Rajah, 2010). The 
amount of neutrophils in the injured lung correlates with the severity of alveolar and 
capillary permeability, as well as hypoxemia. Enhanced neutrophilia serves as marker for 
poor survival (Mackay and Al-Haddad, 2009; Sharp et al., 2015). 
One week after disease onset, the proliferative phase occurs which is characterized by 
more pronounced damage of the alveolar-capillary barrier. AT-I cells undergo necrosis 
which denudes the epithelial basement membrane. This results in massive proliferation of 
AT-II cells (Howell and Bellingan, 2009; Mackay and Al-Haddad, 2009; Sharp et al., 2015). 
Moreover, fibrinous exudates are replaced by collagen fibrils mediating the invasion of 
fibroblasts into the alveolar lumen and interstitium (Howell and Bellingan, 2009). 
In some patients resolution of ALI can be observed which is not yet understood. The 
alveolar and capillary barrier is repaired, which results in the removal of protein-rich 
edema fluid from the alveoli. Furthermore, clearance of neutrophils is a prerequisite for 
this process (Sharp et al., 2015).  
Despite the potential resolution of ALI, most patients progress to the fibrotic and chronic 
phase of the disease starting approximately two weeks after onset (Sharp et al., 2015). 
While neutrophils are the major effector cells during disease onset, fibroblasts are the key 
players in this fibrotic phase. Excessive fibroblast proliferation leads to deposition of ECM 
and collagen. This contributes to epithelial and endothelial fibrosis which is known as 
fibrosing alveolitis (Laycock and Rajah, 2010). The dense fibrosis may cause pulmonary 
hypertension which worsens the impaired lung compliance and gas exchange, and may 
contribute to multi-organ failure in ALI patients (Howell and Bellingan, 2009; Sharp et al., 
2015). In the past, it was thought that these three disease phases progress sequentially. 
However, recent studies revealed that the three phases can also occur simultaneously 
(Howell and Bellingan, 2009). 
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1.3.2 Therapeutic Intervention for ALI 
 
Due to the incomplete understanding of its pathophysiology, treatment of ALI is very 
difficult. In general, it is essential to provide good supportive care while maintaining 
oxygenation. Furthermore, the underlying cause of ALI needs to be identified and 
immediately treated to inhibit further complications. Therapeutic strategies are thus 
based on ventilatory, non-ventilatory and pharmacological approaches. 
The use of many pharmacological approaches is debatable. Various studies have shown 
that most pharmacological agents are not effective in decreasing mortality. 
Application of exogenous lung surfactant improves oxygenation and alveolar surface 
tension (Howell and Bellingan, 2009). Inhaled nitric oxide (NO) has been shown to 
increase vasodilation in aerated areas of the lung which leads to the redistribution of the 
blood flow to these aerated areas (Diaz et al., 2010; Howell and Bellingan, 2009). The use 
of NO, however, is dangerous because it can react with ROS to form reactive nitrogen 
species which is highly cytotoxic to the alveolar epithelium (Diaz et al., 2010). More 
approaches include low-molecular weight heparin to prevent thromboembolism (Saguil 
and Fargo, 2012) and β2-agonists like salbutamol to increase alveolar fluid clearance by 
upregulating alveolar sodium channels and sodium-potassium pumps (Howell and 
Bellingan, 2009; Johnson and Matthay, 2010). 
GCs are popular due to their potent anti-inflammatory and anti-fibrotic activities. Studies, 
however, revealed a controversial role of GCs in the treatment of ALI. On the one hand, 
ALI symptoms were not improved after GC-treatment (Hough, 2014). On the other hand, 
GCs were shown to prevent the progression to ARDS and to reduce the mortality (Diaz et 
al., 2010; Marik et al., 2011). Many clinical trials are currently trying to assess the 
treatment parameters for more effective GC-treatment in ALI. 
If though treatment was successful, ALI survivors tend to have a lower quality of life. They 
have cognitive deficits, suffer from post-traumatic stress disorder and have a decreased 
lung function due to remarkable damage of the lung (Howell and Bellingan, 2009; Mackay 
and Al-Haddad, 2009; Saguil and Fargo, 2012). 
Thus, more research needs to be done to obtain a better understanding of ALI and 
subsequently to develop better strategies to treat this disease while preventing 
complications at the same time.  
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1.3.3 Murine Models of ALI 
 
Similar to asthma, mice are the most popular species to study the pathomechanisms of 
ALI. Murine models mimic major characteristics of human ALI like the disrupted alveolar-
capillary barrier, damaged epithelial and endothelial cells, massive influx of inflammatory 
cells into the airways, and signs of fibrosing lung tissue.  
A frequently employed ALI model is the use of bacterial endotoxins. LPS are glycolipids 
that are found in the outer membrane of gram-negative bacteria. They activate 
CD14/TLR4 receptors on monocytes and other myeloid cells that subsequently secrete 
various pro-inflammatory mediators (Matute-Bello et al., 2008). In addition, LPS plays a 
crucial role in bacterial sepsis which is one of the most common predisposing conditions 
of ALI. In general, LPS exposure primarily affects the endothelium. Apoptosis of 
endothelial cells leads to further tissue damage which is characterized by injured AT-I and 
AT-II cells, as well as accumulation of neutrophils (Matute-Bello et al., 2008). Noteworthy, 
the route of LPS administration in mice can determine the severity of the lung injury. 
Intraperitoneal injection of LPS leads to a mild form of ALI but instead causes a systemic 
inflammation in mice (Bastarache and Blackwell, 2009). In contrast, intratracheal 
application of LPS leads to massive influx of neutrophils and other inflammatory cells into 
the airways (Bastarache and Blackwell, 2009; Matute-Bello et al., 2008). 
Oleic acid (OA) is the most common free fatty acid in the human body that is present in 
plasma, cell membranes and adipose tissue. Intravenous administration of OA in mice 
favorably targets the lung as it comprises around 85% free fatty acids (Gonçalves-de-
Albuquerque et al., 2015). In contrast to LPS, OA induces necrosis of endothelial cells by 
direct toxic effects (Matute-Bello et al., 2008). In addition, an injured alveolar epithelium 
leads to a disturbed barrier function and subsequent pulmonary edema formation. This is 
accompanied by microvascular thrombosis (Gonçalves-de-Albuquerque et al., 2015; 
Matute-Bello et al., 2008). Pulmonary emboli in trauma patients contain approximately 
50% OA (Matute-Bello et al., 2008). Therefore, the OA model has widely been used to 
model trauma-related lung injury.  
Up to now, no single murine model is able to replicate all pathogenic characteristics of ALI 
(Bastarache and Blackwell, 2009; Matute-Bello et al., 2008). Thus, murine models with 
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more than one injurious insults to the lung may reflect of the human situation better 
("two-hit hypothesis") (Matute-Bello et al., 2011).  
 
1.4 Glucocorticoids in Inflammatory Lung Diseases 
 
It has been 70 years since Hench and colleagues discovered the powerful use of the GC 
cortisone to treat symptoms of rheumatoid arthritis, a discovery that revolutionized the 
field of medicine (Kadmiel and Cidlowski, 2013). Since then cortisone and its synthetic 
analogues such as prednisolone, dexamethasone (Dex) and budesonide have been widely 
used to treat various inflammatory disorders like asthma, multiple sclerosis, dermatitis 
and ulcerative colitis (Buttgereit, 2012; Cruz-Topete and Cidlowski, 2015). Up to now, GCs 
have been the most prescribed drug worldwide due to their broad availability, cost-
efficacy and potent anti-inflammatory activities (Cruz-Topete and Cidlowski, 2015; Stahn 
and Buttgereit, 2008). 
GCs such as cortisol in humans and corticosterone in rodents belong to the family of 
steroid hormones. The so-called hypothalamus-pituitary-adrenal (HPA)-axis dynamically 
regulates their synthesis in a circadian and ultradian manner (Kadmiel and Cidlowski, 
2013). In response to stressful stimuli including inflammation, the hypothalamus secretes 
corticotrophin-releasing hormone (CRH), which in turn acts on the pituitary gland to 
secrete adrenocorticotropic hormone (ACTH) (fig. 5). Subsequently, ACTH induces the 
release of GCs such as cortisol by the adrenal cortex (Cruz-Topete and Cidlowski, 2015; 
Gupta and Bhatia, 2008; Rhen and Cidlowski, 2005).  
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Figure 5: GC release is mediated by the HPA-axis. The hypothalamus secretes CRH, which stimulates the 
pituitary gland to release ACTH. This leads to secretion of cortisol (in humans) by the adrenal cortex. 
Biologically active cortisol can be converted to inactive cortisone by type 2 11β-HSD and vice versa by type 1 
11β-HSD. GCs modulate many fundamental processes in the body by interacting with the GR, which is 
expressed in virtually all cell types. Figure taken from Cruz-Topete and Cidlowski, 2015.  
 
After having its release, most cortisol is bound to corticosteroid-binding globulin in blood. 
However, only free cortisol represents the biologically active form of the hormone (Rhen 
and Cidlowski, 2005). Cortisol can be converted to the biologically inactive form cortisone 
by type 2 11β-hydroxysteroid dehydrogenase (HSD). Conversely, cortisone can be 
converted to active form cortisol by type 1 11β-HSD (Cruz-Topete and Cidlowski, 2015; 
Rhen and Cidlowski, 2005). In addition, circulating cortisol can act on the hypothalamus 
and the pituitary gland to inhibit the secretion of further CRH and ACTH thereby 
constituting a negative feedback mechanism. Hereby, cortisol homeostasis is achieved 
(Gupta and Bhatia, 2008; Rhen and Cidlowski, 2005). 
Almost all GC-effects are mediated by the glucocorticoid receptor (GR), which is 
ubiquitously expressed throughout the human body in virtually all cell types and tissues. 
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Hereby, GCs control many biological processes such as immune responses, development, 
reproduction or metabolic homeostasis (Vandevyver et al., 2013). 
 
1.4.1 Genomic and Non-Genomic Effects 
 
The GR belongs to the nuclear receptor family of ligand-activated transcription factors. It 
is encoded by the NR3C1 gene, which is located on chromosome 5q 31-32 in humans 
(Kadmiel and Cidlowski, 2013; Rhen and Cidlowski, 2005). The GR is composed of three 
functional domains comprising an N-terminal transactivation domain (NTD), DNA-binding 
domain (DBD), C-terminal ligand-binding domain (LBD), and a flexible hinge region linking 
the DBD and LBD (fig. 6 A). The NTD contains an activation function (AF-1), which is 
important for the recruitment of co-regulators and the transcriptional machinery (Cruz-
Topete and Cidlowski, 2015; Kadmiel and Cidlowski, 2013). Furthermore, the AF-1 
comprises most residues of the GR that are target of post-transcriptional modifications 
(PTMs) such as the phosphorylation of serine residues (Cruz-Topete and Cidlowski, 2015). 
The DBD contains two zinc finger motifs that are required for DNA binding. Specific DNA 
sequences in GC-target genes are recognized and bound by the DBD (Cruz-Topete and 
Cidlowski, 2015; Kadmiel and Cidlowski, 2013). Besides, dimerization of the GR relies on 
the second zinc finger motif (Vandevyver et al., 2013). The LBD has an ligand-dependent 
AF-2 that interacts with transcriptional co-regulators (Kadmiel and Cidlowski, 2013; Tan 
and Wahli, 2016). Nuclear localization signals present in the DBD, LBD and hinge region 
mediate the GR's translocation into the nucleus (Kadmiel and Cidlowski, 2013). 
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Figure 6: Structure of the GR and its mechanisms of transcriptional regulation. The GR contains several 
functional domains: NTD, DBD, hinge region and LBD (A). Following ligand binding, the GR is released from a 
multi-protein complex consisting HSPs and immunophilins, and then translocates into the nucleus guided by 
importins. Control of target gene expression is regulated in a transactivating manner by GR dimers 
recruiting co-activators, or in a transrepressing manner by GR monomers interacting with other 
transcription factors (TF) and recruiting co-repressors. Besides these two major modes of GC-action, 
additional ones exist (not shown). 
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In absence of ligands, the GR resides in the cytoplasm within a multimeric protein 
complex comprised of chaperone proteins such as heat shock proteins (hsp90 and hsp70), 
immunophilins (FKBP51 and FKBP52) and other inhibitory proteins (p23 and SRC) (Cruz-
Topete and Cidlowski, 2015; Stahn and Buttgereit, 2008). This multimeric protein complex 
inhibits degradation of the GR (Vandevyver et al., 2013). Due to their lipophilic properties, 
GCs can easily diffuse across the cell membrane. Upon GC binding in the cytoplasm, the 
GR undergoes conformational changes, which mediate its dissociation from the protein 
complex. Nuclear import proteins importin-α and importin-13 bind to the GC-GR complex 
allowing the complex to move into the nucleus (Barnes, 2011b; Kadmiel and Cidlowski, 
2013; Stahn and Buttgereit, 2008). 
In the nucleus, the GR is able to either enhance or repress transcriptional activity of GC-
target genes by different mechanisms (fig. 6 B). The GC-GR complex is able to form 
homodimers that bind with high affinity to GC-responsive elements (GREs) present in the 
promoter region of GC-responsive genes (Barnes, 2011b; Kadmiel and Cidlowski, 2013; 
Stahn and Buttgereit, 2008). Once bound to a GRE, the transactivation domains serve as 
docking platforms for transcriptional co-activators like CREB (cAMP response element-
binding protein)-binding protein. These ones have an intrinsic histone-acetyltransferase 
(HAT) activity which mediates chromatin remodeling and association of RNA polymerase 
II. Subsequently, transcription of anti-inflammatory and regulatory proteins is switched-
on in a transactivating manner (Barnes, 2011b; Kadmiel and Cidlowski, 2013). 
Alternatively, the GR is able to interact with other transcription factors such as NF-κB, AP-
1 or STAT3 that regulate the transcription of pro-inflammatory genes, which proceeds in 
similar manner as GR-mediated transactivation (Barnes, 1998; Kadmiel and Cidlowski, 
2013). In this case, however, the ligand-bound GR binds as a monomer to these pro-
inflammatory transcription factors via so-called tethering mechanisms to form a protein-
protein complex thereby initiating the recruitment of co-repressors (Barnes, 1998; 
Vandevyver et al., 2013). These co-repressors are often histone-deacetylases (HDACs) 
that prevent chromatin-remodeling and activation of RNA-polymerase II. Consequently, 
inflammatory gene transcription is repressed in a transrepressing manner (Barnes, 
2011b).  
Less commonly, the homodimerized GR is also capable to repress target gene expression. 
This is mediated by binding to inverted palindromic negative GREs (nGREs) which leads to 
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co-repressor recruitment (Barnes, 2011b; Kadmiel and Cidlowski, 2013; Vandevyver et al., 
2013). Moreover, the monomeric GR can directly bind to GREs by interacting with 
neighboring DNA-bound transcription factors. This composite mechanism can initiate 
both activation and repression of target genes (Cruz-Topete and Cidlowski, 2015).  
PTMs including phosphorylation, acetylation or ubiquitination contribute to the diversity 
of GR-mediated actions. Transcriptional activity can either be increased or decreased by 
distinct PTMs (Kadmiel and Cidlowski, 2013; Tan and Wahli, 2016). Dimerization and DNA-
binding have been shown to be modulated by phosphorylation of AF-1 in the NTD, for 
example (Tan and Wahli, 2016). 
Of note, GCs are able to exert some of their effects more rapidly in a way that is 
independent of changes in target gene expression. These non-genomic mechanisms are 
mediated by the cytosolic GR or a membrane-bound GR (Stahn and Buttgereit, 2008). 
Mainly signal transduction pathways like the MAPK/ERK pathway are thought to be 
modulated by these mechanisms (Kadmiel and Cidlowski, 2013). A well described non-
genomic effect is the influence of GCs on endothelial NO synthase (eNOS) in human 
endothelial cells. The GC-bound GR activates PI3K (phosphatidylinositol-3-kinase), which 
in turn phosphorylates Akt. Subsequently, Akt phosphorylates eNOS which triggers the 
production of NO. Vasodilation and vascular permeability can be influenced by this 
mechanism (Rhen and Cidlowski, 2005). Nevertheless, the non-genomic mechanisms are 
not fully elucidated and their biological implications remain unclear. 
 
1.4.2 Anti-Inflammatory Effects of GCs in Respiratory Diseases 
 
In general, GCs control inflammatory processes in the airways by interfering with the 
expression of both anti-inflammatory and pro-inflammatory genes. Interestingly, 
inhibition of the pro-inflammatory transcription factor NF-κB can be mediated by both GR 
mechanisms. GCs directly suppress NF-κB expression via the transrepressing mechanism 
while it can be indirectly suppressed by upregulation of the inhibitor IκB-α via the 
transactivating mode of action (Barnes, 1998). A plethora of anti-inflammatory and pro-
inflammatory genes encoding for cytokines, chemokines, proteins, enzymes or adhesion 
molecules can be influenced by GC-treatment in the airways, as listed in table 1. 
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Increased Transcription by Transactivation 
Dual Specificity Protein Phosphatase 1 
(DUSP1) 
Inhibitor of MAPK-Pathway 
Glucorticoid-Inducible Leucine Zipper 
(GILZ) 
Transcriptional Regulator of GC Function 
IL-1R, IL-10, IL-12 Anti-Inflammatory Cytokines 
IκB-α Inhibitor of NF-κB 
Lipocortin-1 Inhibitor of Prostaglandin Formation 
Secretory Leukocyte Inhibitory Protein 
(SLPI) 
Inhibitor of Serine Proteases 
β2-Adrenoceptors Mediator of Airway Smooth Muscle 
Relaxation 
 
Decreased Transcription by Transrepression 
CCL1, IL-8, RANTES, MIP-1α, MCP-1/-3/-4,  Chemokines 
ICAM-1, VCAM-1, E-Selectin Adhesion Molecules 
IL-1, IL-2, IL-4, IL-5, IL-6, IL-9, IL-13, TNF-α, 
GM-SCF, TSLP 
Pro-Inflammatory Cytokines 
iNOS, Cyclo-Oxygenase (COX)-2 Inflammatory Enzymes 
MUC2, MUC5a Mediators of Mucus Secretion 
Table 1: Transactivation and transrepression of inflammatory cytokines associated with respiratory 
diseases. Adapted from Barnes, 2011b. 
 
By suppressing various inflammatory mediators, GCs exert profound effects on nearly all 
cells of the immune system. The numbers of immune cells in the inflamed airways, such 
as eosinophils, mast cells, DCs, macrophages, B cells or T cells, can be reduced by 
different mechanisms (Barnes, 1998, 2011b; Kadmiel and Cidlowski, 2013). Migration to 
the site of inflammation is mainly inhibited by repression of adhesion molecules and 
chemokines (table 1), but GCs can also induce apoptosis of immune cells, mainly of 
eosinophils and T cells (Barnes, 2003). Eosinophil survival is mediated by secretion of IL-5 
in the airways which is suppressed by GCs (Barnes, 1998). GCs promote T cell apoptosis 
although the pro-apoptotic mechanisms are not fully understood. In contrast, GCs can 
also promote survival of anti-inflammatory cells like regulatory T (Treg) cells and increase 
their numbers in the inflamed airways (Kadmiel and Cidlowski, 2013). 
Moreover, GCs can influence various immune cells functions. Antigen-presentation of DCs 
is dampened by suppressing DC maturation (Barnes, 1998; Kadmiel and Cidlowski, 2013). 
GCs also decrease the antibody-production of B cells and inhibit the release of further 
pro-inflammatory mediators by other immune cells (Kadmiel and Cidlowski, 2013).  
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GCs also have immunomodulatory and immunosuppressive effects by interfering with the 
maturation, activation and proliferation of immune cells (Barnes, 1998, 2003, 2011b; 
Kadmiel and Cidlowski, 2013). Nevertheless, the exact mechanisms and target sites of GCs 
remain unclear and remain to be investigated for each lung disease. 
 
1.4.3 These Days Pessimism Towards GCs: Adverse Effects and GC-Resistance 
 
Despite their potent anti-inflammatory activities, GCs can also induce numerous adverse 
effects. The development and incidence of side effects is determined by the duration and 
dose of the treatment, the mode of application and the individual susceptibility (Schäcke 
et al., 2002). Prolonged GC-treatment has been shown to be a major risk factor while 
high-dose treatment seemed to be less problematic. Systemic exposure to GCs is directly 
related to the development and severity of side effects (Dahl, 2006; Schäcke et al., 2002). 
However, topic GCs are also known to cause not only local, but systemic side effects as 
well. ICs for instance may be absorbed in the airways and reach the circulation where 
they can affect other organs than the lung (Dahl, 2006; Rhen and Cidlowski, 2005). Of 
note, pharmacokinetic parameters like the clearance rate, half-life, distribution and 
accumulation play a crucial role regarding the systemic exposure of topic GCs (Dahl, 
2006). 
A particular serious side effect is the imbalance of the HPA-axis. Prolonged GC-treatment 
leads to a downregulation of ACTH production thereby disturbing basal cortisol secretion. 
The adrenal gland is no longer able to produce sufficient amounts of cortisol that are 
required for daily physiology (Gupta and Bhatia, 2008). Suppression of the HPA-axis can 
lead to adrenal crisis ("Addison's disease"), whereas excess GCs lead to an upregulation of 
ACTH that causes excessive cortisol release from the adrenal gland ("Cushing's 
syndrome") (Dahl, 2006; Rhen and Cidlowski, 2005). GC-treatment can cause further 
endocrine and metabolic disturbances including growth retardation in children, increased 
body weight and fat redistribution, as well as the development of diabetes. Other adverse 
effects are skin thinning and impaired wound repair, osteoporosis, hypertension and 
myopathy. Of note, there is an increased risk of infections due to the excessive 
immunosuppression (Dahl, 2006; Rhen and Cidlowski, 2005; Schäcke et al., 2002; Stahn 
and Buttgereit, 2008). 
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Dependent on the treatment regimen and particular patient, single or multiple adverse 
effects can develop in different organs with different prevalence (Schäcke et al., 2002). 
Adverse effects may be mediated by genomic or non-genomic mechanisms of GCs. 
Nevertheless, many side effects were found to be associated with the transactivating 
mode of action (Schäcke et al., 2002; Stahn and Buttgereit, 2008).  
It is noteworthy that adverse effects are a limiting factor for the GC-treatment of various 
inflammatory diseases; therefore the benefit-risk ratio needs to be carefully taken into 
account for each patient. 
Another limiting factor for the use of GCs is the occurrence of GC-resistance. Most clinical 
symptoms of patients with inflammatory diseases are well controlled by low dose GC-
treatment. However, a number of patients fail to respond to GCs even at high doses, and 
multiple mechanisms have been speculated to contribute to the development of this 
resistance (Barnes, 2013).  
GC-resistance was identified in families of non-responders. This familial GC-resistance 
(FGR) is characterized by high levels of circulating cortisol without symptoms of Cushing's 
syndrome (Barnes, 1998, 2011b). Furthermore, distinct polymorphisms of the NR3C1 
gene with modified transcripts of the GR were shown to influence the sensitivity to GCs 
(Barnes, 2011b; Kadmiel and Cidlowski, 2013). Defective GR-binding and translocation 
also contribute to GC-resistance which is mainly due to altered phosphorylation by 
kinases such as p38 MAPK (Kadmiel and Cidlowski, 2013). An additional mechanism is an 
increased histone acetylation with reduced HDAC activity (Barnes, 2011b; Kadmiel and 
Cidlowski, 2013). Hyperactivity of pro-inflammatory transcription factors like AP-1 was 
also found to be a critical mechanism, as GR-binding to GREs and other transcription 
factors is impaired (Barnes, 2013; Kadmiel and Cidlowski, 2013). Moreover, many GC-
resistant patients show altered lymphocyte functions. In response to GCs, Treg cells for 
instance fail to secrete IL-10 whereas increased numbers of TH17 cells increase IL-17 
production simultaneously (Barnes, 2013).  
A better understanding of the mechanisms leading to the GC-mediated adverse effects 
and GC-resistance is substantial for the development of novel drugs that maintain the 
beneficial effects of GCs and at the same time overcome these limiting factors. 
 




GCs have been a mainstay in the treatment of asthma for many years despite the severe 
side effects they can induce. However, the exact mechanisms of GCs have not been fully 
elucidated. 
Previous findings indicated that the anti-inflammatory effects of GCs in allergic asthma 
rely on the transactivating mechanism of the GR as shown by the analysis of AAI in GRdim 
mice carrying a point mutation that impairs GR-dimerization (unpublished data). Further 
experiments had revealed that the therapeutic effects of GCs depended on the control of 
cells other than those of hematopoietic origin (unpublished data). From this it was 
concluded that structural cells of the lung rather than immune cells might be crucial 
targets for GC-treatment. 
In particular AECs play an important role in the pathogenesis of asthma by secreting 
various pro- or anti-inflammatory mediators that modulate the immune responses in the 
asthmatic lung. Therefore, it was hypothesized that AECs might be potential targets in the 
treatment of asthma with GCs. 
To test a possible connection between mechanism and site of action, RNA sequencing 
(RNA-seq) analysis should be performed with AECs from wild type and GRdim mice. 
Differences in the transcriptome should be identified during the allergic response, as well 
as following subsequent treatment with Dex. To this end, a protocol for the isolation and 
purification of AECs should be established. Newly identified candidate genes should be 
examined in detail by quantitative real-time PCR (qRT-PCR). 
To further investigate the role of AECs as potential targets for the GC-treatment in 
asthma, AAI should be induced in GRspc mice. These mice are GR-deficient specifically in 
AT-II cells. Different experimental approaches should be employed to address the GC-
efficacy. 
GCs are also used in other inflammatory lung diseases such as ALI. Thus, AECs should also 
be investigated as potential targets of the GC-treatment in murine ALI. Various 
experimental approaches should be used to test the relevance of AECs in the GC-
treatment of ALI. 
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3.1.1 General Equipment 
 
Instrument Manufacturer 
Anesthetic Machine VS 4255 VisualSonics, Toronto, Canada 
Camera Colorview Olympus, Tokio, Japan 
Centrifuges: 
Centrifuge 5804-R 






Eppendorf, Hamburg Germany 
Heraeus, Hanau, Germany 
Sigma Laborzentrifugen, Osterode am 
Harz, Germany 
Eppendorf, Hamburg, Germany 
Carl Roth, Karlsruhe, Germany 
Chemiluminiscence Imaging System 
Chemocam Imager 
Intas, Göttingen, Germany 
Electrophoresis Chamber Systems: 
Horizontal System Type 40-0708, 40-1214,  
40-1410 
Vertical System Mini-Protean Tetra Cell 
 
Peqlab Biotechnology, Erlangen, Germany 
 
BioRad, München, Germany 
Electrophoresis Power Supplies: 
EPS 301 
Power Pac Basic 
 
Amersham Biosciences, Freiburg, Germany 
BioRad, München, Germany 
Flow Cytometer FACS Canto II BD Biosciences, Heidelberg, Germany 
Gel Documentation System Gel iX Imager Intas, Göttingen, Germany 





Zeiss, Jena, Germany 
Olympus, Tokio, Japan 
Magnetic Cell Separator (MACS) 
autoMACS 
Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Microplate Reader and 
Spectrophotometer Power Wave 340 
BioTek Instruments, Bad Friedrichshall, 
Germany 
Microtome SH2000R Leica Biosystems, Wetzlar, Germany 
Neubauer Improved Hemocytometer Henneberg-Sander, Giessen, Germany 
Photometer Nanodrop 2000 Peqlab Biotechnology, Erlangen, Germany 
Table 2: List of general equipment. 
  




Micropipette 0.1-2.5 µl, 2-20µl, 20-200µl 
and 100-1000 µl Research 
Micropipette 0.5-10 µl Reference 
Multichannel Pipette S-12 20-200 µl 
 
Eppendorf, Hamburg, Germany 
 
Eppendorf, Hamburg, Germany 
Brand, Wertheim, Germany 
Pipetting Aid Easypet 3 Eppendorf, Hamburg, Germany 





Sartorius, Göttingen, Germany 
Sartorius, Göttingen, Germany 
Shaker GFL 3006 Gesellschaft für Labortechnik, Burgwedel, 
Germany 
Sterile Bench Hera Safe Heraeus, Hanau, Germany 
Thermocycler Mastercycler EP Gradient Eppendorf, Hamburg, Germany 
Thermomixer Comfort Eppendorf, Hamburg, Germany 
Tissue Embedding System EG1160 Leica Biosystems, Wetzlar, Germany 
Tissue Homogenizer Ultra Turrax T18 Basic  IKA, Staufen, Germany 
Tissue Processor TP1020 Leica Biosystems, Wetzlar, Germany 
Vortex Genie-2 Scientific Industries, Bohemia, NY, USA 
Water Bath W12 Labortechnik Medingen, Dresden, 
Germany 
Water Purification System Arium 611 Sartorius, Göttingen, Germany 





6-Well and 48-Well Suspension Culture 
Plates Cellstar 
Greiner BioOne, Frickenhausen, Germany 
96-Well Flat Bottom Plate Nunc Maxisorp eBioscience, San Diego, CA, USA 
96-Well Optical Reaction Plate MicroAmp Applied Biosystems, Foster City, CA, USA 
Activated Charcoal Adsorption Filter 
Vaporguard 
VetEquip, Livermore, CA, USA 
Animal Feeding Needle 20G x 1.5" Fine Science Tools, Foster City, CA, USA 
Blotting Paper Whatman GB005 Sigma-Aldrich, Taufkirchen, Germany 
Cannula Sterican 26G x ⅟2" (0.45 x 12 mm)  B. Braun, Melsungen, Germany 
Cell Culture Dish Cellstar 100 x 20 mm Greiner BioOne, Frickenhausen, Germany 
Cell Strainer 40 µm and 100 µm Greiner BioOne, Frickenhausen, Germany 
Centrifuge Tubes 15 ml and 50 ml Greiner BioOne, Frickenhausen, Germany 
Table 4: List of consumables. 
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Consumable Manufacturer 
FACS Tubes 5 ml BD Biosciences, Heidelberg, Germany 
Glass Pipettes 5 ml, 10 ml, 20 ml and  
25 ml 
Brand, Wertheim, Germany 
MACS Columns autoMACS Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Microscope Cover Slips 24 x 60 mm Menzel-Gläser, Braunschweig, Germany 
Microscope Slides SuperFrost Plus Menzel-Gläser, Braunschweig, Germany 
Nitrocellulose Membrane Hybond-ECL Amersham Biosciences, Freiburg, Germany 
Optical Adhesive Cover MicroAmp Applied Biosystems, Foster City, CA, USA 
Parafilm Bemis, Neenah, WI, USA 
Pasteur Pipettes Labsolute 3 ml Th. Geyer, Renningen, Germany 
PCR Tubes Multiply-µStrip Pro 8-Strip Sarstedt, Nümbrecht, Germany 
Pipette Tips: 
Clear 0.1-10 µl 
Yellow 10-200 µl 
Blue 100-1.000 µl 
 
Greiner BioOne, Frickenhausen, Germany 
Greiner BioOne, Frickenhausen, Germany 
Greiner BioOne, Frickenhausen, Germany 
Round Bottom Culture Tube 14 ml Greiner BioOne, Frickenhausen, Germany 
Safe-Lock Tubes 1.5 and 2 ml Greiner BioOne, Frickenhausen, Germany 
Serological Pipettes Cellstar 5 ml, 10 ml 
and 25 ml 
Greiner BioOne, Frickenhausen, Germany 
Syringes: 
Diabetic Syringe Micro-Fine + Demi 0.3 ml 
30G x 8 mm 
Diabetic Syringe Micro-Fine + Demi 1 ml 
29G x 12.7 mm 
Syringe Injekt-F Tuberculin 1 m 
Syringe Discardit II 2 ml, 10 ml and 20 ml 
 
BD Medical Diabetes Care, Le Pont de Claix 
Cedex, France 
BD Medical Diabetes Care, Le Pont de Claix 
Cedex, France 
BD Biosciences, Heidelberg, Germany 
BD Biosciences, Heidelberg, Germany 
Tissue Cassettes MacrOflow Microm International, Walldorf, Germany 
Tissue Culture Dish 60 x 15 mm Sarstedt, Nümbrecht, Germany 
Venous Catheter Venflon Pro 0.9 x 25 mm BD Infusion Therapy, Helsingborg, Sweden 
Table 5: List of consumables continued. 
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3.1.3 Chemicals and Reagents 
 
Name Manufacturer 
5x Phusion Reaction Buffer HF with 7.5 
mM Magnesium Chloride 
Genaxxon Biosciences, Ulm, Germany 
10x PCR Buffer S with 1.5 mM Magnesium 
Chloride 
Genaxxon Biosciences, Ulm, Germany 
Acetic Acid Glacial Sigma-Aldrich, Taufkirchen, Germany 
Agarose Ultra Low Gelling Temperature 
Type IX-A 
Sigma-Aldrich, Taufkirchen, Germany 
Agarose Ultrapure Invitrogen, Carlsbad, CA, USA 
Albumine from Chicken Egg White, Grade 
V (Ovalbumine; OVA) 
Sigma-Aldrich, Taufkirchen, Germany 
Alhydrogel 2% (Alum) InVivoGen, Toulouse, France 
Ammonium Persulfate (APS) Sigma-Aldrich, Taufkirchen, Germany 
Bovine Serum Albumine (BSA) Carl Roth, Karlsruhe, Germany 
Bradford Reagent Sigma-Aldrich, Taufkirchen, Germany 
Bromophenol Blue Merck, Darmstadt, Germany 
Chloroform Sigma-Aldrich, Taufkirchen, Germany 
Citric Acid Monohydrate Merck, Darmstadt, Germany 
Dexamethasone (Dex) Dexa-Ratiopharm 
Injection Solution 
Ratiopharm, Ulm, Germany 
Dimethyl Sulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Disodium Hydrogen Phosphate Sigma-Aldrich, Taufkirchen, Germany 
Dispase 50 U/ml BD Biosciences, Heidelberg, Germany 
DNase I 2000 U/mg Sigma-Aldrich, Taufkirchen, Germany 
dNTP Mix PCR Genaxxon Biosciences, Ulm, Germany 
Entellan Merck, Darmstadt, Germany 
Eosin Y Yellowish Merck, Darmstadt, Germany 
Ethanol Carl Roth, Karlsruhe, Germany 
Ethidium Bromide Solution Carl Roth, Karlsruhe, Germany 
Ethylendiaminetetraacetic Acid (EDTA) Sigma-Aldrich, Taufkirchen, Germany 
Fetal Bovine Serum (FBS) Invitrogen, Carlsbad, CA, USA 
Forene 100% (v/v) (Isoflurane) Abbvie, Ludwigshafen, Germany 
Generuler DNA Ladder 1 kb Fermentas, St.-Leon-Rot, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Hemalum Solution Acid acc. to Mayer Carl Roth, Karlsruhe, Germany 
Hydrogen Peroxide 30% Carl Roth, Karlsruhe, Germany 
Igepal CA-630 Sigma-Aldrich, Taufkirchen, Germany 
Table 6: List of chemicals and reagents. 
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Name Manufacturer 
Isopropanol Carl Roth, Karlsruhe, Germany 
Lipopolysaccharide (LPS) from e. coli 
(055:B5) 
Sigma-Aldrich, Taufkirchen, Germany 
Luminol Serva Electrophoresis, Heidelberg, 
Germany 





with Anti-SP-C Antibody (BNPs-SPC) 
 
Prof. Claus Feldmann, Karlsruhe Institute of 
Technology, Karlsruhe, Germany 
Prof. Claus Feldmann, Karlsruhe Institute of 
Technology, Karlsruhe, Germany 
Oleic Acid (OA) Sigma-Aldrich, Taufkirchen, Germany 
Orange G Sodium Salt Sigma-Aldrich, Taufkirchen, Germany 
Paraffin Wax for Histology Sigma-Aldrich, Taufkirchen, Germany 
p-Coumaric Acid Carl Roth, Karlsruhe, Germany 
Penicillin/Streptomycin 10.000 U/ml Invitrogen, Carlsbad, CA, USA 
PfuS DNA Polymerase Own Production 
Protease Inhibitor Cocktail Sigma-Aldrich, Taufkirchen, Germany 
Protein G Plus Agarose Santa Cruz Biotechnology, Heidelberg, 
Germany 
Protein Marker Prestained Broad Range 7-
175 kDa 
New England Biolabs, Frankfurt, Germany 
Proteinase K Applichem, Darmstadt, Germany 
Roti Histofix 4% (Paraformaldehyde; PFA) Carl Roth, Karlsruhe, Germany 
Rotiphorese 30 (30% 
Acrylamide/Bisacrylamide Solution) 
Carl Roth, Karlsruhe, Germany 
Sodium Azide Sigma-Aldrich, Taufkirchen, Germany 
Sodium Carbonate  Merck, Darmstadt, Germany 
Sodium Chloride Merck, Darmstadt, Germany 
Sodium Dodecylsulfate (SDS) Carl Roth, Karlsruhe, Germany 
Sodium Fluoride Merck, Darmstadt, Germany 
Sodium Hydroxide Sigma-Aldrich, Taufkirchen, Germany 
Sodium Molybdate Sigma-Aldrich, Taufkirchen, Germany 
Sodium Orthovanadate Sigma-Aldrich, Taufkirchen, Germany 
Sodium Hydrogen Carbonate Merck, Darmstadt, Germany 
Streptavidin Microbeads for MACS Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Sulfuric Acid Merck, Darmstadt, Germany 
Tamoxifen Free Base Sigma-Aldrich, Taufkirchen, Germany 
Taq DNA Polymerase 5 U/µl Genaxxon Biosciences, Ulm, Germany 
Table 7: List of chemicals and reagents continued. 
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Name Manufacturer 
Tetramethylbenzidine (TMB) Sigma-Aldrich, Taufkirchen, Germany 
Tetramethylethylenediamine (TEMED) Carl Roth, Karlsruhe, Germany 
Tetrasodium Pyrophosphate Sigma-Aldrich, Taufkirchen, Germany 
Thioglycolate Sigma-Aldrich, Taufkirchen, Germany 
Tris Pufferan Carl Roth, Karlsruhe, Germany 
Trypan Blue Carl Roth, Karlsruhe, Germany 
Tween-20 Carl Roth, Karlsruhe, Germany 
Xylene Carl Roth, Karlsruhe, Germany 
β-Mercaptoethanol Carl Roth, Karlsruhe, Germany 
Table 8: List of chemicals and reagents finished. 
 
3.1.4 Commercial Assays 
 
Name Manufacturer 
BsrGI Enzyme Set New England Biolabs, Frankfurt, Germany 
iScript cDNA Synthesis Kit BioRad, München, Germany 
Mouse IL-6 ELISA MAX Standard Set BioLegend, San Diego, CA, USA 
Power SYBR-Green PCR Mastermix Applied Biosystems, Foster City, CA, USA 
Quick-RNA Mini Prep Zymo Research, Irvine, CA; USA 
RNeasy Plus Universal Kit Qiagen, Hilden, Germany 
Table 9: List of commercial assays. 
 
3.1.5 Buffers and Solutions 
 
3.1.5.1 General Buffers and Solutions 
 
H2O 
For all experiments demineralized or deionized water was used, if not stated otherwise. 
 
PBS 
80 g  Sodium Chloride 
29 g  Disodium Hydrogen Phosphate 
2 g  Potassium Chloride 
2 g  Potassium Dihydrogen Phosphate 
1000 ml H2O 
(pH 7.2-7.3)  
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PBS/BSA      PBS-Tween 
0.1% BSA in PBS.     0.05% Tween-20 in PBS. 
 
TAC Buffer      FACS Buffer 
20 mM Tris     0.1%  BSA 
155 mM Ammonium Chloride   0.01%  Sodium Azide 
1000 ml H2O     500 ml  PBS 
(pH 7.2) 
 
MACS Rinse Buffer     MACS Buffer 
2 mM  EDTA     0.5% BSA in MACS Rinse Buffer. 
1000 ml PBS 
 
Trypan Blue Solution 
0.5% Trypan Blue in PBS. 
 
Tail Extraction Buffer     TE Buffer 
5 mM  Tris     10 mM Tris 
100 mM Sodium Chloride   1 mM  EDTA 
100 mM EDTA     1000 ml H2O 
1%  SDS     (pH 8.0) 
1000 ml H2O 
 
Orange G Loading Dye    50x TAE Buffer 
100 mg Orange G Sodium Salt  4.8 g  Tris 
30%  Glycerol    1.1 g  Acetic Acid Glacial 
100 ml  H2O     0.29 g  EDTA 
       1000 ml H2O 
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Ripa Buffer      Laemmli Buffer 
10 mM Tris     62.5 mM Tris 
5 mM  EDTA     20%  Glycerol 
150 mM Sodium Chloride   2%  SDS 
10 mM Sodium Fluoride   5%  β-Mercaptoethanol  
1 mM  Tetrasodium Pyrophosphate  0.025% Bromophenol Blue 
1000 ml H2O     100 ml  H2O 
(pH 7.4) 
 
10% NP-40 solution 
5 mg  Igepal CA-630 
45 ml  H2O 
 
Protein Lysis Buffer 
1%  NP-40 Solution 10% 
1 mM  Sodium Orthovanadate (50 mM) 
10 µM  Sodium Molybdate (10 mM) 
2.5%  Protease Inhibitor Cocktail 
50%  Ripa-Buffer 
1 ml   H2O 
 
3.1.5.2 SDS-PAGE and Western Blot Reagents 
 
SDS-Running Buffer 
25 mM  Tris 
192 mM Glycerol 
3.5 mM SDS 
1000 ml  H2O 
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Lower Buffer      Upper Buffer 
1.5 mM Tris     0.5 mM Tris 
14 mM SDS     14 mM SDS 
1000 ml H2O     1000 ml H2O 
 
10% SDS-Running Gel    10% SDS-Stacking Gel 
1.95 ml Lower Buffer    938 µl  Upper Buffer  
2.7 ml  Rotiphorese 30   600 µl  Rotiphorese 30 
7.5 µl  TEMED    3.75 µl  TEMED 
49.95 µl APS     32.5 µl  APS 
3.3 ml  H2O     2.205 ml H2O 
 
10x Blotting Buffer     Blotting Buffer 
0.5 M   Tris     10%  10x Blotting Buffer 
0.4 M  Glycerol    20%  Methanol 
13 mM SDS     1000 ml  H2O 
15 mM Sodium Azide 
1000 ml H2O 
 
Blocking Solution 
5%  BSA 
0.01%  Sodium Azide 
50 ml  PBS-Tween 
 
Solution A      Solution B 
0.1 M  Tris     1.1 mg  p-Coumaric Acid 
250 mg/l Luminol    10 ml  DMSO 
100 ml  H2O 
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Western Blot Developing Solution 
4 ml  Solution A 
400 µl  Solution B 
1.2 µl  Hydrogen Peroxide 30% 
 
3.1.5.3 ELISA Reagents 
 
Coating Buffer     Assay Diluent 
0.1 M  Sodium Carbonate    10% FBS in PBS. 




1% TMB in DMSO. 
 
Substrate Buffer     TMB-Substrate Solution 
0.1 M  Citric Acid    1%  TMB Solution 
0.2 M  Disodium Hydrogen Phosphate 0.2%  Hydrogen Peroxide 3.5% 
1000 ml H2O     10 ml  Substrate Buffer 
 
Stop Solution 




DMEM (Dulbecco's Modified Eagle Medium) 
DMEM + GlutaMAX (Invitrogen, Carlsbad, CA, USA) 
 
DMEM++ 
10%  FBS 
1%  Penicillin/Streptomycin 
500 ml  DMEM  
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3.1.7 List of Antibodies 
 
3.1.7.1 For Flow Cytometry 
 
Specificity Clone Isotype Conjugation Manufacturer 
CD3ε 17A2 Rat IgG2a, κ APC BioLegend 
CD4 RM4-5 Rat IgG2a, κ PerCp BD Biosciences 
CD8α 53-6.7 Rat IgG2a, κ APC BioLegend 
CD11b M1/70 Rat IgG2a, κ PE-Cy7 BioLegend 
CD16/CD32 
(TruStain fcX) 
93 Rat IgG2a, λ  BioLegend 
EpCAM (CD326) G8.8 Rat IgG2a, κ APC or APC-Cy7 BioLegend 
F4/80 BM8 Rat IgG2a, κ FITC BioLegend 
GR-1 (Ly-6C/G) RB6-8C5 Rat IgG2a, κ APC-Cy7 BD Biosciences 
MHC-II (I-Ab) AF6-120.1 Mouse Balb/C 
IgG2a, κ 
PE BioLegend 
Siglec F E50-2440 Rat IgG2a, κ PE BD Biosciences 
Table 10: List of antibodies for flow cytometry. 
 
3.1.7.2 For Cell Separation 
 
Specificity Clone Isotype Conjugation Manufacturer 
CD3ε 145-2C11 Hamster IgG1, κ Biotin BD Biosciences 
CD11b M1/70 Rat IgG2a, κ Biotin BioLegend 
CD11c N418 Rat IgG2a, κ Biotin BioLegend 
CD45R (B220) RA3-6B2 Rat IgG2a, κ Biotin BD Biosciences 
F4/80 BM8 Rat IgG2a, κ Biotin BioLegend 
Siglec F ES22-10D8 Rat IgG1 Biotin Miltenyi Biotec 
Table 11: List of antibodies for cell separation. 
 
3.1.7.3 For ELISA 
 
Specificity Clone Isotype Conjugation Manufacturer 
Mouse IgE Polyclonal Goat HRP Southern 
Biotech 
Mouse IgG1 Polyclonal Goat HRP Southern 
Biotech 
Mouse IgG2a Polyclonal Goat HRP Southern 
Biotech 
Table 12: List of antibodies for ELISA. 
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3.1.7.4 For Western Blot and Nanoparticles 
 
Specificity Clone Isotype Conjugation Manufacturer 
GR (M-20) Polyclonal Rabbit IgG Purified Santa Cruz 
Biotechnology 
ERK-1 (K23) Polyclonal Rabbit IgG Purified Santa Cruz 
Biotechnology 




Polyclonal Goat IgG HRP Pierce 
Biotechnology 
Table 13: List of antibodies for western blot and nanoparticles. 
 
Manufacturer Information: 
BioLegend   San Diego, CA, USA 
BD Biosciences  Heidelberg, Germany 
Miltenyi Biotec  Bergisch-Gladbach, Germany 
Pierce Biotechnology  Rockford, IL, USA 
Santa Cruz Biotechnology Heidelberg, Germany 
Southern Biotech  Birmingham, AL, USA 
 
  




Name Forward Primer Sequence Reverse Primer Sequence 
ATF6 CGAGTTGTGAGGGAGAGGTG ACAACGTCGACTCCCAGTCT 
CD163 GAAGCCCACAAAGAAAGCTG TGCACACGATCTACCCACAT 
Claudin 5 GAGATCCTGGGGGCACTAGA TGCCCTTTCAGGTTAGCAGG 
Cre GGAAATGGTTTCCCGCAGAA ACGGAAATCCATCGCTCGAC 





GRquant CAGCAACGGGACCACCTCCC GTGCTGTCCTTCCACTGCTCTC 
GT3'-GT5' CCATTACCTTCCAGGTTCATTC GTGTCTTGATGATAGTCTGCT 
HPRT GTCCTGTGGCCATCTGCCTA GGGACGCAGCAACTGACATT 
IL-13 CCCCTGTGCAACGGCAGCAT CGGGGAGGCTGGAGACCGTA 
IL-1b GCCACCTTTTGACAGTGATG GCTCTTGTTGATGTGCTGCT 
IL-33 TCAATCAGGCGACGGTGTGGA AAGGCCTGTTCCGGAGGCGA 
IL-5 TGCTGAAGGCCAGCGCTGAAG GGGACAGGAAGCCTCATCGTCTCAT 
iNOS CCGCACCCGAGATGGTCAGG GCAAGGCTGGGAGGGGTCCT 
ITGAE (CD103) CAAAGACTCAGGACCACACTGA GCGGCCACGGTTACATTTTC 
MCP-1 AGCACCAGCCAACTCTCACT CGTTAACTGCATCTGGCTGA 
Occludin CCTCCACCCCCATCTGACTA CTTCAGGCACCAGAGGTGTT 
RANTES GTGCCCACGTCAAGGAGTAT GGAAGCGTATACAGGGTCA 
Table 14: List of oligonucleotides. All oligonucleotides were designed using Primer-Blast software and 




3.1.9.1 BALB/c Mice 
 
BALB/c is an inbred albino laboratory mouse strain. Mice were bred in the animal facilities 
at the European Neuroscience Institute (ENI) in Göttingen or purchased from Charles 
River (Sulzfeld, Germany). 
 
3.1.9.2 C57BL/6 Mice 
 
C57BL/6 is an inbred mouse strain with characteristic black fur. Mice were obtained from 
Janvier Labs (Le Genest-Saint-Isle, France) or bred in the animal facilities at the ENI in 
Göttingen. 
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3.1.9.3 GRdim Mice 
 
 




GRdim/dim mice (Nr3c1tm3GSc; designated GRdim) carry a single point mutation in the DBD of 
the GR gene, which was introduced via homologous recombination of mouse embryonic 
stem cells (ES cells) (Reichardt et al., 1998). Alanine is replaced by threonine (A458T) in 
the D-loop of the second Zinc-finger in the DBD (fig. 7). This mutation impairs GR-
dimerization and thus the transactivating mode of action whereas the transrepressing 
mechanism remains intact. GRdim mice have been backcrossed to the BALB/c background 
for more than 10 generations. 
 
3.1.9.4 GRspc Mice 
 
GRflox/floxSftpcCreERT2 mice (Nr3c1tm2GScSftpctm1(cre/ERT2)BIh; designated GRspc) carry a specific 
and inducible deletion of the GR in AT-II cells. The conditional knock-out was achieved by 
employing a tamoxifen-inducible Cre/loxP recombination system. GRflox/flox mice (Tronche 
et al., 1999) were intercrossed with SftpcCreERT2 mice (Rock et al., 2011) that have been 
kindly provided by Prof. Brigid Hogan (Duke University, Durham, NC, USA). The Cre-
recombinase in these mice is expressed under the control of the human surfactant 
protein C (SftpC) promoter which is exclusively expressed in AT-II cells. Experiments were 
NTD DBD LBDNH2 COOH
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analySIS Olympus, Tokio, Japan 
Intas GDS Intas, Göttingen, Germany 
Intas Chemostar Intas, Göttingen, Germany 
Nanodrop 2000 Software Thermo Scientific, Wilmington, DE, USA 
Microsoft Office 2007 and 2010 Microsoft, Redmond, WA, USA 
Primer-Blast Software http://www.ncbi.nlm.nih.gov/tools/primer-
blast/  
BD FACS Diva Software 6.1.2 BD Biosciences, Heidelberg, Germany 
Gen 5 1.09.8 BioTek Instruments, Bad Friedrichshall, 
Germany 
GraphPad Prism 5.02 GraphPad Software, La Jolla, CA, USA 
FlowJo 7.6 TreeStar, Ashland, OR, USA 
Zotero 4.0.29.10 Center for History and New Media, Fairfax, 
VA, USA 
7500 System SDS Software 1.4.0.25 Applied Biosystems, Foster City, CA, USA 




3.2.1 Animal Experimentation 
 
Mice were housed and bred under specific pathogen-free (SPF) conditions in the animal 
facilities at the ENI or the University Medical Center in Göttingen (ZTE). Mice were kept in 
individually ventilated cages (IVCs) with a 12 hour light-dark cycle. Food and drinking 
water were provided ad libitum. All animal experiments were performed according to the 
ethical standards of humane animal care and approved by the Lower Saxony State Office 
for Consumer Protection and Food Safety (LAVES). Due to breeding limitations, mice were 
neither age- or sex-matched. Mice were sacrificed by CO2 inhalation. 
 
  
M a t e r i a l  a n d  M e t h o d s  | 47 
 
3.2.2 Genotyping of GRdim and GRspc Mice 
 
Genomic DNA used for genotyping was isolated from mouse tail biopsies. The tissue was 
incubated in 800 µl tail extraction buffer together with 20 µg proteinase K at 56°C under 
constant agitation overnight. Afterwards, 280 µl saturated sodium chloride solution were 
added and samples were incubated for 5 min at room temperature (RT). This was 
followed by centrifugation of the samples at >20.000 x g (Vmax) for 10 min. Supernatants 
were transferred to new tubes. The DNA present in the supernatant was precipitated by 
addition of 600 µl isopropanol. Samples were incubated for 3 min at RT which was 
followed by 10 min centrifugation at Vmax. Supernatants were discarded and 500 µl 70% 
ethanol were added to each pellet. Samples were centrifuged again, the supernatant 
removed and the DNA pellet dried at 50°C for at least 1 hour. Finally, the DNA pellet was 
dissolved in 100 µl TE buffer. 
For genotyping of GRdim and GRspc mice, a PCR was performed with PfuS DNA polymerase. 
GRdim mice were characterized by using GT3'-GT5' primers whereas Cre-primers were 
used for GRspc mice. 
 
Standard Reaction     PCR Protocol 
0.5 µl  DNA     98.5°C  2 min 
4 µl  5x Buffer HF    98.5°C  20 sec 
1 µl  dNTPs     64°C  15 sec  30 Cycles 
1 µl  Primermix (10 µM)   72°C  20 sec 
0.3 µl  PfuS DNA Polymerase  72°C  2 min 
13.2 µl  H2O     4°C  ∞ 
 
An additional GRflox-specific PCR was performed for GRspc mice to distinguish between the 
GRflox-, the GRnull-, and the GRwt-allele. This PCR was done using Taq DNA polymerase. 
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Standard Reaction     PCR Protocol 
1 µl  DNA     95°C  5 min 
2.5µl  10x PCR Buffer   95°C  30 sec 
1 µl  dNTPs     60°C  1 min  35 Cycles 
0.5 µl  Primermix (10 µM)   72°C  1 min 
0.2 µl  Taq DNA Polymerase   72°C  10 min 
19.8 µl  H2O     4°C  ∞ 
 
Enzymatic digestion of the GRdim PCR products was performed with BsrGI. A restriction 
site for BsrGI was present in the amplicon from DNA containing the A458T point mutation 




10 µl  PCR Product 
0.5 µl  BsrGI (10.000 U/ml) 
2 µl  NEBuffer 2.1 
2 µl  10x BSA 
5.5 µl  H2O 
 
The PCR products were digested at 37°C for 2 hours. 
 
The lengths of the PCR products were evaluated by agarose gel electrophoresis. Seven µl 
of orange G DNA loading dye were added to each sample that was loaded on a 1.5% (w/v) 
agarose gel in 1x TAE buffer (from 50x TAE buffer; containing 1 µg/ml ethidium bromide). 
In a separate lane, 13 µl of a DNA standard (Generuler 1 kb DNA ladder) were loaded. 
Electrophoresis was performed at 120 Volt and DNA bands were visualized under UV-
light. 
After restriction of the GRdim PCR product with BsrGI, the wild type-allele resulted in a 
band of 240 bp. In the case of the dim-allele, two smaller bands of approximately half of 
this size were obtained.  
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The Cre PCR product in GRspc mice had a length of 225 bp. Depending on the genotype, 
the GRflox PCR products resulted in bands of 390 bp lengths for the GRnull-allele, 225 bp for 
the GRwt-allele, and 275 bp for the GRflox-allele. 
 
3.2.3 Induction of Recombination by Tamoxifen Treatment 
 
GRspc mice were treated with tamoxifen to induce the GR-deletion in AT-II cells. 
Tamoxifen was prepared in a mixture of 70% ethanol together with sunflower oil (1:20 
ratio). The mixture was warmed at 37°C and agitated until the tamoxifen was completely 
dissolved. Tamoxifen was applied to mice with the help of a feeding needle by oral 
gavage. Tamoxifen was administered three times at a concentration of 20 mg/ml in 150 µl 
every other day (Lee et al., 2012). GRspc and wild type GRflox mice both received tamoxifen 
to exclude any potential side effects. 
 
3.2.4 Induction of AAI 
 
For the induction of AAI, mice were sensitized i.p. with 10 µg OVA together with 2 mg of 
the adjuvant alum in a total volume of 200 µl in PBS over a period of 4 weeks on days 0, 7, 
14 and 21 (fig. 8). Mice underwent allergen exposure on days 28 and 29 (Brandt et al., 
2007). To this end, 20 µl of 250 µg OVA solubilized in PBS were applied intranasally under 
slight isoflurane anesthesia. Part of the mice was i.p. injected with the synthetic GC Dex at 
a dose of 10 mg/kg body weight. In case of the GRspc mice, gene recombination was 
induced prior to the first immunization on days -14, -12 and -10; tamoxifen treatment was 
repeated on days 14, 16 and 18. In all experiments, mice were sacrificed on day 31 and 
different samples were taken for further ex vivo analyses. 
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Figure 8: Induction of AAI. Mice were immunized four times by i.p. injections of OVA in alum and PBS 
followed by two intranasal challenges with OVA in PBS. Part of the mice was treated i.p. with Dex on the 
same days as the challenges. In case GR
spc
 were investigated, they were treated with tamoxifen two weeks 
prior to the first immunization and again four weeks later. Mice were sacrificed on day 31. 
 
3.2.5 Induction of ALI 
 
ALI model was induced by combined treatment with LPS and OA with slight modifications 
as described by Zhou (Zhou et al., 2005). Mice were injected i.p. with 10 mg/kg 
bodyweight LPS (fig. 9). In the case of GC-treatment, mice received i.p. injections of 10 
mg/kg Dex simultaneously with the LPS injections. Thirty minutes afterwards, OA was 
applied intravenously (i.v.) at a concentration of 2.6 µl/g body weight. OA was prepared 
as a 4%-solution in 0.1% PBS/BSA. Control mice were treated with PBS only. Mice were 
sacrificed 15 hours later and different samples were taken for further analyses. 
  
-14 -12 -10 0 7 14 16 18 21 28 29 31
1 2 3 4
Days
Sensitization Steps: 
10 µg OVA with 2mg Alum in PBS i.p.
Challenge Steps:
12.5 mg/ml OVA in PBS i.n.
+/- 10 mg/kg Dex
1 2 3 4 5 6
Induction of Recombination:
20 mg/ml Tamoxifen in EtOH/ 
Sunflower Oil by Oral Gavage
†
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Figure 9: Induction of ALI. Mice were treated with LPS i.p., with or without i.p. Dex. Thirty minutes later, OA 
was i.v. injected. Mice were sacrificed 15 hours later. 
 
3.2.6 Sample Collection 
 
3.2.6.1 Isolation of Bronchoalveolar Lavage Fluid Cells 
 
The thoracic cavity was opened and a venous catheter was inserted into the trachea. The 
catheter was fixed with a thread and the needle removed. A syringe containing 1 ml ice 
cold PBS/BSA was attached to the catheter. Bronchoalveolar lavage fluid (BALF) was 
collected by infusing the lung gently with the PBS/BSA. This washing step was repeated 
until a total volume of approximately 3 ml BALF was collected. The samples were 
centrifuged at 350 x g at 4°C for 7 min. The supernatant was discarded and the cell pellet 
was resuspended in 1 ml PBS. To remove erythrocytes, 6 ml TAC buffer were added to the 
cell suspension and samples were incubated at RT for 12 min. The reaction was stopped 
by adding 8 ml PBS/BSA. Then, BALF samples were centrifuged, the supernatant removed 
and the cell pellet resuspended in the reflux. The total volume of BALF samples was 
determined by using pipettes. Depending on the expected cell number, an adequate 
volume of the cell suspension was diluted in trypan blue to distinguish between living 




Blood samples were obtained by cardiac puncture and left for coagulation at RT for 2 
hours. Subsequently, the samples were centrifuged at Vmax for 30 min. The serum was 
removed and stored at -20°C before it was used for ELISA.  
10 mg/kg LPS i.p.





2.6 µl/g Oleic Acid i.v.
(4%-Solution in PBS/BSA)
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3.2.7 Isolation of AECs 
 
AECs were isolated using previously described protocols by Corti and Gereke with several 
modifications (fig. 10) (Corti et al., 1996; Gereke et al., 2012). 
As for the isolation of the BALF, the thoracic cavity was opened and a venous catheter 
was inserted into the trachea (see 3.2.6.1). A lavage of the lungs was performed using 
800 µl PBS supplemented with 15 mM EDTA to remove infiltrating cells including 
macrophages. Lungs were perfused via the right heart ventricle with 15 ml PBS to remove 
the remaining blood. Afterwards, lungs were filled with 2 ml pre-warmed (37°C) dispase 
(50 U/ml) and then allowed to collapse naturally. This was followed by infusing the lungs 
slowly with 1 ml pre-warmed (45°C) low-melt agarose. Subsequently, lungs were 
immediately covered with crushed ice for 2 min to let the agarose solidify. This was done 
to stiffen the lung tissue as low melt agarose provides a positive alveolar pressure to 
maintain the inflated state (Sanderson, 2011). The lungs were removed from the thoracic 
cavity and transferred to a round bottom culture tube with additional 2 ml dispase. Lungs 
were incubated at RT for 45 min. Then, the digested lungs were placed in a 60 mm tissue 
culture dish and were carefully minced with the help of a scissor. Seven ml DMEM were 
added together with 100 µl DNase I (10 mg/ml) to the lung tissue. The culture dish was 
placed on a shaker at RT for 10 min.  
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Figure 10: Scheme of AEC isolation. Lungs were lavaged to remove infiltrating cells followed by perfusion to 
remove remaining blood. Lung tissue was enzymatically digested with dispase together with low melt 
agarose. Lungs were minced and treated with DNase I. Afterwards, the lung tissue was serially passed 
through filters to obtain single cell suspensions. Hematopoietic cells were magnetically labeled and 
removed by MACS to obtain AECs by negative selection. 
 
The resulting cell suspension was serially passed through 100 µm and 40 µm cell strainers 
and extensively washed with DMEM to prevent loss of cells. The filtered cell suspensions 
were centrifuged at 130 x g and 4°C for 12 min. Cells were treated with TAC buffer to 
achieve erythrocyte lysis (see 3.2.6.1) and centrifuged again. The cell pellet was 
1. Remove Infiltrating
Cells
2. Perfuse the Lung
3. Instill Dispase 4. Instill Low Melt
Agarose and Chill
5. Remove the Lung 
and Incubate in Dispase
6. Mince the Lung and
Incubate with DNase I
7. Pass Cells to Filter to
Obtain Single Cell
Suspensions





CD3+ CD45R+ CD11c+ CD11b+ F4/80+ Siglec F+
Remove
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resuspended in 1 ml DMEM and cell numbers were determined with the help of a 
Neubauer hemocytometer. Fc blockage was performed by adding 100 µl TruStain fcX 
(anti-CD16/CD32) to the cells for incubation at 4°C for 15 min. This step was necessary to 
minimize unspecific binding of FcR-expressing cells including myeloid cells. Afterwards, 
cells were washed in MACS buffer and centrifuged at 300 x g and 4°C for 7 min. The cell 
pellet was resuspended and labeled with 10 µl per 1 x 107 cells biotinylated antibody-
cocktail plus 40 µl MACS buffer at 4°C for 20 min. The biotinylated antibody-cocktail 
includes a mixture of anti-mouse CD3, anti-mouse CD45R, anti-mouse CD11b, anti-mouse 
CD11c, anti-mouse F4/80 and anti-mouse Siglec F antibodies to deplete all remaining cells 
of the hematopoietic lineage. Following a washing step with MACS buffer, cells were 
resuspended in 10 µl per 1 x 107 cells streptavidin microbeads together with 90 µl MACS 
buffer and incubated at 4°C for 15 min. Cells were washed again and the resulting cell 
pellet was resuspended in 500 µl MACS buffer. Magnetic separation was performed using 
the autoMACS program DEPLETE S to remove all unwanted cells. The remaining CD3-
CD45R-CD11b-CD11c-F4/80-Siglec F- cells were considered to be mainly AECs (although 
they contained other cells of non-hematopoietic origin as well). Following MACS, the 
negative selected cell fraction was washed in MACS buffer and cells were ready to be 
used for different purposes. 
 
3.2.8 Isolation of Peritoneal Macrophages 
 
Mice were injected i.p. with 1 ml 4% thioglycolate solution to attract macrophages into 
the peritoneal cavity. Four days later, mice were sacrificed and a small incision was made 
along the midline of the abdominal wall. Peritoneal exudate cells were obtained by 
rinsing the peritoneal cavity several times with PBS/BSA with the help of a pasteur 
pipette. The collected peritoneal lavage was centrifuged at 328 x g and 4°C for 6 min. The 
resulting cell pellet was resuspended in 1 ml DMEM++ and cell numbers were determined. 
To obtain monolayers of peritoneal macrophages, cells were seeded in 100 mm cell 
culture dishes at a concentration of 1 x 106 cells per ml and cultured with 10 ml DMEM++. 
Macrophages were allowed to adhere at 37°C for 1 hour. To remove non-adherent cells, 
the medium was aspirated and the dishes were extensively washed with PBS. Peritoneal 
macrophages were detached with 2 ml PBS supplemented with 2 mM EDTA at 37°C for 30 
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min. Afterwards, cells were washed and cell numbers determined. Peritoneal 




3.2.9.1 Anti-OVA Antibody Isotype ELISA 
 
The levels of different isotypes of anti-OVA antibodies in serum samples of mice with AAI 
were determined by ELISA (Michel et al., 2013). To this end, 96-well flat bottom plates 
were coated with 50 µg/ml OVA dissolved in coating buffer. Plates were incubated at 4°C 
overnight. Thereafter, plates were washed four times with PBS-Tween. Wells were 
blocked with assay diluent at RT with shaking for 1 hour. This was done to prevent 
unspecific binding of the reactants and thus to minimize the background. Plates were 
washed again with PBS-Tween and serum samples were diluted depending on the Ig 
isotype. For the detection of the IgG1 isotype, samples were diluted 1:200.000, for the 
IgG2a isotype 1:2500 and for the IgE isotype 1:100 in assay diluent. To improve IgE 
detection, protein G plus agarose was added to the respective wells for 1 hour incubation 
at RT on a shaker to remove IgG antibodies. After three additional washing steps, diluted 
serum samples were added to the plates and were incubated at 4°C overnight. Plates 
were washed and HRP-conjugated anti-IgG1, anti-IgG2a, or anti-IgE antibodies were 
added to the respective wells at a 1:1000 dilution for 1 hour incubation at RT with 
shaking. Finally, plates were washed five times with soaking for 30 sec between each 
step. TMB substrate solution was added to each well and incubated at RT in the dark until 
the color developed. The color reaction was stopped by adding stop solution to the wells. 
The absorbance was determined at 450 nm and 570 nm with a spectrophotometer. 
 
3.2.9.2 IL-6 ELISA 
 
Secretion of IL-6 was quantified in serum samples of mice with ALI. The mouse IL-6 ELISA 
kit was used according to the manufacturer's instructions. Flat bottom plates were coated 
with IL-6 capture antibody in coating buffer at 4°C overnight. Afterwards, plates were 
washed four times with PBS-Tween and blocked with assay diluent at RT with shaking for 
1 hour. Plates were washed and diluted serum samples, as well as IL-6 standards were 
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added to the respective wells. Samples were incubated at RT on a shaker for 2 hours. In 
all cases, serum samples were diluted 1:1.000 in assay diluent. Following washing, avidin-
HRP solution was added to each well for 30 min incubation at RT with shaking. As 
described before, wells were washed five times and TMB substrate solution was added. 
Finally, the color reaction was stopped with stop solution and the absorbance measured 
at 450 nm and 570 nm. 
 
3.2.10 Flow Cytometry 
 
In order to investigate the cellular composition of the BALF, samples were analyzed by 
fluorescence activated cell sorting (FACS). Prior to each analysis, antibodies were titrated 
using either BALF cells or splenocytes to determine optimal working dilutions for each 
antibody-fluorochrome conjugate. Compensation for spectral overlaps was done when 
multi-color immunofluorescence staining was performed. This was achieved by using cells 
that had been stained with a single antibody solution. Compensation was automatically 
performed by the FACS Diva software. 
After preparation of BALF samples, 1 x 105 up to 1 x 106 cells were resuspended in 200 µl 
FACS buffer and transferred to FACS tubes. Unspecific antibody binding was inhibited by 
Fc blockage (see 3.2.7). To this end, cells were treated with 20 µl TruStain fcX for at 4°C 
for 15 min. Afterwards, cells were stained with 20 µl of an antibody-cocktail and 
incubated at 4°C in the dark for 20 min. Following antibody staining, BALF cells were 
washed with FACS buffer and centrifuged at 450 x g and 4°C for 5 min. The supernatant 
was removed and the cell pellet was resuspended in the reflux by vortexing. Data were 
acquired on the BD FACS Canto II flow cytometer and analyzed using FlowJo software. 
 
3.2.10.1 Gating Strategy for BALF Cells 
 
BALF cells were stained for the surface markers Siglec F, F4/80, CD11b, GR-1, CD4 and 
CD3 (for AAI experiments) or CD8 instead (for ALI experiments). 
First, live and apoptotic cells were separated on the basis of their size and granularity 
using their forward and sideward scatter (FSC-A and SSC-A). Doublets were eliminated to 
detect disproportions between cell size and cell signal. Therefore, cells were scaled for 
the area against height with FSC-A against FSC-H. Amongst the live cell population, 
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leukocytes subsets (eosinophils, macrophages, monocytes, neutrophils and CD4+ or CD8+ 
T cells) were identified by plotting different antibody markers against each other in three 
different dot-plots (fig. 11).  
 
 
Figure 11: Gating strategy for BALF samples. Representive dot plots showing gating of live cells, singlets 
and distinct cell populations such as eosinophils, macrophages, monocytes, neutrophils and CD4
+
 T cells, as 
well as CD8
+
 T cells for ALI samples. 
  
or
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3.2.10.2 Lysotracker Staining 
 
Lysotracker Green DND-26 has been shown to be a marker for AT-II cells (Van der Velden 
et al., 2013). It is a fluorescent dye that stains acidic cell compartments, especially 
lamellar bodies exclusively found in AT-II cells. After cell surface staining with antibodies, 
MACS-sorted cells were washed with DMEM and centrifuged at 300 x g and 4°C for 7 min. 
Afterwards, cells were pelleted in 1 ml of 50 mM Lysotracker diluted in DMEM and 
incubated at 37°C in the dark for 45 min. Finally, cells were washed again in DMEM and 
then ready for flow cytometric analysis. 
 
3.2.11 Hemalum and Eosin Staining of Lung Tissue 
 
For the preparation of lung samples, a venous catheter was placed into the trachea and 1 
ml 4% Roti Histofix was injected into the lungs. Subsequently, whole lungs were excised 
and placed in 6-well culture plates with additional 3 ml Roti Histofix. After 24 hours 
fixation at RT, Roti Histofix was replaced by PBS and lungs were kept at 4°C before use.  
Fixed lungs were placed in tissue cassettes and further processed by using an automatic 
tissue processor. Tissue dehydration was achieved using increasing concentrations of 
ethanol followed by clearance with xylene, and finished by incubating the tissue with 
paraffin wax.  
 
Tissue Processing 
1 h  50% Ethanol 
1 h  70% Ethanol 
2 h  80% Ethanol  Dehydration 
3 h  96% Ethanol 
3 h  99% Ethanol 
2 h  Xylene  → Clearance 
4 h  Paraffin → Paraffinization 
 
Finally, lungs were embedded in paraffin blocks using tissue embedding system. Lungs 
were cut at 5 µm thickness and the sections were adhered to microscope slides using a 
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water bath at 37°C. Microscope slides were dried overnight at the same temperature. 
Lung sections were deparaffinized with xylene and rehydrated through a series of 
descending ethanol concentrations followed by one short washing step with H2O. For 
nuclear staining, lung sections were incubated with hemalum solution which was 
followed by bluing under running tap water. Afterwards, lung sections were incubated 
with eosin solution to stain the cytoplasm. Slides were shortly washed with H2O and 
dehydrated again with increasing concentrations of ethanol followed by clearance with 
xylene.  
 
Hemalum and Eosin Staining 
30 min  Xylene   → Deparaffinization 
4 min  99% Ethanol 
4 min  96% Ethanol   Rehydration 
4 min  70% Ethanol 
1 min  H2O 
10 min  Hemalum Solution 
10 min  Running Tap Water   Staining of Nuclei and Cytoplasm 
5 min  Eosin Solution 
1 min  H2O 
4 min  70% Ethanol 
4 min  96% Ethanol   Dehydration 
4 min  99% Ethanol 
30 min  Xylene   → Clearance 
 
Microscope slides were mounted in Entellan and analyzed microscopically.  
 
  
M a t e r i a l  a n d  M e t h o d s  | 60 
 
3.2.12 RNA Isolation 
 
3.2.12.1 RNA Isolation from Lungs 
 
RNA isolation from lungs was carried out using the RNeasy Plus Universal kit according to 
the manufacturer's instructions. Lungs were homogenized in 900 µl Qiazol using the 
tissue homogenizer Ultra Turrax T18. The lung homogenates were transferred to new 
tubes and incubated at RT for 5 min. To minimize contamination with genomic DNA, 100 
µl gDNA Eliminator solution were added to samples that were vortexed for 15 sec. 
Afterwards, 180 µl were added and samples were vortexed again for 15 sec and 
incubated at RT for 3 min. Homogenates were centrifuged at Vmax and 4°C for 15 min. The 
aqueous supernatant was transferred to new tubes and mixed with the same volume of 
70% ethanol. Half of this mixture was loaded onto RNeasy Mini Spin columns which were 
placed in collection tubes. Samples were centrifuged at Vmax and 20°C for 20 sec. The 
flow-through was discarded and depending on the sample volume, this step was 
repeated. Thereafter, 700 µl RWT buffer were added to the columns and samples were 
centrifuged at 8.000 x g for 20 sec. The flow-through was discarded again and 500 µl RPE-
buffer were added to the samples and centrifuged at 8.000 x g for 2 min. Afterwards, 
columns were dried by spinning down the tubes for 1 min. Columns were placed in new 
tubes and 35 µl RNase-free water were directly loaded to the column membrane. RNA 
was collected by centrifugation at 8.000 x g for 1 min. The eluate was kept and the whole 
step was repeated to increase the RNA yield. Isolated lung RNA was used immediately or 
stored at -20°C. 
 
3.2.12.2 RNA Isolation from AECs 
 
RNA isolation from MACS-sorted AECs was performed using the Quick RNA MiniPrep kit 
according to the manufacturer's instructions. After sorting, AEC samples were centrifuged 
at 300 x g and 4°C for 7 min. Cells were lysed with 600 µl RNA Lysis buffer and centrifuged 
at 10.000 x g and 20°C for 1 min to clear the lysate. To minimize the amount of genomic 
DNA, the supernatant was transferred to Spin-Away filters in collection tubes and 
centrifuged at 10.000 x g for 1 min. The eluate was kept and mixed with the same volume 
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of 99.8% ethanol. Half of this mixture was loaded to Zymo-Spin III G columns in collection 
tubes and spun down for 30 sec at 10.000 x g. The flow-through was discarded and the 
columns were loaded with the rest of the sample for additional centrifugation. 
Afterwards, 800 µl RNA Prep buffer were added to the columns and samples were 
centrifuged again. The flow-through was removed again and 700 µl RNA Wash buffer 
were loaded to the columns. Samples were centrifuged for 30 sec. The washing step was 
repeated with 400 µl RNA Wash buffer for 2 min centrifugation to ensure complete 
removal of the wash buffer. The columns were placed in new collection tubes and 30 µl 
DNase/RNase-free water were directly loaded to the column membrane. RNA was eluted 
by centrifugation at Vmax for 30 sec. Isolated RNA was used immediately or stored at -
20°C.  
The concentration of the isolated RNA was determined using a Nanodrop 2000 
photometer. In addition, the quality of the isolated RNA was assessed by agarose gel 
electrophoresis (see 3.2.2). To this end, 1 µg RNA were loaded together with orange G 
loading dye on a 1% gel. Intact RNA should appear as two sharp bands representing the 
18s and 28s rRNA. 
 
3.2.13 Synthesis of cDNA 
 
RNA samples from lungs and AECs were reversely transcribed into complementary DNA 
(cDNA) using the iScript cDNA Synthesis kit according to the manufacturer's instructions. 
 
Standard Reaction 
1 µg  RNA Template 
0.25 µl  Reverse Transcriptase 
4 µl  5x iScript Reaction Mix 
16 µl  Nuclease-Free Water 
 
Samples were incubated in the reaction mix at 25°C for 5 min, followed by 30 min at 42°C. 
The reaction was stopped by incubation at 85°C for 5 min. Successful cDNA synthesis was 
verified by performing a PCR reaction with PfuS polymerase (see 3.2.2) using 
amplification of hypoxanthine phosphoribosyl transferase (HPRT), a housekeeping gene. 
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The PCR product was visualized on a 1.5% agarose gel (see 3.2.2). The amplified PCR 
product should appear as one sharp band. 
 
3.2.14 Quantitative Real-Time PCR 
 
The mRNA expression levels of several genes were determined via qRT-PCR. To this end, 
cDNA was analyzed using the real-time PCR system 7500. 
 
Standard Reaction 
1 µl  cDNA 
0.5 µl  Primermix 
12.5 µl  SYBR-Green Powermix 
11 µl  H2O 
 
Real-Time PCR Protocol 
2 min  50°C  → Preheating 
10 min  95°C  → Initial Denaturation and Enzyme Activation 
15 sec  95°C    
1 min  60°C    
15 sec  95°C  → Denaturation of DNA 
1 min  60°C  → Hybridization 
15 sec  95°C  → Test of the Melting Curve 
15 sec  60°C  → Final Elongation of the Amplicon 
 
Normalization of target gene expression is necessary to compensate for intra- and 
interkinetic qRT-PCR variations occurring during the PCR run. Therefore, all gene 
expression levels were normalized to an invariant endogenous control, e.g. HPRT, which is 
a housekeeping gene that is equally expressed in all cells of an organism under normal 
and pathophysiological conditions. Data analysis was performed using the ΔΔCT method. 
 
  
50 Cycles Amplification 
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3.2.15 Next Generation Sequencing 
 
Transcriptome profiling of AECs was performed in collaboration with Dr. Gabriela Salinas-
Riester at the Microarray and Deep-Sequencing facility of the University Medical Center in 
Göttingen.  
Total RNA was isolated from MACS-sorted AECs using the Trizol method (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer's instructions and treated with DNase I 
to remove contamination with genomic DNA. RNA quality was determined using the 2100 
bioanalyzer (Agilent Technologies, Santa Clara, CA; USA). Library preparation for RNA-seq 
was performed using the TruSeq RNA sample preparation kit (ID RS-122-2002; Illumina, 
San Diego, CA, USA) according to the manufacturer's instructions. Size range and purity of 
final cDNA libraries were assessed using the 2100 bioanalyzer. Libraries were captured on 
a flow cell (Illumina, San Diego, CA, USA) for cluster generation and subsequently 
amplified and sequenced on the HiSeq 2000 (Illumina, San Diego, CA, USA) deep 
sequencing system. Single read sequencing with 50 bp was conducted with 17.5 to 35 
million reads per sample. Sequence images were transformed to bcl-files with the 
BaseCaller software (Illumina, San Diego, CA, USA) and demultiplexed to fastq-files with 
CASAVA software (version 1.8.2; Illumina, San Diego, CA, USA). Sequences were aligned to 
the murine reference genome sequence (UCSC genome mm10) using Bowtie2 software 
(version 2.1.0) (Langmead and Salzberg, 2012). The reads were counted to each gene to 
the reference gene annotation using HTSeq (version 0.5.4.p3; Anders et al., 2015). Data 
was preprocessed and analyzed in the R/Bioconductor software (version 3.0.2/2.13; 
Huber et al., 2015) loading DESeq (Anders and Huber, 2010), gplots (Warnes, 2016) and 
biomaRt (Durinck et al., 2009) packages. Genes were filtered exceeding more than 20 
counts for at least one sample, which was followed by normalization, estimation of 
dispersions and testing for differentially expressed genes. This was based on a test 
assuming that negative binomial data distribution was computed via DESeq (version 
1.14.0). Candidate genes were filtered to a minimum of two times fold change and FDR-
corrected p-value < 0.05. Regarding the functional association, the candidate genes were 
analyzed for gene ontology enrichment via GoSeq (version 1.4.0; Young et al., 2010).  
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3.2.16 Protein Extraction from Lungs 
 
Lungs were homogenized in 500 µl protein lysis buffer using the tissue homogenizer Ultra 
Turrax T18. The resulting lung homogenate was incubated on ice for 1 hour and 
subsequently centrifuged at Vmax and 4°C for 20 min. The supernatant containing the 
protein lysate was transferred to new tubes and stored at -20°C. 
Total protein was measured with the Nanodrop 2000 photometer. The protein 
concentration was determined using Bradford reagent and calculated with the help of a 
BSA standard curve. 
 
3.2.17 Western Blot 
 
Samples were diluted to 15 µg/ml in Ripa buffer and boiled together with 10 µl Laemmli 
buffer for 5 min at 95°C. Proteins were separated by SDS-PAGE using a 10% stacking and 
running gel for 1 hour at 20 mA. A protein marker was added to the gel to identify the size 
of the protein bands. Afterwards, the gel was placed on a nitrocellulose membrane 
between two Whatman papers that were wetted with blotting buffer before. Protein 
transfer was performed using the semi-dry method for 1 hour at 16 Volt. Subsequently, 
proteins on the membrane were blocked with blocking solution for 1 hour at RT with 
shaking. The membrane was washed with PBS-Tween three times for 5 min. After 
washing, the membrane was incubated with the primary antibody overnight at 4°C with 
shaking. Unbound antibodies were removed by three washing steps with PBS-Tween. 
Then, the HRP-conjugated secondary antibody was added to the membrane. Following 1 
hour incubation at RT, the nitrocellulose membrane was washed again three times with 
PBS-Tween. Proteins were detected by chemiluminiscence by adding 2 ml western blot 
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3.2.18 Statistical Analyses 
 
Statistical evaluation was achieved using GraphPad Prism 5 software and Microsoft Office 
Excel 2007 and 2010. The unpaired, two-tailed t-test was chosen to compare two groups. 
Results were depicted as mean ± standard error of the mean (SEM) and a p-value < 0.05 
was considered to indicate statistical significance: p < 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 
(***) and p ≤ 0.0001 (****). Outlying sample exclusion was performed using Grubb's test 
with α = 5%. 




4.1 GC-Treatment in a Murine Model of AAI Requires an Intact GR-Dimerization 
Interface 
 
In the treatment of various diseases, the anti-inflammatory effects of GCs rely either on 
the transactivating or on the transrepressing mechanisms of the GR. Though, it is unclear 
which mechanism is more important in mediating these beneficial effects. 
An AAI was induced in GRdim mice to dissect the GR mechanisms in the treatment of 
asthma. GRdim mice carry a point mutation that impairs GR-dimerization and subsequently 
the transactivating mode of action. At the same time, the transrepressing mechanism is 
still intact allowing interaction with pro-inflammatory transcription factors. Previous 
findings indicated that dimerization was required for the treatment of AAI (unpublished 
data). To confirm these findings, GRdim mice and wild type (GRwt) mice were sensitized to 
OVA along with the adjuvant alum by i.p. injections on four consecutive weeks. 
Thereafter, allergen exposure was performed by intranasal instillation of OVA to elicit the 
allergic inflammation in the airways. At the same time, part of the mice received i.p. 
injections with Dex which represents systemic GC-treatment. Control groups were 
administered PBS and alum by i.p. injections and PBS only by intranasal instillation.  
 
4.1.1 OVA-specific Antibody Production Is Increased after AAI Induction 
 
As mentioned before, CSR is an important feature of AAI in asthma. Following allergen 
sensitization, B cells undergo CSR to produce IgE antibodies in response to TH2 cell-
secreted IL-4 and IL-13. To prove the efficiency of the OVA-immunization protocol, Ig 
isotype class-switch was analyzed in serum samples of GRwt and GRdim mice. Levels of 
OVA-specific IgE and IgG1 antibodies (characteristic for a TH2 response) and TH1-specific 
IgG2a antibodies were determined by ELISA.  
In comparison to control groups, levels of OVA-specific IgG1 and IgE isotypes were 
significantly increased in both genotypes following the induction of AAI (fig. 12 A and B). 
The same could also be observed for IgG2a (fig. 12 C). Regardless of the isotype, Dex-
treatment did not influence the OVA-induced Ig production (fig. 12 A-C) as differences 
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were not significant. Moreover, no clear differences in the Ig levels were found between 
GRwt and GRdim mice. Thus, immunization with OVA led to the AAI-characteristic Ig isotype 
class-switch with elevated levels of IgG1 and IgE in both genotypes. 
 




 mice. For the detection of allergen-induced 
Ig isotype class-switch IgG1 (A), IgE (B) and IgG2a (C) levels were determined with the respective antibodies 
by ELISA. Serum samples were taken by cardiac puncture two days after the last allergen challenge step 
from control groups (Ctrl), OVA-immunized groups (OVA) and additionally Dex-treated groups (OVA + Dex). 
Ig levels were determined spectrophotometrically and are depicted as optical density (OD). Data are 
presented as mean values ± SEM (GR
wt
: IgG1 n = 13-17, IgE n = 7-9 and IgG2a n = 9-10; GR
dim
: IgG1 n = 14-
17, IgE n = 7-9 and IgG2a n = 8-11; each group). Statistical significances were determined using unpaired, 
two-tailed t-test (*: p < 0.05; **: p ≤ 0.01;***: p ≤ 0.001). 
 
4.1.2 GC-Treatment Does Not Abolish Pulmonary Infiltrates in GRdim Mice with AAI 
 
To specifically analyze the AAI in the lungs of GRwt and GRdim mice, quantitative analysis of 
pulmonary infiltrates was performed. Bronchoalveolar lavage (BAL) was performed to 
obtain the airway infiltrating cells. For investigating the cellular composition of the BALF 
samples, cell numbers were determined and cells were stained with distinct cell surface 
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In contrast to control animals, a significant increase of inflammatory cells could be 
observed in both genotypes (fig. 13 A). This inflammatory influx was dominated by 
eosinophils (60%; data not shown) which mimics the characteristic eosinophilia of AAI in 
asthma (fig. 13 C). 
 




 mice. Following 
immunization and challenge with OVA, lungs were extensively lavaged to obtain infiltrating inflammatory 
cells. BALF samples were taken from control groups (Ctrl), OVA-immunized groups (OVA) and additionally 
Dex-treated groups (OVA + Dex). Absolute cell numbers were determined for total BALF cells (A), CD4
+
 T 
cells (B), eosinophils (C), macrophages (D), monocytes (E) and neutrophils (F). BALF cells were stained with 
respective cell surface markers and analyzed by flow cytometry. Data are presented as mean values ± SEM 
(GR
wt
: n = 10-13; GR
dim
: n = 8-12; each group). Statistical significances were determined using unpaired, two-
tailed t-test (*: p < 0.05; **: p ≤ 0.01;***: p ≤ 0.001). 
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Other cell types including macrophages, CD4+ T cells, neutrophils and monocytes 
contributed a minor part to this cellular influx (fig. 13 B, D, E and F). The overall cell 
numbers in the BALF samples of OVA-sensitized GRdim mice were slightly higher in 
comparison to GRwt mice, but this difference was not significant.  
When Dex-treatment was applied in GRwt mice, cell numbers were significantly reduced in 
BALF samples. This was in conjunction with significant decreases in eosinophil, 
macrophage, monocyte and neutrophil numbers. CD4+ T cell numbers were also reduced 
although this was not significant. 
Interestingly, Dex did not have any effect on BALF cell numbers in GRdim mice as numbers 
remained unaltered in comparison to OVA-sensitized mice without Dex-treatment (fig. 13 
A). This was due to unchanged cell numbers of eosinophils, CD4+ T cells and monocytes 
(fig. 13 B, C and E). Neutrophils numbers were increased following Dex-treatment 
whereas macrophages were the only cell type that showed reduced cell numbers (fig. 13 
D and F). These data indicate that GC-treatment is not effective in GRdim mice to abolish 
the inflammatory cell influx in the allergic airways. 
 
4.1.3 Dex-Treatment Has No Effect on Airway Remodeling in GRdim Mice 
 
AAI is not only characterized by massive infiltration of inflammatory cells, but also by 
structural changes of the airways which is also known as airway remodeling. To this end, 
histological analyses of lung sections from GRwt and GRdim mice were performed. 
Following the induction of AAI, lungs were embedded in paraffin and sections were 
stained with hemalum and eosin (H & E) (fig. 14 A and B).  
In healthy animals, the alveolar compartment was free of inflammatory cellular infiltrates. 
At the same time, bronchioles of GRwt and GRdim mice showed the characteristic round 
shape with no signs of structural changes (fig. 14 A and B). In line with the previous 
findings, large numbers of infiltrating cells could be observed in the alveolar tissue of 
mice of both genotypes following induction of AAI. This was accompanied by airway 
remodeling which was shown by bronchoconstriction. In addition, goblet cell hyperplasia 
could be seen together with large amounts of mucus inside the constricted bronchioles 
(fig. 14 A and B). Dex-treatment resulted in a remarkable reduction of the inflammatory 
cell influx and reversed airway remodeling in GRwt mice (fig. 14 A). However, Dex did not 
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have any effect in GRdim mice as airway remodeling and cell influx were still present (fig. 
14 B). 
 




 mice. Following induction of AAI, lungs 
were taken from control groups (Ctrl), OVA-immunized groups (OVA) and additionally Dex-treated groups 
(OVA + Dex). Lungs were embedded in paraffin, sectioned and stained with H & E. Structural and cellular 
changes within the lung were analyzed, in particular in bronchioles and alveolar tissue. Each section is 
representative for each condition and genotype (GR
wt
: n = 3-4; GR
dim
: n = 2-4; each group). The size bars 
correspond to 100 µm for bronchioles (20 x magnification) and 200 µm for alveolar tissue (10 x 
magnification). 
 
Taken together, GRdim mice are completely refractory to GC-treatment in AAI which 
correlates to the previous findings (unpublished data). These data indicate that GR-
















Bronchioles Alveolar tissue Bronchioles Alveolar tissue
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4.2 Isolation and Purification of AECs from Murine Lungs 
 
Besides the GC mechanism, it is important to identify target cells relevant for GC-
treatment of asthma. Previous findings revealed that the lung itself and pulmonary 
structural cells have to be the target rather than the infiltrating immune cells 
(unpublished data). Thus, AECs have been proposed to be potential targets of the GC-
treatment due to their crucial role in the immune responses of the lung. 
To specifically examine AECs, a protocol for the isolation and purification needed to be 
established. The previously published protocols (Corti et al., 1996; Gereke et al., 2012) 
were used with slight modifications. Lung tissue was enzymatically digested with dispase 
which has been shown to specifically dissociate AECs from the organ (Corti et al., 1996). 
Dispase-treated lung cells were magnetically labeled with an antibody-cocktail to remove 
contaminating leukocytes including T cells, B cells and myeloid cells by MACS. Unlabeled 
cells should represent the AEC positive cell fraction. 
Dispase treatment of lung tissue alone yielded in 32 million cells that were subsequently 
sorted by MACS (table 16). After elimination of leukocytes, 6 million cells were obtained 
per lung. The viability of these isolated cells was around 92% which was assessed by 
trypan blue staining. 
 
Cell Counts Before MACS Cell Counts After MACS Cell Viability 
31.94 Million Cells/Lung 6.33 Million Cells/Lung 92.4% of Live Cells 
± 4.92 ± 0.28 ± 1.21 % 
Table 16: Statistics of AEC isolation protocol. (Data ± SEM; n = 18) 
 
The purity of the MACS-sorted cells was tested by flow cytometry using the standard 
epithelial cell marker EpCAM together with the AT-II cell marker lysotracker green DND-
26 (Van der Velden et al., 2013). 
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Figure 15: Purity of isolated AECs. MACS-sorted AECs were stained with the epithelial cell marker 
EpCAM together with the AT-II cell marker lysotracker for flow cytometry to assess the purity. 
 
Only 10% of the sorted cells were indeed epithelial cells (fig. 15 A). This means that only 
0.6 million AECs were present in the sorted lung cells. The majority of the epithelial 
population was AT-II cells as 79% of all EpCAM+ cells were positive for lysotracker (fig. 15 
B). It is unclear which other cell types are included in the MACS-sorted cell mixture. While 
no markers for other structural lung cells were included, it might be that fibroblasts, 
endothelial cells or airway smooth muscle cells were the remaining cells. 
Thus, this protocol for isolation of primary AECs from murine lungs could not yield in a 
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4.3 Transcriptome Analysis of LPCs from GRdim Mice 
 
Dimerization of the GR was required for the therapeutic efficacy in murine AAI. 
Moreover, AECs were proposed to be potential GC-targets. To assess a potential link, 
transcriptome analysis was performed with LPCs from GRwt and GRdim mice as the 
employed protocol did not result in a pure population of AECs. LPCs were isolated 
following the induction of AAI and additional Dex-treatment. Transcriptome analysis 
allows the identification of novel candidate genes that are differentially regulated in the 
different experimental settings of both genotypes. RNA-seq was performed by the TAL-
facility of the University Medical Center in Göttingen. 
Results of the transcriptome profiling were visualized with a heatmap showing the 50 
most differentially regulated candidate genes (fig. 16). These candidate genes were 
hierarchically clustered across the different samples. Validity of the analysis could be 
confirmed by similar expression patterns between the biological replicates of each 
experimental condition.  
In line with the previous findings, expression patterns of Dex-treated groups were 
substantially different between GRwt and GRdim mice. In both genotypes different genes 
were either up- or downregulated in LPCs following Dex-treatment. In addition, Dex-
treated GRwt mice showed different gene expression patterns in comparison to untreated 
GRwt mice. The same could also be observed for both experimental conditions in GRdim 
mice. Moreover, LPCs showed different expression patterns of both genotypes during AAI 
itself, even without additional Dex-treatment. Several candidate genes were chosen for 
further analysis including activating- transcription factor (ATF)-6, integrin α E (ITGAE), 
elastase neutrophil-expressed (ELANE) and CD163. 
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 mice in AAI and following Dex-treatment. 





 mice after the induction of AAI (OVA) and subsequent Dex-treatment (OVA + Dex). 
Each row shows the relative expression level for a single gene whereas each column shows the expression 
pattern of a single sample. Expression levels are indicated in the Z-score and are plotted in a yellow-blue 
color scale. Color intensity represents the relative gene expression levels that are either higher (yellow) or 
lower (blue) than the median expression across all samples. Biological replicates were used for each 
condition (GR
wt
: n = 2-3; GR
dim
: n = 3; each group). 
 
Taken together, RNA-seq analysis identified different transcriptomes in LPCs of GRwt and 
GRdim mice. Impaired GR-dimerization and transactivation resulted in a distinct expression 
pattern after Dex-treatment. These data once more highlighted the importance of GR-
dimerization in efficient treatment of AAI as well as drew the attention to the pulmonary 
structural cells as potential target sites. 
 
  
OVA OVAOVA + Dex OVA + Dex
GRdim GRwt
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4.4 Impaired GR-Dimerization Interface Disrupts GC-Mediated Repression of 
Inflammatory Genes in AAI 
 
4.4.1 GC-Treatment Is Not Effective in Repressing Inflammatory Gene Expression in 
LPCs of GRdim Mice 
 
In contrast to the wild type situation, an impaired GR-dimerization interface resulted in a 
different transcriptome profile in LPCs following GC-treatment. For the verification of the 
RNA-seq analysis, qRT-PCR was performed with LPCs from GRwt and GRdim mice. Following 
induction of AAI and selective treatment with Dex, LPCs were isolated from both 
genotypes. RNA was isolated, reversely transcribed into cDNA and processed to qRT-PCR 
analysis. Various genes were analyzed for differential mRNA expression levels. IL-5 and IL-
13 are TH2-specific cytokines that help to maintain the allergic inflammation in asthma 
(Holgate, 2011a; Verstraelen et al., 2008). IL-33, MCP-1 and RANTES are all known to be 
secreted by AECs and are also associated to asthma pathogenesis (Fehrenbach, 2001; 
Holgate, 2012a; Kato and Schleimer, 2007). Occludin and claudin 5 are components of 
tight junctions that are required for epithelial integrity (Arora and Kale, 2013; Holgate, 
2007). Along with these asthma- and AEC-related genes, several candidate genes were 
analyzed that had been shown to be differentially expressed in LPCs of wild type and 
mutant mice. ITGAE also known as CD103 is an integrin that mediates the migration of 
lymphocytes into epithelial tissues (Smyth et al., 2007). CD163 is a scavenger receptor 
which is mainly known as marker for monocytes and macrophages (Onofre et al., 2009). 
ATF-6 is a transcription factor for unfolded protein responses and has been linked to 
asthma pathogenesis (Miller et al., 2012). ELANE is known as neutrophil elastase that 
mediates airway damage (Chua, 2006). 
AAI led to significant increases of IL-5, IL-13, IL-33, MCP-1 and RANTES mRNA expression 
in LPCs of both GRwt and GRdim mice (fig. 17 A-E). Subsequent Dex-treatment markedly 
repressed this induction in LPCs of GRwt mice (fig. 17 A-E). In contrast, inflammatory gene 
expression was even enhanced in LPCs following Dex-treatment in GRdim mice (fig. 17 A-
E). This effect was significant for IL-33 and MCP-1 (fig. 17 C and D).  
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 mice. AAI was induced by 
immunization with OVA together with the adjuvant alum, followed by intranasal challenge with the same 
antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice received PBS with alum or 
PBS alone (Ctrl). LPCs were isolated by enzymatic digestion of lung tissue with dispase and subsequent 
removal of immune cells by MACS. RNA was isolated and analyzed by qRT-PCR for expression of IL-5 (A), IL-
13 (B), IL-33 (C), MCP-1 (D) and RANTES (E). Relative quantities were normalized with respect to the mRNA 
expression levels in the OVA-groups of the respective genotype (fold change = 1). HPRT was used as 
endogenous control. All values are depicted as mean ± SEM (GR
wt
: n = 5-11; GR
dim
: n = 5-11; each group). 
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AAI was induced by immunization with OVA together with the adjuvant alum, followed by intranasal 
challenge with the same antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice 
received PBS with alum or PBS alone (Ctrl). LPCs were isolated by enzymatic digestion of lung tissue with 
dispase and subsequent removal of immune cells by MACS. RNA was isolated and analyzed by qRT-PCR for 
expression of occludin (A), claudin 5 (B), ITGAE (C), ELANE (D), ATF-6 (E) and CD163 (F). Relative quantities 
were normalized with respect to the mRNA expression levels in the OVA-groups of the respective genotype 
(fold change = 1). HPRT was used as endogenous control. All values are depicted as mean ± SEM (GR
wt
: n = 
5-11; GR
dim
: n = 5-11; each group). Statistical significances were determined using unpaired, two-tailed t-
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Furthermore, AAI also led to remarkable increases of occludin, claudin 5, ITGAE, ELANE, 
ATF-6 and CD163 expression in GRwt mice which was dampend by Dex-treatment (fig. 18 
A-F). LPCs of GRdim mice showed induction of occludin, ITGAE, ELANE, ATF-6 and CD163 
when AAI was induced (fig. 18 A, C, D, E and F). GC-treatment with Dex enhanced the 
increased expression of occludin and ELANE whereas levels of ITGAE and CD163 remained 
unaltered (fig. 18 A, C, D and F). In contrast, a slight decrease of ATF-6 expression could 
be observed in GRdim mice after treatment although this effect was not significant (fig. 18 
E). In case of claudin 5, no clear alterations could be found in LPCs of mutant mice (fig. 18 
B). Thus, qRT-PCR analyses of LPCs from both mouse strains revealed different expression 
levels of the analyzed genes. Expression of several examined genes was not diminished by 
Dex-treatment in GRdim mice and in some cases expression was even increased.  
 
4.4.2 Inflammatory Gene Expression in Lungs of GRdim Mice Is Not Abolished by Dex-
Treatment 
 
LPCs contain AECs among other cells and represent only a small proportion of the whole 
lung. Therefore, qRT-PCR was performed to obtain an overview of how the impaired 
dimerization interface affects the GC-responsiveness and inflammatory gene expression 
in the whole organ. After induction of AAI and Dex-treatment, infiltrating immune cells 
were removed by lavage from the lungs. RNA was isolated from homogenized lung tissue, 
reversely transcribed and analyzed by qRT-PCR. 
In line with qRT-PCR analysis of LPCs, remarkable increases of IL-5, IL-13, IL-33, MCP-1 and 
RANTES mRNA expression were found in the lungs of GRwt and GRdim mice with AAI (fig. 
19 A-E). At the same time, Dex abolished these increases in GRwt mice (fig. 19 A-E). In 
addition, enhanced levels of IL-5, IL-33 and RANTES in lungs of Dex-treated GRdim mice 
correlated with the LPC data (fig. 19 A, C and E). MCP-1 expression levels remained 
unaltered in mutant mice following GC-treatment (fig. 19 D). IL-13 mRNA expression was 
slightly decreased whereas this effect was not significant (fig. 19 B). 
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 mice. AAI was induced 
by immunization with OVA together with the adjuvant alum, followed by intranasal challenge with the same 
antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice received PBS with alum or 
PBS alone (Ctrl). Lungs were extensively lavaged to remove infiltrating immune cells. RNA was isolated and 
analyzed by qRT-PCR for expression of IL-5 (A), IL-13 (B), IL-33 (C), MCP-1 (D) and RANTES (E). Relative 
quantities were normalized with respect to the mRNA expression levels in the OVA-groups of the respective 
genotype (fold change = 1). HPRT was used as endogenous control. All values are depicted as mean ± SEM 
(GR
wt
: n = 4-8; GR
dim
: n = 3-11; each group). Statistical significances were determined using unpaired, two-
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AAI was induced by immunization with OVA together with the adjuvant alum, followed by intranasal 
challenge with the same antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice 
received PBS with alum or PBS alone (Ctrl). Lungs were extensively lavaged to remove infiltrating immune 
cells. RNA was isolated and analyzed by qRT-PCR for expression of occludin (A), claudin 5 (B), ITGAE (C), 
ELANE (D), ATF-6 (E) and CD163 (F). Relative quantities were normalized with respect to the mRNA 
expression levels in the OVA-groups of the respective genotype (fold change = 1). HPRT was used as 
endogenous control. All values are depicted as mean ± SEM (GR
wt
: n = 4-8; GR
dim
: n = 3-11; each group). 
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In lung samples of both mouse strains, also increases of occludin, claudin 5, ITGAE, ELANE, 
ATF-6 and CD163 mRNA expression could be observed after induction of AAI (fig. 20 A-F). 
Dex repressed these genes in lungs of GRwt mice. Although slight decreases of these 
analyzed genes were observed in the lungs of Dex-treated GRdim mice, this effect was not 
significant.  
 
Taken together, qRT-PCR analysis using LPCs and lungs from GRwt and GRdim mice revealed 
differential expression of the analyzed asthma- and AEC-related genes as well as the 
novel candidate genes. Although statistical significances were not always achieved, clear 
tendencies were obtained. The findings of differential gene expression correlated with 
the different transcriptome profiles that had been identified by RNA-seq. The impaired 
GR-dimerization interface deteriorated the GC-responsiveness in AAI, as Dex-treatment 
failed to abolish the inflammatory gene expression. These observations were more 
distinct in LPCs than in lung samples. Thus, GCs mediate their beneficial effects in AAI by 
the transactivating mechanism that is potentially linked to LPCs and especially to AECs. 
 
4.5 AECs Are Important Targets of GCs in the Treatment of Murine AAI 
 
As mentioned before, previous findings drew the attention to structural cells of the lung 
as potential GC-targets. Immune cells were found to be dispensable for GC-treatment of 
AAI. AECs were hypothesized to be important targets because of their crucial functions in 
the immune responses of the lung. They drive the immune responses by the secretion of 
a plethora of anti- and pro-inflammatory mediators. This mediates the differentiation and 
recruitment of various immune cells (Kato and Schleimer, 2007; Schleimer et al., 2007).  
Isolation and purification of AECs resulted in a heterogeneous population of LPCs which 
presumably also include other structural cells of the lung. Transcriptome profiling and 
subsequent qRT-PCR analysis of LPCs and lungs from GRwt and GRdim mice revealed 
different expression patterns of inflammatory genes following Dex-treatment of AAI. 
These effects were found to be more distinct in LPCs than in the whole organ. This 
highlighted an important link to GC-targets in AECs. 
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4.5.1 Inducible GR Inactivation in AT-II Cells of GRspc Mice 
 
To specifically analyze the role of AECs in the GC-treatment of AAI, GRspc mice were 
employed. These mice are GR-deficient specifically in AT-II cells in a temporally defined 
manner. The tissue specific knock-out was achieved by using an inducible Cre/loxP 
recombination system. Recombination was induced by application of tamoxifen. 
Prior to the induction of AAI, successful ablation of the GR needed to be assessed. 
Proteins were isolated from homogenized lung samples of wild type (GRflox) and GRspc 
mice for western blot analysis. On protein level, no differences in GR expression were 
observed between the lungs of both genotypes (fig. 21 A). 
In addition, GR mRNA expression levels were determined by qRT-PCR analysis in lung 
samples of both mouse strains. In comparison to GRflox mice, GR expression was reduced 
to 86% in the lungs of GRspc mice (fig. 21 B). It is estimated that the AT-II cell population 
represents approximately 15% of the total lung cells (Mason, 2006). Therefore, a 
reduction in the GR expression of 14% correlates with the number of AT-II cells in the 
total lung.  
Thus, tamoxifen treatment presumably led to a successful knock-out of the GR in AT-II 
cells of GRspc mice which could be shown on mRNA level, but not on protein level. 
  
R e s u l t s  | 83 
 
 
Figure 21: GR expression in lungs of GR
spc
 mice after induction of recombination. GR
spc
 mice are GR-
deficient specifically in AT-II cells in a temporally defined manner. The knock-out was achieved by 




 mice by 
western blot analysis. ERK served as loading control (A). GR mRNA expression was analyzed in lung samples 
of both mouse strains. RNA was isolated from homogenized lungs, reversely transcribed into cDNA and 
analyzed by qRT-PCR. Relative quantities were normalized with respect to the mRNA expression levels in 
lungs of GR
flox
 mice (fold change = 1). HPRT was used as endogenous control. All values are depicted as 
mean ± SEM (GR
flox
: n = 15; GR
spc
: n = 14) (B). 
 
4.5.2 AAI Leads to an Increase of OVA-Specific Antibodies in GRspc Mice 
 
AAI was induced in GRflox and GRspc mice by immunization and challenge with OVA with 
selective Dex-treatment. Prior to and in between the immunization period, mice were 
treated with tamoxifen for the induction of recombination. 
Efficient immunization with OVA was assessed by ELISA. OVA-specific Ig isotype class-
switch was tested in serum samples of both genotypes. To this end, IgG1, IgE and IgG2a 
levels were determined. Irrespective of the genotype, induction of AAI led to significant 
increases of all Ig isotype levels in serum (fig. 22 A-C). In comparison to AAI, additional 
Dex-treatment did not significantly alter Ig levels in the serum of GRflox and GRspc mice 
(fig. 22 A-C). Thus, elevated levels of IgG1, IgE and IgG2a revealed efficient immunization 
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 mice. For the detection of allergen-induced 
Ig isotype class-switch IgG1 (A), IgE (B) and IgG2a (C) levels were determined with the respective antibodies 
by ELISA. Serum samples were taken by cardiac puncture two days after the last allergen challenge step 
from control groups (Ctrl), OVA-immunized groups (OVA) and additionally Dex-treated groups (OVA + Dex). 
Ig levels were determined spectrophotometrically and are depicted as optical density (OD). Data are 
presented as mean values ± SEM (GR
flox
: IgG1 n = 11-13, IgE n = 10-12 and IgG2a n = 13-15; GR
spc
: IgG1 n = 
12-13, IgE n = 11-12 and IgG2a n = 15; each group). Statistical significances were determined using 
unpaired, two-tailed t-test (*: p < 0.05; **: p ≤ 0.01;***: p ≤ 0.001). 
 
4.5.3 Dex Partially Represses Pulmonary Infiltrates in GRspc Mice 
 
Pulmonary infiltrates were analyzed with regard to the impact of the GR knock-out in AT-
II cells on the GC-efficacy in AAI. After induction of AAI, lungs were extensively lavaged to 
obtain infiltrating immune cells. BALF cells were counted and stained with different cell 
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 mice. Following 
immunization and challenge with OVA, lungs were extensively lavaged to obtain infiltrating inflammatory 
cells. BALF samples were taken from control groups (Ctrl), OVA-immunized groups (OVA) and additionally 
Dex-treated groups (OVA + Dex). Absolute cell numbers were determined for total BALF cells (A), CD4
+
 T 
cells (B), eosinophils (C), macrophages (D), monocytes (E) and neutrophils (F). BALF cells were stained with 
respective cell surface markers and analyzed by flow cytometry. Data are presented as mean values ± SEM 
(GR
flox
: n = 7-13; GR
spc
: n = 10-14; each group). Statistical significances were determined using unpaired, 
two-tailed t-test (*: p < 0.05; **: p ≤ 0.01;***: p ≤ 0.001).  
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Induction of AAI resulted in significant increases of inflammatory cells in the airways of 
GRflox and GRspc mice (fig. 23 A). The inflammatory cell influx was dominated by 
eosinophils. Elevated numbers of CD4+ T cells, macrophages, monocytes and neutrophils 
contributed to this increase (fig. 23 B-F). Additional Dex-treatment in GRflox mice led to a 
significant reduction of absolute BALF cell numbers (fig. 23 A). Eosinophilia was 
significantly repressed along with reduced numbers of CD4+ T cells, macrophages, 
monocytes and neutrophils (fig. 23 B-F). 
Decreased numbers of infiltrating cells could be observed in the airways of GRspc mice 
following GC-treatment (fig. 23 A). Although numbers of eosinophils, CD4+ T cells and 
monocytes were reduced, AAI could not completely be abolished (fig. 23 B, C and E). 
Despite reduced eosinophil numbers, eosinophilia was still present in the airways of 
mutant mice as 30% of all BALF cells were still eosinophils (data not shown). In addition, 
macrophage and neutrophil cell numbers remained unaltered (fig. 23 D and F).  
Thus, GC-treatment was not able to completely abolish the AAI in GRspc mice highlighting 
AT-II cells as potential GC-targets. 
 
4.5.4 Dex Cannot Completely Reverse Airway Remodeling in GRspc Mice 
 
Furthermore, histological analysis of lung tissue from GRflox and GRspc mice was performed 
to visualize airway remodeling. Lungs were isolated following induction of AAI and Dex-
treatment, embedded in paraffin and sections were stained with H & E for microscopical 
analysis.  
In contrast to control animals, AAI led to a massive influx of inflammatory cells in the 
alveolar compartment of both mouse strains which correlated to the flow cytometry data. 
AAI also induced airway remodeling which was revealed by bronchoconstriction. Mucus 
hypersecretion and goblet cell hyperplasia were associated with the constricted 
bronchioles (fig. 24 A and B). Dex-treatment completely reversed these structural 
changes in the airways of GRflox mice (fig. 24 A). At the same time, treatment was not able 
to completely clear the inflammation in the airways of GRspc mice. Numbers of infiltrating 
cells were slightly reduced in the alveolar compartment and bronchioles were still 
constricted (fig. 24 B). 
Thus, Dex was not able to completely reverse airway remodeling in lungs of GRspc mice. 
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 mice. Following induction of AAI, lungs 
were taken from control groups (Ctrl), OVA-immunized groups (OVA) and additionally Dex-treated groups 
(OVA + Dex). Lungs were embedded in paraffin, sectioned and stained with H & E. Structural and cellular 
changes within the lung were analyzed, in particular in bronchioles and alveolar tissue. Each section is 
representative for each condition and genotype (GR
flox
: n = 1-2; GR
spc
: n = 1-2; each group). The size bars 

















Bronchioles Alveolar tissue Bronchioles Alveolar tissue
GRflox GRspcA B
R e s u l t s  | 88 
 
4.5.5 Inflammatory Gene Expression in LPCs of GRspc Mice Is Partially Repressed by 
Dex 
 
To further analyze the role of AT-II cells in the GC-treatment of AAI, qRT-PCR was 
performed with LPC samples from GRflox and GRspc mice. Following induction of AAI with 
subsequent Dex-treatment, LPCs were isolated from lung tissue by enzymatic digestion 
and removal of leukocytes by MACS. TH2-specific cytokines IL-5 and IL-13 were analyzed 
together with IL-33, MCP-1 and RANTES that are secreted by AECs. In addition, tight 
junction proteins occludin and claudin 5, as well as the novel candidate genes ITGAE, 
ELANE, ATF-6 and CD163 were analyzed. 
AAI induced increased mRNA expression levels of IL-5, IL-13, IL-33, MCP-1 and RANTES in 
LPC samples of GRflox and GRspc mice (fig. 25 A-E). Dex-treatment reversed these increased 
expression levels in GRflox mice (fig. 25 A-E). In mutant mice, an enhancement of the 
increased mRNA expression could be observed for IL-5, IL-13 and MCP-1 after treatment 
with Dex (fig. 25 A, B and D). Levels of IL-33 and RANTES were slightly decreased although 
this was not significant (fig. 25 C and E).  
Upon AAI induction, elevated expression levels were also found for occludin, claudin 5, 
ITGAE, ELANE, ATF-6 and CD163 in LPCs of both genotypes (fig. 26 A-F). Levels of occludin, 
ITGAE, ELANE and ATF-6 were found to be markedly reduced in LPCs of GRflox mice 
following GC-treatment (fig. 26 A, C, D and E). A reduction of mRNA expression levels for 
the same genes could be observed in GRspc mice. Noteworthy, the reduction of occludin, 
ITGAE, ELANE and ATF-6 expression was not as strong as in GRflox mice (fig. 26 A, C, D and 
E). In both genotypes, no effect on CD163 and claudin 5 expression were found after Dex-
treatment (fig. 26 B and F).  
Thus, Dex-treatment could not completely repress the AAI-induced inflammatory gene 
expression in LPC samples of GRspc mice. 
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 mice. AAI was induced 
by immunization with OVA together with the adjuvant alum, followed by intranasal challenge with the same 
antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice received PBS with alum or 
PBS alone (Ctrl). LPCs were isolated by enzymatic digestion of lung tissue with dispase and subsequent 
removal of immune cells by MACS. RNA was isolated and analyzed by qRT-PCR for expression of IL-5 (A), IL-
13 (B), IL-33 (C), MCP-1 (D) and RANTES (E). Relative quantities were normalized with respect to the mRNA 
expression levels in the OVA-groups of the respective genotype (fold change = 1). HPRT was used as 
endogenous control. All values are depicted as mean ± SEM (GR
flox
: n = 4-8; GR
spc
: n = 4-9; each group). 
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AAI was induced by immunization with OVA together with the adjuvant alum, followed by intranasal 
challenge with the same antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice 
received PBS with alum or PBS alone (Ctrl). LPCs were isolated by enzymatic digestion of lung tissue with 
dispase and subsequent removal of immune cells by MACS. RNA was isolated and analyzed by qRT-PCR for 
expression of occludin (A), claudin 5 (B), ITGAE (C), ELANE (D), ATF-6 (E) and CD163 (F).Relative quantities 
were normalized with respect to the mRNA expression levels in the OVA-groups of the respective genotype 
(fold change = 1). HPRT was used as endogenous control. All values are depicted as mean ± SEM (GR
flox
: n = 
4-8; GR
spc
: n = 4-9; each group). Statistical significances were determined using unpaired, two-tailed t-test 
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4.5.6 Dex-Treatment Cannot Completely Abolish the Inflammatory Gene Expression 
in the Lungs of GRspc Mice 
 
In addition to LPCs, mRNA expression levels of the same genes were analyzed in the 
whole organ. RNA was isolated from lungs of both genotypes after induction of AAI and 
additional Dex-treatment, reversely transcribed into cDNA and processed to qRT-PCR 
analysis. 
In line with the qRT-PCR analysis of LPCs, expression of IL-5, IL-13, IL-33, MCP-1 and 
RANTES were highly increased in lungs of GRflox and GRspc mice (fig. 27 A, C, D and E). This 
increase could be significantly reduced in the lungs of GRflox mice by Dex-treatment (fig. 
27 A, C, D and E). IL-5, IL-13 and RANTES levels were slightly reduced in GRspc mice 
following Dex-treatment whereas this reduction was not significant and not as strong as 
in GRflox mice (fig. 27 A, B and E). Expression of IL-33 was unaltered in comparison to AAI 
and MCP-1 expression was even enhanced upon Dex-treatment (fig. 27 C and D). 
Moreover, occludin, claudin 5, ITGAE, ELANE, ATF-6 and CD163 were all significantly 
increased in lungs of GRflox mice with AAI. This increase could be significantly reversed by 
additional Dex-treatment (fig. 28 A-F). In the lungs of mutant mice, occludin, ITGAE, 
ELANE, ATF-6 and CD163 expression levels were also found to be strongly increased in AAI 
(fig. 28 A, C, D, E and F). Upon Dex-treatment, mRNA expression of occludin and ITGAE 
was slightly decreased in lungs of GRspc mice but this effect was not significant (fig. 28 A 
and C). In contrast, a slight enhancement of elevated ELANE and ATF-6 expression were 
found (fig. 28 D and E). Dex did not have any impact on CD163 mRNA expression (fig. 28 
F). No clear alterations were found for the claudin 5 expression in the lungs of GRspc mice 
(fig. 28 B). 
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 mice. AAI was induced 
by immunization with OVA together with the adjuvant alum, followed by intranasal challenge with the same 
antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice received PBS with alum or 
PBS alone (Ctrl). Lungs were extensively lavaged to remove infiltrating immune cells. RNA was isolated and 
analyzed by qRT-PCR for expression of IL-5 (A), IL-13 (B), IL-33 (C), MCP-1 (D) and RANTES (E). Relative 
quantities were normalized with respect to the mRNA expression levels in the OVA-groups of the respective 
genotype (fold change = 1). HPRT was used as endogenous control. All values are depicted as mean ± SEM 
(GR
flox
: n = 4-11; GR
spc
: n = 5-13; each group). Statistical significances were determined using unpaired, two-
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AAI was induced by immunization with OVA together with the adjuvant alum, followed by intranasal 
challenge with the same antigen (OVA). Part of the mice was treated with Dex (OVA + Dex). Control mice 
received PBS with alum or PBS alone (Ctrl). Lungs were extensively lavaged to remove infiltrating immune 
cells. RNA was isolated and analyzed by qRT-PCR for expression of occludin (A), claudin 5 (B), ITGAE (C), 
ELANE (D), ATF-6 (E) and CD163 (F). Relative quantities were normalized with respect to the mRNA 
expression levels in the OVA-groups of the respective genotype (fold change = 1). HPRT was used as 
endogenous control. All values are depicted as mean ± SEM (GR
flox
: n = 4-11; GR
spc
: n = 5-13; each group). 
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Inflammatory gene expression analysis with qRT-PCR in LPC and lung samples of GRspc 
mice revealed that the allergic inflammation could not be completely abolished by GC-
treatment. Nevertheless, Dex did not have any impact on the AAI-induced expression of 
some analyzed genes or even led to an enhancement of mRNA expression of other 
analyzed genes. 
 
Taken together, GC-treatment of AAI in GRspc mice was not able to completely clear the 
inflammatory responses in the airways. However, AT-II cells were shown to be important 
targets for the GC-efficacy in AAI. Hence, AT-II cells might not seem to be the only GC-
targets as other structural cells of the lung endothelial cells or airway smooth muscle cells 
might serve as target as well. Differential expression of the analyzed genes correlated to 
the GRdim findings providing a link between GC mechanism and target site. 
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4.6 AECs Do Not Mediate the GC-Efficacy in ALI 
 
AECs and in particular AT-II cells could be identified as important targets for the GC-
treatment of murine AAI. As GCs have also been used in the treatment of ALI, AECs could 
be important targets in this disease as well. To analyze the role of AT-II cells as potential 
GC-targets, ALI was induced in GRflox and GRspc mice. To this end, mice were injected i.p. 
with LPS to induce a systemic inflammatory response. Along with LPS, mice were 
additionally injected i.v. with OA that specifically triggers lung injury. Part of the mice was 
also treated with Dex by i.p. injections representing systemic GC-treatment. 
 
4.6.1 Pulmonary Infiltrates Are Reduced in the Lungs of GRspc Mice by Dex-Treatment 
of ALI 
 
Pulmonary infiltrates from GRflox and GRspc mice were analyzed by flow cytometry to 
evaluate the GC-efficacy in murine ALI. After induction of ALI, BALF cells were obtained by 
extensively lavaging the lung. Cell numbers were determined and BALF cells were stained 
with distinct cell surface markers for flow cytometric analysis.  
In both mouse strains, elevated numbers of inflammatory cells were found after induction 
of AAI (fig. 29 A). This increased influx was dominated by neutrophils and also 
macrophages to a minor degree which is characteristic for ALI (fig. 29 D and F). Moreover, 
numbers of CD4+ T cells, CD8+ T cells, monocytes and eosinophils were markedly 
increased (fig. 29 B, C, E and G). Dex-treatment repressed this increase of inflammatory 
cells in the airways of GRflox mice and also in GRspc mice (fig. 29 A). Numbers of all 
analyzed cell types were strongly reduced to a similar extent in both mouse strains (fig. 
29 B-G). 
Thus, GC-treatment with Dex effectively repressed the inflammatory cell influx in the 
airways of GRspc mice as similar to GRwt mice. 
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 mice with ALI. Following 
induction of ALI with LPS and OA, lungs were extensively lavaged to remove infiltrating inflammatory cells. 
BALF samples were taken from control groups (Ctrl), LPS- and OA-treated groups (LPS + OA) and additionally 
Dex-treated groups (LPS + OA + Dex). Absolute cell numbers were determined for total BALF cells (A), CD4
+
 
T cells (B), CD8
+
 T cells (C), macrophages (D), monocytes (E), neutrophils (F) and eosinophils (G). BALF cells 
were stained with respective cell surface markers and analyzed by flow cytometry. Data are presented as 
mean values ± SEM (GR
flox
: n = 5-8; GR
spc
: n = 4-8; each group). Statistical significances were determined 
using unpaired, two-tailed t-test (*: p < 0.05; **: p ≤ 0.01;***: p ≤ 0.001).  
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4.6.2 GCs Suppress IL-6 Levels in Serum of GRspc Mice 
 
Furthermore, IL-6 levels were determined in serum of GRflox and GRspc mice following 
induction of ALI and subsequent Dex-treatment. IL-6 is a pro-inflammatory cytokine that 
is mainly secreted by alveolar macrophages in response to lung injury (Johnson and 
Matthay, 2010). 
 




 mice. Concentrations of IL-6 were determined by ELISA 
with respective antibodies. Serum samples were taken by cardiac puncture 15 hours after the induction of 
ALI from control groups (Ctrl), LPS- and OA-treated groups (LPS + OA) and additionally Dex-treated groups 
(LPS + OA + Dex). IL-6 concentrations were determined spectrophotometrically and are depicted as pg/ml. 
Data are presented as mean values ± SEM (GR
flox
: n = 6-9; GR
spc
: n = 6-10). Statistical significances were 
determined using unpaired, two-tailed t-test (*: p < 0.05; **: p ≤ 0.01;***: p ≤ 0.001). 
 
Induction of ALI resulted in elevated IL-6 levels in serum of both genotypes (fig. 30). These 
elevated levels were reduced by Dex-treatment in GRflox mice. In GRspc mice, Dex led to a 
significant decrease of the IL-6 concentration in serum (fig. 30). 
Thus, GC-treatment effectively suppressed IL-6 levels in serum samples of both mouse 
strains. 
 
4.6.3 Dex Reduces Leukocyte Infiltration in the Alveolar Tissue of GRspc Mice 
 
Histological analysis of alveolar tissue was performed to visualize the inflammatory 
responses in the injured airways. In contrast to healthy lungs, AAI resulted in a strong 
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Dex-treatment abolished this influx as the alveolar compartment was comparable to that 
of control groups. This beneficial effect was the same in both genotypes (fig. 31 A and B). 
Thus, Dex was able to reduce the leukocyte infiltration in the alveolar tissue of GRspc mice 
as effective as in GRwt mice. 
 




 mice. Following induction of ALI, 
lungs were taken from control groups (Ctrl), LPS- and OA-treated groups (LPS + OA) and additionally Dex-
treated groups (LPS + OA + Dex). Lungs were embedded in paraffin, sectioned and stained with H & E. 
Structural and cellular changes within the lung were analyzed in the alveolar compartment. Each section is 
representative for each condition and genotype (GR
flox
: n = 2; GR
spc
: n = 2; each group). The size bars 
correspond to 100 µm (20 x magnification). 
 
4.6.4 GR-Deletion in AT-II Cells Does Not Affect the GR-Dependent Gene Regulation 
in the Treatment of ALI 
 
In addition, qRT-PCR analysis was performed with lung samples from GRflox and GRspc 
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inflammatory gene expression by qRT-PCR. IL-1β, MCP-1 and iNOS are all pro-
inflammatory molecules which are expressed by inflammatory cells in response to ALI. 
Enhanced expression of these molecules is associated with the pathogenesis of ALI (Butt 
et al., 2016; Johnson and Matthay, 2010). 
As expected, all analyzed genes showed increased mRNA expression levels after 
treatment with LPS and OA in both mouse strains (fig. 32 A-C). Increased inflammatory 
gene expression was efficiently suppressed by Dex-treatment to the same extent in GRflox 
and GRspc mice. All analyzed genes showed reduced mRNA expression levels (fig. 32 A-C). 
Thus, the GR-deletion in AT-II cells had no influence on the GR-dependent gene regulation 
in the treatment of ALI as the expression of the analyzed genes was effectively repressed 
by Dex-treatment. 
 





ALI was induced by combined treatment of LPS and OA (LPS + OA). Part of the mice was treated with Dex 
(LPS + OA + Dex). Control mice received PBS alone (Ctrl). Lungs were extensively lavaged to remove 
infiltrating immune cells. RNA was isolated and analyzed by qRT-PCR for expression of IL-1β (A), MCP-1 (B) 
and iNOS (C). Relative quantities were normalized with respect to the mRNA expression levels in the ALI 
groups of the respective genotype (fold change = 1). HPRT was used as endogenous control. All values are 
depicted as mean ± SEM (GR
flox
: n = 4-8; GR
spc
: n = 3-8; each group). Statistical significances were 
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Taken together, GRspc mice completely responded to GC-treatment of ALI. In contrast to 
AAI, AT-II cells are not required for effective GC-treatment of ALI. 
 
4.7 Targeted Delivery of GCs in Inflammatory Lung Diseases Using Inorganic-
Organic Hybrid Nanoparticles 
 
In recent years, nanoparticles have been of major interest because they can easily serve 
for the diagnosis and treatment of various diseases. As carrier for different drugs, 
nanoparticles allow target site-directed drug delivery. This novel therapeutic system can 
potentially prevent the development of severe side effects that develop after systemic 
and also topic administration of drugs. These side effects are also a limiting factor for the 
use of GCs in the treatment of various inflammatory disorders like asthma. Recently 
developed betamethasone nanoparticles (BNPs) have been shown to suppress the 
production of pro-inflammatory cytokines (Heck et al., 2015). These inorganic-organic 
hybrid nanoparticles have been synthesized by precipitating cationic zirconiumoxide 
together with the anionic GC betamethasonephosphate (BMP) and the fluorescent dye 
flavinmononucleotide (FMN) in aqueous solution (Heck et al., 2015; Roming et al., 2010). 
These BNPs have a hydrodynamic diameter of 30-40 nm and show green fluorescence 
(Heck et al., 2015). Studies with a murine model of multiple sclerosis revealed the efficacy 
of BNPs, which were as potent as systemic GCs in improving disease symptoms and 
suppressing inflammation (unpublished data). 
 
4.7.1 BNPs-SPC Are Not Effective in the Treatment of AAI 
 
AT-II cells have been shown to be important targets in the GC-treatment of murine AAI. 
To specifically deliver BNPs to AT-II cells, nanoparticles were conjugated with an anti-SPC 
antibody; designated as BNPs-SPC (collaboration with Prof. Dr. Claus Feldmann, Karlsruhe 
Institute of Technology). AAI was induced in wild type mice by immunization and 
challenge with OVA. Mice were treated with Dex systemically by i.p. injections. BNPs and 
BNPs-SPC (20 µl of 4.4 µmol/ml) were applied topically by intranasal instillation following 
allergen challenge. Pulmonary infiltrates were analyzed by flow cytometry to evaluate the 
BNP-SPC efficacy in the treatment of AAI in comparison to systemic Dex-application. BALF 
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cell numbers were determined and distinct cell surface markers were used for flow 
cytometric analysis of inflammatory cells. As observed before, AAI induced a significant 
increase of inflammatory cells in the allergic airways which could be significantly reduced 
by Dex-treatment (fig. 33 A). In line with this, eosinophilia in the allergic airways was 
repressed by Dex (fig. 33 B). BNPs did not have any impact on the increased BALF cell 
numbers and eosinophilia (fig. 33 A and B). Unfortunately, BNPs-SPC even enhanced the 
increase in cell numbers which could also be observed for eosinophils (fig. 33 A and B).  
OVA-specific Ig isotype class-switch was assessed in serum samples by ELISA to prove the 
immunization efficiency. Immunization with OVA was successful as levels of IgG1 were 
increased (fig. 33 C). Neither Dex, nor BNPs and BNPs-SPC had any impact on the elevated 
IgG1 levels (fig. 33 C).  
Thus, BNPs-SPC were not able to suppress AAI as similar to Dex. The same could be 
observed for BNPs. Targeted delivery of GCs to AT-II cells by using these nanoparticles 
seemed to have failed. 
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Figure 33: BNPs-SPC in the treatment of AAI. Mice were immunized with OVA and the adjuvant alum which 
was followed by intranasal challenge with the same antigen to elicit the AAI (OVA). Part of the mice was 
additionally treated with Dex (OVA + Dex) whereas others were intranasally treated either with BNPs (OVA 
+ BNPs) or with BNPs-SPC (OVA + BNPs-SPC). Control mice were treated with PBS and alum or with PBS 
alone (Ctrl). BALF-cells were obtained by extensively lavaging the lung to obtain infiltrating cells. Cell 
numbers were determined and BALF-cells were stained with distinct cell surface markers for flow 
cytometric analysis. Absolute cell numbers of total BALF cells (A) and eosinophils (B) are shown (n = 2-5; 
each group). OVA-specific Ig isotype class-switch was determined in serum samples by ELISA with respective 
antibodies. IgG1 levels were determined spectrophotometrically and are depicted as optical density (OD) (n 
= 2-5; each group). Data are presented as mean values ± SEM. Statistical significances were determined 
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4.7.2 BNP-SPC Uptake Is Not AT-II Cell-Specific 
 
BNPs-SPC aim to specifically target AT-II cells for GC delivery in AAI. To test this specificity, 
nanoparticle uptake was analyzed in LPCs in comparison to peritoneal macrophages. LPCs 
were isolated from lungs by enzymatic digestion and subsequent removal of immune cells 
by MACS. LPCs were treated with increasing concentrations of BNPs and BNPs-SPC and 
cultured for 24 hours. To obtain macrophages, mice were treated with thioglycolate to 
attract macrophages to the peritoneal cavity. Four days later, the peritoneal cavity was 
extensively lavaged to obtain the peritoneal macrophages. Like LPCs, macrophages were 
treated with different nanoparticle concentrations for 24 hours. 
Nanoparticle uptake was assessed by flow cytometry using the mean fluorescence 
intensity (MFI) of FMN as measure. In case of LPCs, the uptake was analyzed in EpCAM+ 
cells. 
LPCs showed an increase of green fluorescence that correlated with the increasing 
concentrations of both BNPs and BNPs-SPC (fig. 34 A and B). Uptake of BNPs-SPC seemed 
to be more efficient than that of BNPs as MFI values were higher in LPCs (fig. 34 A and B). 
BNP uptake could also be observed for peritoneal macrophages with higher MFI values 
depending on higher concentrations (fig. 34 C). BNPs-SPC were also internalized by 
macrophages (fig. 34 D). Uptake of both nanoparticle types occurred similarly as MFI 
values were comparable (fig. 34 C and D). In comparison to peritoneal macrophages, 
nanoparticles seemed to have a higher uptake in LPCs as MFI values were much higher 
(fig. 34 A-D). 
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Figure 34: Nanoparticle uptake in LPCs and peritoneal macrophages. LPCs were isolated by enzymatic 
digestion of lung tissue followed by removal of immune cells by MACS. To obtain peritoneal macrophages, 
mice were treated with thioglycolate. After 4 days, the peritoneal cavity was extensively lavaged to remove 
the peritoneal macrophages. LPCs and macrophages were treated with increasing concentrations of BNPs 
(A and C) or BNPs-SPC (B and D) and cultured for 24 hours. Nanoparticle uptake was analyzed by flow 
cytometry and measured as MFI of the green nanoparticle fluorescence. In case of LPCs, EpCAM
+
 cells were 
analyzed to specifically examine the uptake in AECs. Data are presented as mean ± SEM (LPCs: n = 2; 
macrophages: n = 2; each group). 
 
Thus, this uptake analysis revealed that BNPs-SPC were not able to specifically target AT-II 
cells. Macrophages were also able to take up these nanoparticles despite the presence of 
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4.7.3 BNPs Are Not Effective in the Treatment of ALI 
Furthermore, the efficacy of BNPs was investigated in the treatment of ALI. Wild type 
mice were injected with LPS and OA to induce ALI which was followed by additional 
treatment either with Dex i.p. or BNPs intranasally. Control mice were treated with PBS 
only. Pulmonary infiltrates were analyzed by flow cytometry using BALF cells. As 
expected, Dex significantly reduced increased BALF cell numbers in the injured airways 
(fig. 35 A). Likewise, Dex reduced the ALI-characteristic neutrophilia (fig. 35 B). In line 
with the AAI findings, BNPs were not able to reduce the number of inflammatory cells. 
Neutrophil numbers were even slightly enhanced after mice with ALI were treated with 
BNPs. 
In line with the increased local inflammatory cell recruitment, systemic IL-6 levels were 
elevated as well following the induction of ALI (fig. 35 C). Dex significantly decreased IL-6 
production whereas BNPs had no effect on the concentration in serum (fig. 35 C). 
Thus, BNPs were not effective in the treatment of ALI as inflammatory responses were 
not suppressed. 
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Figure 35: BNPs in the treatment of ALI. Mice were treated with LPS and OA to induce ALI (LPS + OA). Part 
of the mice was treated i.p. with Dex (LPS + OA + Dex) whereas others were intranasally treated with BNPs 
(LPS + OA + BNPs). Control animals were injected with PBS only (Ctrl). BALF cells were obtained by 
extensively lavaging the lungs to remove the infiltrating immune cells. Cell numbers were determined and 
distinct cells surface markers were used for flow cytometric analysis. Absolute cell numbers of total BALF 
cells (A) and eosinophils (B) are shown (n = 4-6; each group). IL-6 levels were determined in serum samples. 
Serum was obtained by cardiac puncturing and IL-6 concentrations were determined by ELISA with 
respective antibodies. Concentrations are depicted as pg/ml (n = 5-6; each group). Data are presented as 
mean values ± SEM. Statistical significances were determined using unpaired, two-tailed t-test (*: p < 0.05; 
**: p ≤ 0.01;***: p ≤ 0.001).  
 
Taken together, target site-directed delivery of GCs using BNPs or BNPs-SPC failed in the 
treatment of both AAI and ALI. Therefore, these nanoparticles are no promising tool in 

























































































































































For decades, GCs have been successfully employed in the treatment of multiple diseases 
such as asthma, rheumatoid arthritis and multiple sclerosis. They are powerful drugs 
because they efficiently suppress inflammatory responses and therefore improve disease 
symptoms. They have also been popular because of their broad availability and cost-
effectiveness. Beneficial effects are mediated by various mechanisms of the GR. 
Inflammatory gene expression is regulated by GCs mainly through transactivating and 
transrepressing mechanisms of the GR, but also include other genomic actions (Barnes, 
2011b; Rhen and Cidlowski, 2005). In addition, GCs are also known to exert non-genomic 
effects for instance on the PI3K-pathway (Rhen and Cidlowski, 2005). Nonetheless, it is 
unknown how and to which extent these mechanisms contribute to the therapeutic 
efficacy. Unfortunately, the use of GCs is limited by the development of severe side 
effects such as osteoporosis, growth retardation and drug resistance (Dahl, 2006; Rhen 
and Cidlowski, 2005; Stahn and Buttgereit, 2008). Adverse effects are mainly due to the 
ubiquitous expression of the GR throughout the human body. Systemically and also 
topically applied GCs are known to enter the systemic circulation where they can affect 
organs that are not associated with the underlying disease (Dahl, 2006; Rhen and 
Cidlowski, 2005). Moreover, GC-treatment is also limited by the occurrence of resistance 
in selected patients (Barnes, 2013; Kadmiel and Cidlowski, 2013). With regard to these 
limiting factors, a better understanding of the different GC mechanisms is substantial to 
improve GC-treatment. Tolerability and specificity of GC-treatment need to be optimized. 
 
5.1 Therapeutic Efficacy of GCs in AAI Requires an Intact GR-Dimerization Interface 
 
Asthma is a major global health problem as millions of people are affected worldwide. It 
is characterized by chronic lung inflammation that is associated with bronchoconstriction 
and airway remodeling. Patients suffer from symptoms such as wheezing, shortness of 
breath and AHR which considerably impairs the quality of life. Until today, asthma 
treatment remains challenging in terms of disease endotypes that only respond to distinct 
therapeutic agents. Nevertheless, the majority of asthma patients respond well to 
treatment with GCs. In combination with or without β2-agonists, GCs achieve long-term 
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control of asthma symptoms. However, it is unclear which GC mechanism is relevant for 
exerting the beneficial effects in the treatment of asthma. To address this question, GRdim 
mice were used to study the GC-treatment of murine AAI. GRdim mice carry the point 
mutation A458T in the DBD of the GR which impairs its dimerization capability. This 
mutation mainly affects the transactivating mode of GR action whereas transrepression of 
pro-inflammatory transcription factors is still possible (Reichardt et al., 1998). Since mice 
do not develop asthma naturally, an AAI was induced which is a hallmark of human 
asthma (Kips et al., 2003; Nials and Uddin, 2008). Mice were sensitized to OVA, which was 
administered together with the adjuvant alum thus mounting a TH2-specfic immune 
response. To specifically elicit the allergic inflammation in the airways, mice were 
challenged intranasally with OVA. Dex was applied by i.p. injections to mimic systemic GC-
treatment as performed in patients with severe asthma. Albeit relying on the 
immunization with an artificial antigen, the applied OVA-model recapitulates many 
although not all features of human asthma and is therefore a suitable model to study its 
mechanisms (Bates et al., 2009; Kips et al., 2003; Shin et al., 2009). 
Allergen induced CSR is an important feature of AAI in asthma. After allergen exposure, 
TH2 cells secrete a plethora of cytokines including IL-4 and IL-13 that are responsible to 
induce CSR in B cells. Consequently, allergic inflammation is associated with elevated IgE 
levels (Bloemen et al., 2007; Gould and Sutton, 2008; Holgate, 2012a). Following the 
induction of AAI, OVA-induced Ig class-switch was assessed in serum samples of GRwt and 
GRdim mice to prove whether immunization was efficient. Irrespective of the genotype, 
OVA-induced AAI led to elevated levels of IgE, but also of IgG1 and IgG2a. This is in line 
with clinical studies demonstrating that asthma patients also have increased levels of 
allergen-specific IgGs (Williams et al., 2012b). Thus, immunization with OVA was 
successful in both mouse strains. 
Dex, however, had no influence on the elevated Ig levels. This could be due to the short 
treatment duration as well as due to the time point sampling occurred, as it is known that 
GCs are able to interfere with CSR in B cells (Benko et al., 2014; Jabara et al., 2001).  
Similar to human asthma, OVA-induced AAI is characterized by a massive influx of 
inflammatory cells in the allergic airways, which occured in GRwt and GRdim mice. Airway 
infiltration was dominated by eosinophils which is characteristic for AAI in asthma. GC-
treatment significantly diminished inflammatory cell numbers in GRwt mice. In contrast, 
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Dex did not have any impact on the overall cell numbers in the allergic airways of GRdim 
mice. Similarly, eosinophilia was still present and neutrophil numbers were even 
increased. 
In addition to leukocyte infiltration, airway remodeling, bronchoconstriction, mucus 
hypersecretion and goblet cell hyperplasia were observed in lungs of both mouse strains. 
These alterations were completely resolved in GRwt mice after treatment with Dex. The 
opposite could be observed for lungs of GRdim mice, which were refractory to GC-
treatment. These findings correlated with the flow cytometric analysis of pulmonary 
infiltrates, and indicated that an intact GR-dimerization interface was essential to exert 
the beneficial effects of GCs in murine AAI. The transactivating mechanism of the GR thus 
appears to be more relevant than the transrepressing mechanism. 
Interestingly, GRdim mice are not only refractory to GC-treatment in AAI but also in other 
disease models. For instance, Dex failed to resolve inflammatory responses in murine 
models for rheumatoid arthritis, atopic dermatitis, sepsis and ALI (Baschant et al., 2011; 
Kleiman et al., 2012; Tuckermann et al., 2007; Vandevyver et al., 2012; Vettorazzi et al., 
2015).  
In the past, the transactivating mode of action was associated with the development of 
the GC-mediated adverse effects. Recent findings, however, revealed that GR-
dimerization was not required for the induction of osteoporosis, a complication of long-
term GC-therapy (Rauch et al., 2010). Therefore, the development of novel therapeutic 
approaches, that selectively target the GR-dimerization, might help to avoid adverse 
effects. 
 
5.2 AECs Are Important Targets in the GC-Treatment of AAI 
 
In addition to the mechanistic basis of GC-action, it is crucial to identify the target cells of 
GCs in the treatment of asthma. Previous studies had demonstrated that immune cells 
were dispensable for the efficacy of GCs in the treatment of murine AAI. Dex-treatment 
completely abolished inflammatory responses in mice that were GR-deficient specifically 
in T cells, B cells, DCs and myeloid cells (unpublished data). Furthermore, bone marrow 
chimeras were created with GRwt and GRdim mice. The A458T mutation is ubiquitously 
present in all cell types of GRdim mice and consequently also affects all cells of the 
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hematopoietic lineage. To confirm that immune cells were indeed dispensable in the 
treatment of AAI, bone marrow of GRdim mice was transplanted into irradiated GRwt mice 
and vice versa. Surprisingly, GRwt mice with a hematopoietic system of GRdim origin 
responded normally to Dex-treatment of AAI. At the same time, GRdim mice with 
hematopoietic cells from GRwt mice were refractory to the treatment with Dex 
(unpublished data). These findings indicated that the lung itself with its structural cells is 
most likely the target of GC-treatment, rather than immune cells. 
It was hypothesized that AECs might be the targets being responsible for the efficacy of 
GCs in murine AAI due to their crucial role in maintaining the immune responses in the 
lung.  
To test this assumption, a protocol for the isolation and purification of AECs was 
established based on the enzymatic digestion of lung tissue followed by removal of 
hematopoietic cells. However, it turned out that only a minor part of these cells was 
indeed epithelial cells. Although for practical reasons no markers for other structural cells 
of the lung could be included, the isolated cells presumably also include fibroblasts, 
airway smooth muscle cells, endothelial cells and mesenchymal cells. Thus unfortunately, 
isolation of AECs resulted in a heterogeneous population of LPCs rather than in a single 
uniform cell population. 
Despite the problem that the employed protocol did not result in a pure population of 
AECs, transcriptome profiling was performed with the resulting LPCs from GRwt and GRdim 
mice following the induction of AAI and additional Dex-treatment. RNA-seq analysis 
allows the identification of novel candidate genes that are differentially expressed upon 
Dex-treatment of AAI and thus helps to obtain a better insight into the transcriptional 
regulation by GCs. Furthermore, a potential link between the mechanism and target cells 
of GCs, in particular AECs, should be assessed. The analysis revealed different 
transcriptome profiles in LPC samples of GRwt and GRdim mice following Dex-treatment. 
Numerous differentially expressed genes were identified such as ATF-6, CD163, ELANE 
and ITGAE which were chosen for further analysis. In line with the bone marrow chimera 
analysis, these data suggested a crucial role of AECs and other pulmonary structural cells 
in the efficacy of GCs in AAI that is presumably linked to the transactivation of target 
genes. 
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It is against this background that GRspc mice were used to particularly examine the role of 
AT-II cells in the treatment of AAI. These mice are GR-deficient specifically in AT-II cells in 
a temporally defined manner. A tamoxifen-inducible Cre/loxP recombination system was 
used to prevent potential changes in lung morphology because the GC-GR interaction is 
essential in embryonic development and organogenesis. These changes could be indeed 
observed in conventional GRspc mice with a constant knock-out. Alveolar walls were 
increased in thickness resulting in close apposition of endothelial and epithelial layers 
(Habermehl et al., 2011).  
Inducible GRspc mice were treated with tamoxifen for GR ablation in AT-II cells. The knock-
out was assessed on protein level and mRNA level. Western blot analysis could not reveal 
a reduced GR expression in the lungs of mutant mice, but qRT-PCR analysis showed a 
moderately reduced GR mRNA expression. This result was not unexpected as whole lungs 
were analyzed and GR expression therefore cannot be completely abolished. Namely, AT-
II cells only represent a small proportion of total lung cells and other lung cells still 
express the GR. The total percentage of AT-II cells in the lung is 15% which correlates with 
the detected reduction (Mason, 2006). Thus, it is likely that tamoxifen treatment 
successfully induced gene recombination in GRspc mice. 
AAI was induced in GRspc mice with OVA to examine the impact of GR-deficient AT-II cells 
on the GC-efficacy. Both mouse strains showed elevated levels of IgG1, IgE and IgG2a and 
Dex had no effect on these levels. Nevertheless, the elevated Ig levels revealed that 
immunization with OVA had been efficient in GRspc mice. Similar to the findings obtained 
with GRdim mice, flow cytometric and histological analysis revealed a significant increase 
of pulmonary infiltrates in the allergic airways of GRflox and GRspc mice which was 
characterized by eosinophilia. Dex-treatment efficiently reduced the immune cell influx in 
GRflox mice as expected. Although infiltration was also reduced in GRspc mice, Dex-
treatment was not as effective as in GRflox mice. Furthermore, macrophage and neutrophil 
numbers were unaltered and eosinophilia was not completely abolished in GRspc mice.  
Histological analysis of the lung from both mouse strains provided a comparable picture. 
AAI led to the same structural changes in of GRflox and GRspc mice with 
bronchoconstriction and mucus hypersecretion. These changes were completely resolved 
in GRflox mice, but only partially in GRspc mice. Taken together, these findings remarkably 
demonstrated that AT-II cells contribute to the GC-efficacy in the treatment of murine AAI 
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because disease symptoms could not be completely repressed by Dex. At the same time, 
partial repression was still observed in mutant mice since other structural cells of the lung 
such as airway smooth muscle cells and endothelial cells presumably contribute to the 
GC-efficacy as well. Remarkably, AAI is the first disease model in which GCs do not target 
immune cells. In other disease models of multiple sclerosis, rheumatoid arthritis, graft-
versus-host disease or contact allergy, either T cells or myeloid cells had been the target 
for effective GC-treatment (Baschant et al., 2011; Theiss-Suennemann et al., 2015; 
Tuckermann et al., 2007; Wüst et al., 2008).  
The finding that AT-II cells are targets of GC-treatment in asthma is supported by a study 
dealing with the GR distribution in the lungs of healthy and asthmatic individuals. Highest 
GR expression was found in alveolar walls while no differences were detected in the 
analyzed groups (Adcock et al., 1996). This increased GR expression might hint at AT-II 
cells as target site of GC-action in the treatment of asthma. 
Noteworthy, the importance of AECs in the development of asthma is well established. In 
recent years, it has become evident that asthma is a disease of the airway epithelium 
(Holgate, 2007, 2011b; Wang et al., 2008). The development of asthma relies on the 
altered or damaged epithelial barrier function rather than on the allergic pathways alone 
(Holgate, 2011b). Several GWAS identified numerous candidate genes such as PCDH1 or 
ORMDL3 that were not only associated with a higher risk for the development of asthma, 
but were also associated with the airway epithelium. The airway epithelium of genetically 
susceptible individuals is more prone to inflammatory insults like viral infections which 
triggers ongoing inflammatory responses that eventually give rise to asthma (Holgate, 
2011b).  
All in all, it appears that AECs are valuable targets for the development of novel 
therapeutic approaches in asthma. Target site-directed delivery of GCs to AECs would 
potentiate the efficacy and would also reduce the development of adverse effects. 
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5.3 Inflammatory Genes Are Regulated by the Transactivating GR Mechanism in 
AECs 
 
GRdim mice were refractory to GC-treatment of AAI indicating that an intact dimerization 
interface was crucial for exerting the therapeutic efficacy. At the same time, AECs were 
also shown to be required for the GC-efficacy. Thus, mechanism and target site of GC-
action in murine AAI were elucidated which might both be linked in the transcriptional 
control of GC-target genes in AECs. 
To address this issue, lungs and LPCs were isolated from GRdim, GRspc and wild type mice 
following the induction of AAI and selective Dex-treatment, and various inflammatory 
genes were analyzed concerning differential mRNA expression by qRT-PCR. 
One hallmark of asthma is the secretion of the TH2-specific cytokines IL-5 and IL-13 that 
maintain the allergic inflammation in the airways (Bloemen et al., 2007). IL-5 is crucial for 
the maturation, recruitment and survival of eosinophils (Finkelman et al., 2010; Williams 
et al., 2012a). Increased levels of IL-13 are linked to CSR in B cells, mucus hypersecretion 
and to AHR (Corren, 2013; Finkelman et al., 2010; Williams et al., 2012a). In asthma 
therapy, GCs suppress these cytokines via the transrepressing mode of action (Barnes, 
2011b). As expected, AAI induced a remarkable increase of IL-5 and IL-13 mRNA 
expression in lungs and LPCs of all analyzed mouse strains. Dex-treatment efficiently 
reduced these increased cytokine levels in wild type mice, an effect that could not be 
observed in both mutant mouse strains. It was unexpected that Dex could not repress 
these TH2 cytokines in GR
dim mice although transrepression was still possible. TH2 cells and 
their cytokines are regulated by the transcription factors STAT6 and GATA3 which are 
targets for the GC-mediated transrepression (Barnes, 1998, 2011b; Ho et al., 2009; Shen 
and Stavnezer, 1998). In this model, however, transactivation seems to be more 
important to modulate TH2 cell function. This might be mediated by GILZ which is an 
important transcriptional regulator of GCs (Vandevyver et al., 2013). GILZ is a target of 
GC-mediated transactivation and its induction is inhibited in GRdim mice (Rauch et al., 
2010). GILZ is able to inhibit both DNA binding and transcriptional activation of various 
transcription factors (Stellato, 2007; Vandevyver et al., 2013). Interaction between GILZ 
and STAT6 as well as GATA3 has been reported to modulate TH2 cell functions (Ronchetti 
et al., 2015). Thus, GCs regulate TH2 cells and their cytokines in parallel by transactivation 
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and transrepression although the results obtained in the asthma model at hand suggest 
that activation of GILZ is possibly the more important mechanism. Alternatively, the way 
how GCs repress these cytokines depends on the specific cell type. 
Since IL-5 and IL-13 mRNA expression was not repressed by Dex-treatment in GRspc mice, 
AT-II cells could also be an important source of these cytokines in AAI which has not been 
reported before.  
AECs are a prominent source of IL-33, MCP-1 and RANTES that are all secreted in 
response to inflammatory stimuli (Fehrenbach, 2001; Makrinioti et al., 2014; Stellato, 
2007). IL-33 is expressed at higher levels in asthmatic lungs and induces robust TH2 cell-
specific immune responses, eosinophilic inflammation and AHR (Kabata et al., 2013; 
Makrinioti et al., 2014; Nabe et al., 2015). Increased levels of MCP-1 and RANTES are 
found in asthma patients. Both chemokines provoke mast cell activation and mediate the 
recruitment of other immune cells into the allergic airways (Alam et al., 1996; Conti and 
DiGioacchino, 2001; Holgate et al., 1997). All three genes have been shown to be 
repressed by treatment with GCs (Nabe et al., 2015; Stellato, 2007). Analyzed lungs and 
LPCs of all mouse strains were characterized by increased levels of IL-33, MCP-1 and 
RANTES. As expected, treatment with Dex could abolish this increased mRNA expression 
in wild type mice. In contrast, GC-treatment failed to diminish the elevated levels in GRdim 
and GRspc mice. As for the analyzed TH2 cytokines, expression of MCP-1 and RANTES has 
been suggested to be regulated by transrepression although the experiments at hand 
suggest that GR-dimerization was essential for suppression (Barnes, 2001). Of note, the 
relative contribution of these cytokines and chemokines produced by AECs in response to 
AAI in comparison to TH2 cells, ILC2 cells and other immune cells is not known. 
In addition to the analyzed pro-inflammatory cytokines and chemokines, expression of 
the tight junction proteins occludin and claudin 5 was investigated in lung and LPC 
samples. The epithelial integrity is impaired in asthma patients making them highly 
susceptible to infections and other inflammatory insults (Cummins, 2012; Davies, 2014; 
Soini, 2011). Several in vitro studies demonstrated that GCs increase the expression of 
these tight junction proteins by transactivation thereby improving the epithelial barrier 
function (Felinski et al., 2008; Förster et al., 2005; Kielgast et al., 2016). Contrariwise, 
mRNA expression of occludin and claudin 5 was increased following induction of AAI. 
Treatment with Dex led to a reduction of these elevated levels in wild type mice. Again 
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AAI-induced expression could not be repressed in mutant mouse strains although this 
result was not always clear. Transcriptional control of these tight junction proteins is 
difficult to evaluate as the in vivo findings in AAI were opposed to the reported in vitro 
studies. Thus, it is not clear whether GC mechanisms mediate the transcriptional control 
of tight junction proteins and whether AECs can directly control the epithelial integrity by 
production of tight junction proteins. 
Transcriptome profiling of LPCs from GRdim mice has identified many novel candidate 
genes such as ITGAE, ELANE, ATF-6 and CD163 that were chosen for further qRT-PCR 
analysis. ITGAE is an integrin mediating cell-cell or cell-ECM interactions. It is highly 
expressed by DCs and T cells on mucosal sites and binds to E-cadherin on epithelial cells 
(Annacker et al., 2005; Smyth et al., 2007). Several studies suggested an involvement in 
the development of asthma (Bernatchez et al., 2015; Nakano et al., 2012). ELANE is 
mainly secreted by neutrophils and causes major tissue damage by mediating the 
recruitment of further immune cells to the site of inflammation (Koga et al., 2013; 
Sandhaus and Turino, 2013). Furthermore, it contributes to the development of AAI and 
AHR in asthma as well (Koga et al., 2013; McGarvey et al., 2002; Nadel et al., 1999). ATF-6 
is a transcription factor that is involved in protein folding processes (Hsu and Turvey, 
2013). The asthma candidate gene ORMDL3, which is expressed by AECs, regulates the 
activation of this transcription factor. Therefore, ATF-6 expression is also associated with 
asthma pathogenesis (Hsu and Turvey, 2013; Miller et al., 2012, 2014).  
Expression of ITGAE, ELANE and ATF-6 was increased in analyzed lung and LPC samples 
after AAI was induced. Subsequent GC-treatment with Dex repressed the expression of 
these candidate genes in wild type mice but was not effective in GRdim and GRspc mice.  
These findings indicate that the three genes are promising candidates contributing to the 
resolution of AAI by GCs in AECs requiring an intact GR-dimerization interface. 
The scavenger receptor CD163 is mainly known to be a marker for alternatively activated 
monocytes and macrophages (Onofre et al., 2009). CD163-expressing macrophages have 
an anti-inflammatory function and CD163 is a well-known target of GR transactivation. In 
addition, asthma is associated with differential expression of this receptor (van de Garde 
et al., 2014; Kowal, 2004; Kowal et al., 2014). CD163 mRNA expression was induced 
during AAI in lung tissue and LPCs of all mouse strains. Dex abolished the increased CD163 
expression in wild type mice whereas treatment was ineffective in both mutant mouse 
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strains. Thus, CD163 presumably exerts a different and pro-inflammatory role when 
expressed by AECs compared to when it is expressed by macrophages. 
This finding demonstrates that the novel candidate genes including CD163 might in fact 
be important targets for effective GC-treatment of AAI. Nevertheless, the exact function 
and role of these genes in the pathogenesis of AAI and GC-therapy need to be further 
investigated.  
Taken together, GRdim and GRspc mice behaved similarly with regard to the transcriptional 
control of all analyzed genes. In contrast to wild type mice, GCs were not able to suppress 
the AAI-induced gene expression in both mutant mouse strains. This was independent of 
the analyzed type of sample as most genes showed similar expression patterns in lungs 
and LPCs. Noteworthy, transcriptional control of GC-target genes in AAI is not only 
mediated by the transactivation but also by other mechanisms of GCs. It has already been 
reported that transcriptional control of a subset of GC-target genes can be maintained in 
the presence of the A458T mutation (Frijters et al., 2010; Lim et al., 2015). Furthermore, 
AECs were implicated to be a more prominent source of cytokines and other 
inflammatory mediators than previously expected.  
In conclusion, these data revealed a novel mechanism of GC-therapy of AAI mainly being 
dependent on the GR-transactivation of GC-responsive genes in AECs. 
 
5.4 AECs Are Dispensable for the GC-Treatment of ALI 
 
In the treatment of AAI, AECs have been shown to be important targets of GCs. Since GCs 
are also used in the treatment of other inflammatory lung diseases, it is not known 
whether AECs might be generally required for therapeutic efficacy. 
ALI is an inflammatory insult to the lung which can be caused either directly or indirectly 
by e.g. sepsis, trauma or gastric aspiration. It is a common condition in critically ill 
patients with high morbidity and mortality. The disease is characterized by acute onset 
with massive pulmonary influx of leukocytes, hypoxia and edema (Saguil and Fargo, 
2012). GC-treatment of ALI is still under debate, because its efficacy is unclear. 
Nevertheless, numerous clinical trials are investigating the use of GCs in ALI (Meduri et 
al., 2016; Zhang et al., 2015). So far, a beneficial role in the early phase of the disease has 
been revealed (Diaz et al., 2010; Marik et al., 2011).  
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ALI was induced in GRspc mice with a combined treatment of LPS and OA. LPS elicits a 
systemic inflammatory response whereas OA selectively targets the lung. Part of the mice 
was injected i.p. with Dex representing systemic GC-treatment. ALI led to a significant 
increase of inflammatory cells in the airways of both GRflox and GRspc mice which was 
characterized by neutrophilia in both mouse strains. Dex-treatment significantly 
repressed the number of inflammatory cells not only in GRflox mice but also in GRspc mice 
as revealed by flow cytometric and histological analysis. Serum analysis of IL-6, which is 
an important cytokine in the pathogenesis of ALI, demonstrated that GCs were effective 
in reducing its level in both mouse strains. Moreover, mRNA expression of IL-1β, MCP-1 
and iNOS has been investigated in lung samples by qRT-PCR. These pro-inflammatory 
mediators drive the neutrophilic inflammation and promote tissue damage in ALI (Han 
and Mallampalli, 2015; Johnson and Matthay, 2010). Of note, AECs are known to express 
all of these mediators (Stellato, 2007). As expected, ALI induced a remarkable increase of 
IL-1β, MCP-1 and iNOS mRNA expression in lungs of both mouse strains. In line with the 
previous findings, Dex effectively repressed these inflammatory genes in wild type and 
mutant mice.  
In contrast to AAI, these findings clearly demonstrated that AECs were dispensable for the 
GC-efficacy of ALI although both diseases were dependent on the transactivating mode of 
action (Vettorazzi et al., 2015). However, while GC repression of AAI depends at least in 
part on the GR in AT-II cells, macrophages were reported to be essential for the 
repression of ALI (Vettorazzi et al., 2015). 
 
5.5 BNPs Are No Option to Optimize the GC-Treatment of Inflammatory Lung 
Diseases 
 
Despite their beneficial effects, the awareness to induce severe side effects has limited 
the use of GCs in the treatment of inflammatory diseases. Therefore, the benefit-risk ratio 
of GC-treatment needs to be carefully taken into account. Over the past few years, many 
attempts have been made to optimize GC-treatment by enhancing the efficacy and drug 
safety.  
The development of selective GR agonists (SEGRAS) or dissociated steroids is based on 
the suggestion that the anti-inflammatory effects rely on the transrepressing mechanism 
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while the undesirable adverse effects rely on the transactivating mechanism. Several 
substances have already been developed (Barnes, 2011b; Buttgereit et al., 2015; Stahn 
and Buttgereit, 2008). The efficacy of this strategy, however, has not been proven yet. 
Aside from this issue, the work at hand and other experimental findings contradict the 
concept of SEGRAS as transactivation has been shown to be essential to exert the anti-
inflammatory activities of GCs in several disease models (Baschant et al., 2011; Kleiman et 
al., 2012; Tuckermann et al., 2007; Vandevyver et al., 2012; Vettorazzi et al., 2015).  
The targeted delivery of GCs to the site of inflammation using liposomal formulations is 
another promising approach to optimize GC-treatment. In comparison to conventional 
GC-treatment, PEGylated GC liposomes were more effective and induced fewer side 
effects in murine models of multiple sclerosis and rheumatoid arthritis (Metselaar et al., 
2003; Rauchhaus et al., 2009; Schmidt et al., 2003; Schweingruber et al., 2011). Despite 
being promising, these PEGylated liposomes can unfortunately cause hypersensitivity 
reactions by complement activation (van den Hoven et al., 2013). 
Recently developed BNPs have been shown to be a novel interesting approach for 
optimized GC-therapy (Heck et al., 2015). These BNPs are based on inorganic-organic 
hybrid nanoparticles formed of cationic zirconium oxide together with anionic 
betamethasonephosphate and the green fluorescent dye flavinmononucleotide (Heck et 
al., 2015; Roming et al., 2010). In a murine model of multiple sclerosis, BNPs effectively 
repressed inflammatory responses and ameliorated disease symptoms (unpublished 
data).  
As this work had demonstrated that GR-dependent gene regulation in AECs was a crucial 
mechanism for the therapeutic efficacy in AAI, target site-directed delivery of BNPs was 
investigated in the treatment of AAI. BNPs were conjugated with an anti-SPC antibody 
(BNPs-SPC) to selectively deliver GCs to AT-II cells. BNPs-SPC were applied topically by 
intranasal instillation to potentiate the efficacy. In comparison to antibody-coated 
nanoparticles, mice were also treated with BNPs via the same route.  
As expected, Dex-treatment significantly diminished the AAI-induced increase of 
pulmonary infiltrates, but surprisingly, BNPs had no impact on BALF cell numbers whereas 
BNPs-SPC even caused an increase. The same tendencies were observed for eosinophil 
numbers in the BALF. Thus, neither BNPs nor BNPs-SPC were able to suppress AAI.  
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As BNPs-SPC were not effective to target AT-II cells by GCs, their uptake was investigated 
in LPC samples as well as in peritoneal macrophages in vitro. The MFI of the green 
fluorescent dye FMN contained in the nanoparticles was used as measure of uptake. 
EpCAM+ LPCs were used as a representative population for AECs. BNP-SPC and BNP 
uptake occurred in a concentration-dependent manner in AECs as high nanoparticle 
concentrations correlated with high MFI values. In general, BNP-SPC uptake was more 
efficient than that of BNPs in AECs. 
Interestingly, however, BNP and also BNP-SPC uptake could also be observed in 
peritoneal macrophages in a similar concentration-dependent manner. As macrophages 
were able to internalize both types of nanoparticles, macrophages presumably interfere 
with BNPs-SPC targeting to AECs in vivo. It is a well-described mechanism that 
nanoparticles that are deposited in the lung are rapidly removed by phagocytosis. Thus, 
nanoparticles have to circumvent the mucociliary and macrophage clearance to reach the 
AECs (Da Silva et al., 2013). In line with this notion, BNPs were shown to be preferentially 
taken up by macrophages in the treatment of the multiple sclerosis model (unpublished 
data). Thus, BNP treatment allows GC delivery specifically to macrophages. This is 
presumably why these nanoparticles were not effective in the treatment of AAI. 
Macrophages are dispensable in the GC-treatment of AAI (unpublished data) but at the 
same time, BNPs-SPC cannot reach AT-II cells as GC-target in AAI because of macrophage 
clearance. 
Instead of BNPs-SPC, other approaches should be considered for the AT-II cell-directed 
delivery of GCs in AAI. Lipoplexes conjugated with the anti-SPC antibody have been 
shown to be promising drug carriers. These lipoplexes were able to specifically target AT-
II cells without accumulating in other lung cells. Moreover, lipoplexes did not induce lung 
toxicity (Wu et al., 2015). 
Since BNPs were shown to selectively target macrophages, their use in the treatment ALI 
was investigated. As mentioned before, macrophages are essential for the GC-efficacy in 
ALI rather than AECs. Analysis of pulmonary infiltrates expectedly demonstrated 
therapeutic efficacy of Dex in ALI therapy as BALF cell numbers were significantly reduced 
and neutrophilia efficiently repressed. Surprisingly, BNPs had no effect on total BALF cell 
and neutrophil numbers. In addition, IL-6 levels in serum were not diminished by BNPs in 
contrast to Dex. Thus, BNPs were not able to repress the inflammatory responses in ALI.  
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In contrast to Dex, BNPs were applied topically which might be another reason for the 
inefficacy in ALI. Systemic administration could presumably repress the inflammatory 
responses as ALI is characterized by systemic inflammation. 
Even though macrophages are targets of BNPs and GC-efficacy in ALI, many factors can 
influence the nanoparticle effects in the lung. The occurrence of pulmonary disease can 
affect many physiological aspects of the lung like bronchoconstriction. This may prevent 
the deposition of nanoparticles into the desired regions of the lung or even prevent 
cellular uptake. Besides, nanoparticle properties can be influenced by e.g. low pH (Da 
Silva et al., 2013; Kuzmov and Minko, 2015). Hypoxia is a major symptom of ALI and might 
lead to degradation of BNPs. These pulmonary factors, however, need to be further 
investigated with regard to the BNP efficacy in ALI.  
Taken together, target cell-directed delivery of BNPs failed in the treatment of both AAI 
and ALI. In the treatment of inflammatory lung diseases, these inorganic-organic hybrid 
nanoparticles are therefore not suitable for optimizing GC-treatment and other 
approaches thus need to be considered instead.  
 




This work provides provocative new insights into the mechanisms of GCs in the treatment 
of asthma. It is the first example where GC-targeting of non-immune cells is required for 
therapeutic efficacy. Although GCs could partially repress the inflammatory responses in 
GRspc mice, it is indisputable that AT-II cells are crucial targets of the beneficial effects of 
GC-therapy of AAI (fig. 36). Nevertheless, other structural cells of the lung such as airway 
smooth muscle cells and endothelial cells presumably contribute to the efficacy as well. 
So far, AT-II cells have only been linked to GC-therapy of AAI while they are dispensable 
for the treatment of ALI. 
Furthermore, this work demonstrated that an intact GR-dimerization interface, which is 
responsible for the transactivation of many GC-target genes, is a prerequisite for the 
therapeutic efficacy in AAI, rather than the transrepressing mode of action. Thus, GR-
dependent regulation of target genes in AECs is a critical mechanism of the therapeutic 
efficacy in AAI.  
Although first approaches to selectively deliver GCs to AT-II cells using nanoparticles 
failed, target site-directed approaches might improve GC-treatment with fewer side 
effects. At the present time, the findings on the mechanisms of GCs in allergic asthma 
therapy are still limited to the mouse. However, it is likely that they will nonetheless pave 
the way for the development of improved asthma therapies in humans in the future.  
  
















Figure 36: Model of GC activities in the treatment of allergic asthma. AECs are important targets of GCs in 
AAI. The conducting airways consist mainly of secretory goblet cells and clara cells as well as ciliated cells. 
The alveoli in the lung parenchyma are formed by AT-I and AT-II cells. Airway epithelial barrier function is 
regulated by tight junction proteins that are essential for the epithelial integrity. In response to allergen 
exposure, AT-II cells secrete a broad range of pro-inflammatory mediators including IL-33, MCP-1, RANTES 
and also the TH2-specific cytokines IL-5 and IL-13. GCs repress the cytokine expression by AT-II cells. This 
impairs the activation of ILC2 cells and TH2 cells while secretion of additional cytokines is also reduced. At 
the same time, GCs can interfere with the infiltration of eosinophils, macrophages and neutrophils. Release 
of granule proteins and other pro-inflammatory mediators that promote airway remodeling and tissue 
damage can be diminished. Expression of the tight junction proteins occludin and claudin 5 is controlled 
either directly or indirectly by GCs. GCs repress the AEC-secreted cytokines in a transactivating manner 
which reverses airway remodeling processes. Bronchoconstriction, mucus hypersecretion and AHR can be 
abolished. In addition to AT-II cells, GCs presumably also act on other structural cells of the lung such as 
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7.2 List of Abbreviations 
 
AAI     Allergic Airway Inflammation 
Acc.     According 
ACE     Angiotensin Converting Enzyme 
ACOS     Asthma-COPD Overlap Syndrome 
ACTH     Adrenocorticotropic Hormone 
AECs     Airway Epithelial Cells 
AF     Activation Function 
AHR     Airway Hyperresponsiveness 
ALI     Acute Lung Injury 
Alum     Aluminum Hydroxide 
AP-1     Activator Protein-1 
APC     Antigen-Presenting Cell 
APRIL     A Proliferation Inducing Ligand 
APS     Ammonium Persulfate 
ARDS     Acute Respiratory Distress Syndrome 
ATF-6     Activating Transcription Factor 
AT-I Cell    Alveolar Type I Epithelial Cell 
AT-II Cell    Alveolar Type II Epithelial Cell 
 
BAFF     B Cell Activating Factor 
BAL     Bronchoalveolar Lavage 
BALF     Bronchoalveolar Lavage Fluid 
BMP     Betamethasonephosphate 
BNP     Betamethasonephosphate Nanoparticle 
bp     Base Pairs 
BSA     Bovine Serum Albumine 
 
CCL     CC Chemokine Ligand 
CD     Cluster of Differentiation 
cDNA     Complementary DNA 
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COX-2     Cyclo-Oxygenase-2 
CREB     cAMP Response Element-Binding Protein 
CRH     Corticotropin-Releasing Hormone 
CSR     Class-Switch Recombination 
Ctrl     Control 
CXC     CXC Chemokine Ligand 
 
Da     Dalton 
DAMP     Danger-Associated Molecular Pattern 
DBD     DND-Binding Domain 
DC     Dendritic Cell 
Dex     Dexamethasone 
DMEM     Dulbecco's Modified Eagle Medium 
DMSO     Dimethyl Sulfoxide 
DNA     Deoxyribonucleic Acid 
DNase     Deoxyribonuclease 
dNTP     Deoxyribonucleotide Triphosphate 
DUSP1     Dual Specificity Protein Phosphatase 1 
 
e.g.     Exempli Gratia 
ECM     Extracellular Matrix 
ECP     Eosinophilic Cationic Protein 
EDN     Eosinophil-Derived Neurotoxin 
EDTA     Ethylendiaminetetraacetic Acid 
ELANE     Elastase Neutrophil-Expressed 
ELISA     Enzyme-Linked Immunsorbent Assay 
EMA     European Medicines Agency 
EMTU     Epithelial Mesenchymal Trophic Unit 
ENI     European Neuroscience Institute 
eNOS     Endothelial Nitric Oxide Synthase 
EP     Eosinophil Peroxidase 
et al.     Et Alii  
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FACS     Fluorescence Activated Cell Sorting 
FasL     Fas Ligand 
FBS     Fetal Bovine Serum 
FDA     Food and Drug Administration 
FGR     Familial GC-Resistance 
FMN     Flavinmononucleotide 
FSC     Forward Scatter 
 
g     Gram 
GC     Glucocorticoid 
GILZ     Glucocorticoid-Induced Leucine Zipper 
GM-CSF    Granulocyte-Macrophage Colony-Stimulating Factor 
GR     Glucocorticoid Receptor 
GRE     Glucocorticoid-Responsive Elements 
GWAS     Genomewide-Association Study 
 
HAT     Histone-Acetyltransferase 
HDAC     Histone-Deacetylase 
H & E     Hemalum and Eosin 
HPA     Hypothalamus-Pituitary-Adrenal  
HPRT     Hypoxanthine Phosphoribosyl Transferase 
HSD     Hydroxysteroid Dehydrogenase 
Hsp     Heat Shock Proteins 
 
i.e.     Id Est 
i.p.     Intraperitoneal 
i.v.     Intravenous 
IAV     Influenza A Virus  
ICs     Inhaled GCs 
IFN     Interferon 
Ig     Immunoglobulin 
IL     Interleukin  
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iNOS     Inducible Nitric Oxide Synthase 
ITGAE     Integrin α E 
IVC     Individually Ventilated Cage 
 
JAM     Junctional Adhesion Molecule 
 
k     Kilo 
 
l     Liter 
LABA     Long-Acting β2-Agonist 
LAVES     Lower Saxony State Office for Consumer Protection 
     and Food Safety 
LBD     C-Terminal Ligand-Binding Domain 
LPC     Lung Parenchymal Cell 
LPS     Lipopolysaccharide 
 
m     Milli/ Meter 
M     Molar 
MACS     Magnetic Cell Separation 
MBP     Major Basic Protein 
MCP     Monocyte Chemoattractant Protein 
MFI     Mean Fluorescence Intensity 
MHC     Major Histocompatibility Complex 
min     Minute 
mRNA     Messenger RNA 
 
n     Nano 
NEB     Neuroepithelial Bodies 
NET     Neutrophil-Extracellular Trap 
NF-κB     Nuclear Factor Kappa-Light-Chain-Enhancer of  
     Activated B Cells 
nGRE     Negative Glucocorticoid-Responsive Elements 
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NLR     Nod-Like Receptor 
NO     Nitric Oxide 
NTD     N-Terminal Transactivation Domain 
 
OA     Oleic Acid 
OD     Optical Density 
OVA     Ovalbumine 
 
PAF     Platelet-Activating Factor 
PAMP     Pathogen-Associated Molecular Pattern  
PBS     Phosphate-Buffered Saline 
PCR     Polymerase Chain Reaction 
PFA     Paraformaldehyde 
PI3K     Phosphatidylinositol-3-Kinase 
PRR     Pattern Recognition Receptor 
PTM     Post-Transcriptional Modifications 
 
qRT-PCR    Quantitative Real-Time PCR 
 
RANTES    Regulated upon Activation, Normal T Cell-  
     Expressed, and Secreted 
RNA     Ribonucleic Acid 
RNase     Ribonuclease 
RNA-Seq    RNA Sequencing 
ROS     Reactive Oxygen Species 
RSV     Respiratory Syncytial Virus 
RT     Room Temperature 
 
Sec     Seconds 
SABA     Short-Acting β2-Agonist 
SDS     Sodium Dodecylsulfate 
SEGRA     Selective GR Agonist 
SEM     Standard Error of the Mean  
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SLPI     Secretory Leukocyte Inhibitory Protein 
SP     Surfactant Protein 
SPC     Surfactant Protein C 
SPF     Specific Pathogen-Free 
SSC     Sideward Scatter 
TEMED    Tetramethylethylenediamine 
TGF     Transforming Growth Factor 
TH     T Helper Cell 
TLR     Toll-Like Receptor 
TMB     Tetramethylbenzidine 
TNF     Tumor Necrosis Factor 
Treg     Regulatory T Cell 
TSLP     Thymic Stromal Lymphopoietin 
 
U     Unit 
 
VEGF     Vascular Endothelial Growth Factor 
 
WHO     World Health Organization 
 
ZO     Zonula Occludens 
 
α     Alpha 
β     Beta 
Δ     Delta 
ε     Epsilon 
λ     Gamma 
µ     Mikro 
p     Piko 
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